

# **Toxicological Evaluation and Limit Values for 2-Ethylhexyl acrylate, Propylene carbonate, Quaternary ammonium compounds, triglycidyl isocyanurate and tripropyleneglycol diacrylate**

Pia Berthelsen, Vibe Beltoft, Inger Thorup, Inge Søborg and Elsa Nielsen

The Institute of Food Safety and Toxicology  
Danish Veterinary and Food Administration

The Danish Environmental Protection Agency will, when opportunity offers, publish reports and contributions relating to environmental research and development projects financed via the Danish EPA.

Please note that publication does not signify that the contents of the reports necessarily reflect the views of the Danish EPA.

The reports are, however, published because the Danish EPA finds that the studies represent a valuable contribution to the debate on environmental policy in Denmark.

# Contents

**Preface** 5

**Principles for setting of limit values for chemical substances** 7

**2-Ethylhexyl acrylate** 11

**Propylene carbonate** 35

**Quaternary ammonium compounds** 51

**Triglycidyl isocyanurate** 81

**Tripropyleneglycol diacrylate** 111



# Preface

This series of reports constitutes a part of the work related to the setting of health based limit values for chemical substances in air, soil and drinking water.

In this report, the toxicological documentation for the setting of limit values for 2-ethylhexyl acrylate, propylene carbonate, quaternary ammonium compounds, triglycidyl isocyanurate, and tripropyleneglycol diacrylate are presented.

For every substance, the following items are considered:

- part 1, physicochemical properties, production and uses, environmental occurrence and fate, and human exposure
- part 2, toxicokinetic properties and toxicological mechanisms
- part 3, human toxicity
- part 4, animal toxicity
- part 5, regulations and limit values in different media
- part 6, summary of sections 1 to 5
- part 7, evaluation of toxicity and identification of critical effects
- part 8, estimation of tolerable daily intake (TDI) and health based limit values
- part 9, implementation of health based limit values to quality criteria

The work has been carried out by the Institute of Food Safety and Toxicology, Danish Veterinary and Food Administration as a contract work for the Danish Environmental Protection Agency.

The work has been followed by a Steering Committee who has contributed to the work with professional expertise, proposals and criticism:

Linda Bagge, Chairman, Danish Environmental Protection Agency  
Poul Bo Larsen, Danish Environmental Protection Agency  
Erik Thomsen, Danish Environmental Protection Agency  
Hans Chr. Ellehauge, Danish Environmental Protection Agency  
Anders Carlsen, Medical Health Office for Viborg County  
Elle Laursen, National Board of Health  
Ole Ladefoged, Institute of Food Safety and Toxicology  
Elsa Nielsen, Institute of Food Safety and Toxicology



# Principles for setting of health based limit values for chemical substances

In the following, the principles upon which the Danish Environmental Protection Agency bases the health based limit values, in the following referred to as limit values, for chemical substances are briefly outlined. For further and more specific information, the reader is referred to the references mentioned below.

## *Purpose*

The purpose of setting limit values for chemical substances is to prevent health hazards in the human population caused by chemicals as pollutants. The scientific method for setting of limit values comprises a hazard identification and hazard assessment which together with an exposure assessment constitute the risk assessment part in the process of setting limit values.

## *Selection of data*

Data concerning exposure and harmful effects of a chemical substance are collected from national and international criteria documents, monographs and original scientific literature. During the review of the data, the quality and reliability of the studies and research work are critically assessed. This is an important step since conflicting viewpoints regarding the hazards may be present. Unpublished data from industry or other sources are only seldom used, as such data have not been published in scientific journals and have not been subjected to critical review by other scientists.

If adequate human data are available these are preferred as the basis for the assessment. For most substances however, human data are not adequate or available. In these cases, limit values are based upon data from experimental animal studies.

When all the relevant data have been evaluated, the hazard considered most important - "the critical effect" - for setting the limit value, is identified. In this step it is assessed whether an effect should be considered as adverse and of relevance to humans.

A substance may have different effects at different concentrations or doses. Generally, the effects are of more concern the lower the concentration or dose at which they occur, and the effect observed at the lowest concentration or dose often forms the basis for setting the limit value.

## *Threshold chemicals, NO-AEL or LOAEL*

The next step for assessment of a limit value is to identify the "no observed adverse effect level" (NOAEL) which is the highest dose at which the critical effect was not observed or, in cases where a NOAEL cannot be identified, the "lowest observed adverse effect level" (LOAEL) which is the lowest dose at which the critical effect was observed.

## *TDI / safety factors*

Having identified a NOAEL or a LOAEL, three "safety factors" (SF) are used to extrapolate from NOAEL or LOAEL to the tolerable daily intake, TDI (expressed in mg/kg b.w. per day) or the limit value for air,  $LV_{air}$ ,

(expressed in mg/m<sup>3</sup>). The purpose of the safety factors is to take into account the fact that:

SF<sub>1</sub>: The toxicological effect of a chemical substance on animals need not reflect the toxicological effect on "normal" humans, this factor is historically set at 10.

SF<sub>2</sub>: The toxicological effect of a chemical substance may vary considerably between different persons, and that i.e. children, elderly or sick people may be much more sensitive to exposure than "normal" people, this factor is often set at 10.

SF<sub>3</sub>: The data may be of varying quality and relevance to the actual problem, this factor is set at a value from 1 to 1000 depending on a concrete evaluation.

Thus in cases where a threshold value for the toxic effect is assumed and a NOAEL or a LOAEL can be identified, the TDI or the LV<sub>air</sub> are obtained by the following calculation:

$$\text{TDI} / \text{LV}_{\text{air}} = \frac{\text{NOAEL or LOAEL}}{\text{SF}_1 \times \text{SF}_2 \times \text{SF}_3}$$

#### *Exposure routes*

In general, limit values for air are based upon data from inhalation studies and limit values for soil (LV<sub>soil</sub>) and drinking water (LV<sub>dw</sub>) are based upon data from oral studies. However, if data for the relevant exposure route are not available, data from alternative exposure routes may be used as well, although it is realized that the degree of uncertainty may increase. This will then influence the value of the SF<sub>3</sub>.

#### *Analogy*

In cases where no data on harmful effects are available, an evaluation may be made upon the basis of data for related substances and a consequent increase in the value of the SF<sub>3</sub>.

#### *Non threshold chemicals*

For chemical substances where a threshold value for the toxic effect cannot be assumed (i.e. genotoxic carcinogenic substances), the concept of lifetime risk is applied. Thus, for these potential carcinogenic substances, the TDI corresponding to a specific lifetime risk, is calculated upon the basis of animal studies by means of the "One Hit" model. A lifetime risk of 10<sup>-6</sup> (life-time exposure to the dose that may lead to cancer for one in a million) is considered as tolerable.

#### *Exposure air, water, soil*

Having obtained the tolerable daily intake for a chemical substance, the limit values for drinking water and soil are calculated taking into account the daily exposure from the various media. The following exposure standard estimates for the various media are used in the calculation of limit values:



	Soil* oral intake	Soil* dermal contact	Air inhalation	Water oral intake
Child, 10 kg average/maximum	0.2 / 10 g	1 / 10 g	10 / 12 m <sup>3</sup>	1 / 2 liter
Adult, 70 kg average/maximum	0.025 / 0.1 g	0.1 / 1 g	20 / 30 m <sup>3</sup>	2 / 4 liter

\*For the soil exposure estimates, it has to be emphasized that these are based upon exposure scenarios which cover the most sensitive applications, e.g. domestic gardens, play grounds or kindergartens.

To ensure that the total daily intake of a chemical substance from the various media does not exceed the tolerable daily intake, a certain percentage of the tolerable intake to the various media may be assigned (allocation).

### *Limit values*

The limit value for soil and drinking water are obtained by the following calculations:

$$LV_{\text{soil}} = \frac{\text{TDI}^* \times w_{\text{child}}}{\text{ingestion}_{\text{soil}}}$$

$$LV_{\text{dw}} = \frac{\text{TDI}^* \times w_{\text{adult}}}{\text{ingestion}_{\text{dw}}}$$

$$LV_{\text{dw}} = \frac{\text{TDI}^* \times w_{\text{adult}}}{\text{inhalation}_{\text{air}}}$$

\*TDI or a percentage of the TDI (allocation)  
w: body weight for a child (10 kg) or an adult person (70 kg)

### *C-value, quality criteria*

Finally, the limit values are used as the basis for the setting of quality criteria for soil, drinking water, and air (C-values). In this step, other than health based viewpoints may be taken into account. This may include aesthetical factors such as odour (all media), discoloration (soil, drinking water), taste and microbial growth (drinking water). Furthermore, economic or political administrative factors may be taken into account.

It has to be stressed that no ecotoxicological considerations are taken into account in the process of setting health based limit values.

### *References*

Industrial Air Pollution Control Guidelines. Vejledning fra Miljøstyrelsen Nr. 9 1992. Ministry of the Environment, Denmark, Danish Environmental Protection Agency.

Health Based Evaluations of Chemical Substances in Drinking Water. Vejledning fra Miljøstyrelsen Nr. 1 1992. Ministry of the Environment, Denmark, Danish Environmental Protection Agency. In Danish.

Risk Evaluation of Contaminated Sites. Miljøprojekt Nr. 123 1990.  
Ministry of the Environment, Denmark, Danish Environmental Protection Agency. In Danish.

**Evaluation of health hazards  
by exposure to**

***2-Ethylhexyl acrylate***

**and estimation of a limit value in air.**

**Pia Berthelsen**


**The Institute of Food Safety and Toxicology  
Danish Veterinary and Food Administration**

# 1 General description

## 1.1 Identity

Molecular formula:  $C_{11}H_{20}O_2$

Structural formula:



Molecular weight: 184.3

CAS-no.: 103-11-7

Synonyms: Acrylic acid, 2-ethylhexyl ester  
1-Acryloyloxy-2-ethyl-hexan  
3-Acryloyloxymethyl-heptan  
2-Ethylhexyl 2-propenoate  
1-Hexanol, 2-ethyl-, acrylate  
Octyl-acrylate  
2-Propenoic acid, 2-ethylhexyl ester  
2-Propenoic acid, octyl ester

## 1.2 Physical / chemical properties

Description: Colourless liquid with a sharp and musty odour.

Purity: 99.5%

Melting point:  $-90^{\circ}\text{C}$

Boiling point:  $213-218^{\circ}\text{C}$

Density: 0.887 g/ml (at  $20^{\circ}\text{C}$ )

Vapour pressure: 0.14 mmHg (19 Pa) at  $20^{\circ}\text{C}$

Concentration of saturated vapours: 184 ppm (calculated) at  $20^{\circ}\text{C}$  and 760 mmHg.

Vapour density: 6.35 (air = 1)

Conversion factor:  $1 \text{ ppm} = 7.66 \text{ mg/m}^3 \quad 20^{\circ}\text{C}$   
 $1 \text{ mg/m}^3 = 0.130 \text{ ppm} \quad 1 \text{ atm}$

Flash point:  $82-92^{\circ}\text{C}$  (open cup),  $86^{\circ}\text{C}$  (closed cup)

Flammable limits:	0.8-6.4 (v/v% in air)
Autoignition temp.:	252°C
Solubility:	Water: 0.1g/l (at 20°C). Soluble in alcohols, ethers, and many organic solvents (acetone, benzene, ethyl ether, heptane, methanol, carbon tetrachloride).
logP <sub>octanol/water</sub> :	3.67 - 4.32
Henry's constant:	3.54 x 10 <sup>-4</sup> (atm x m <sup>3</sup> )/mole at 20°C.
pK <sub>a</sub> -value:	-
Stability:	Polymerises readily unless inhibited. Rapid, uncontrolled polymerisation can cause explosion. Reacts readily with electrophilic, free-radical, and nucleophilic agents.
Incompatibilities:	-
Odour threshold, air:	0.55-1.36 mg/m <sup>3</sup>
References:	BUA (1994), HSDB (1999), IARC (1994), ICSC (1993), IUCLID (1996), Ruth (1986)

### 1.3 Production and use

Direct, acid-catalysed esterification of acrylic acid with 2-ethylhexanol is the principal method for the manufacture of 2-ethylhexyl acrylate. A polymerisation inhibitor is added. (IARC 1994).

The major current use of 2-ethylhexyl acrylate is in acrylic pressure-sensitive adhesives. An adhesive for general purpose tape typically contains about 75% 2-ethylhexyl acrylate. Other uses of 2-ethylhexyl acrylate is in the production of plastics, latex, paints, textile and leather finishes, coatings for paper and industrial metal finishing. (HSDB 1999, IARC 1994).

In Denmark, the principal use of 2-ethylhexyl acrylate is in UV curable inks, lacquers and varnishes. Emission occurs in the form of aerosols.

### 1.4 Environmental occurrence

2-Ethylhexyl acrylate is not known to occur as a natural compound. It may be released into the environment in fugitive and stack emissions or in wastewater during its production and use. (HSDB 1999, IARC 1994).

## 1.5 Environmental fate

<i>Air</i>	2-Ethylhexyl acrylate is expected to exist almost entirely in the vapour phase based on its vapour pressure. It may photolyse in sunlight. It will react with photochemically produced hydroxyl radicals and ozone with an estimated half-life of 10.3 hours. (HSDB 1999).
<i>Water</i>	2-Ethylhexyl acrylate is not expected to adsorb to sediment or suspended particulate matter. It may hydrolyse, especially in alkaline waters based upon hydrolysis data for the structurally similar ethyl acrylate. It may photolyse in sunlight. It may biodegrade based upon the biodegradability of butyl acrylate and ethyl acrylate. It will significantly volatilise from water with an estimated half-life of between 7.3 hours and 2.7 days. (HSDB 1999).
<i>Soil</i>	2-Ethylhexyl acrylate is expected to exhibit moderate mobility in soil and, therefore, it may leach to groundwater. It may hydrolyse, especially in alkaline soils based upon hydrolysis data for the structurally similar ethyl acrylate. It may biodegrade based upon the biodegradability of butyl acrylate. It may volatilise from near surface soil and other surfaces. (HSDB 1999).
<i>Bioaccumulation</i>	According to HSDB (1999) 2-Ethylhexyl acrylate is not expected to bio-concentrate in aquatic organisms. However BUA (1994) is stating that considerable bioaccumulation is to be expected.

## 1.6 Human exposure

The most probable route of human exposure of 2-ethylhexyl acrylate is by inhalation of contaminated air especially at plants where it is manufactured and used. Workers also may be exposed dermally during spills or leaks. (Samimi & Falbo 1982).

## 2 Toxicokinetics

### 2.1 Absorption, distribution.

<i>Inhalation</i>	Urinary excretion of metabolites following inhalational exposure indicates absorption occurring by this route (Vodicka et al. 1990).
<i>Oral intake</i>	Excretion of a radioactive marked dose following oral exposure indicate absorption occurring by this route (Sapota 1988).
<i>Dermal contact</i>	No data were found.
<i>Intraperitoneal application</i>	In one study male Wistar rats were administrated an intraperitoneal dose of 10 mg/kg bw of ( <sup>14</sup> C)-2-ethylhexyl acrylate labelled on the vinyl carbons (Gut et al. 1988). In another study male Wistar albino rats were administrated an intraperitoneal dose of 100 mg/kg bw of 2-ethylhexyl [2,3- <sup>14</sup> C]-acrylate (Sapota 1988). In both studies plasma radioactivity concentration reached a peak level at about 2-3 hours after administration indicating easy absorption through this route. In tissues the highest concentrations of radioactivity was found in kidney, liver, spleen and the lungs. In the study with a dose of 100 mg/kg bw 6.5% of the dose was found in tissues at 3 hours after administration. The radioactivity in the tissues decreased slowly with time. At 72 hours after administration 1% of the dose was still found in the examined tissues. The radioactivity in adipose tissue and sciatic nerve was still relatively high.
<i>Intravenous application</i>	In one study male Wistar rats were administrated an intravenous dose of 10 mg/kg bw of ( <sup>14</sup> C)-2-ethylhexyl acrylate labelled on the vinyl carbons (Gut et al. 1988). In another study male Wistar rats were administrated an intravenous dose of 10 mg/kg bw or 50 mg/kg bw of ( <sup>14</sup> C)-2-ethylhexyl acrylate (Cikrt et al. 1986). The highest concentrations of radioactivity in tissues was found in kidney, liver, brain, thymus and spleen.

### 2.2 Elimination

*Metabolism* 2-Ethylhexyl acrylate is believed to undergo carboxylesterase-catalysed hydrolysis to 2-ethylhexanol and acrylic acid, like other acrylate esters (Cikrt et al. 1986, Miller et al. 1981 - quoted from IARC 1994).

2-Ethylhexyl acrylate to a minor extent reacts with non-protein SH groups in for instance glutathione causing depletion of the non-protein SH groups and excretion of thioethers in urine as described in the following studies:

Male Wistar rats exposed by 6 hours inhalation to 2-ethylhexyl acrylate in concentrations from 250 to 4800 mg/m<sup>3</sup> over 24 hours excreted thioethers in urine in a dose dependent manner decreasing from 8.0 to 3.0% (at 1000 mg/m<sup>3</sup>) of the dose of 2-ethylhexyl acrylate indicating saturable metabolism along this pathway. Dose related depletion of non-protein SH groups in blood, liver and brain was seen at concentrations of and above 2400 mg/m<sup>3</sup>. (Vodicka et al. 1990).

When male Wistar rats were administered an intraperitoneal dose of 10 mg/kg bw of (<sup>14</sup>C)-2-ethylhexyl acrylate labelled on the vinyl carbons 2% of the dose was found as thioethers in the urine (Gut et al. 1988). The principal eliminated metabolite in expired air was carbon dioxide in two studies in male Wistar rats given an intraperitoneal or intravenous dose of (<sup>14</sup>C)-2-ethylhexyl acrylate (Gut et al. 1988, Sapota 1988).

When 2-ethylhexyl acrylate and its metabolite acrylic acid reacts with the reduced form of glutathion (GSH), mercapturic acids can be formed (Cikrt et al. 1986).

### *Excretion*

Two mercapturic acids N-acetyl-S-(2-carboxyethyl) cysteine and N-acetyl-S-2-(2-ethylhexyloxycarbonyl)ethyl-cysteine is excreted in the bile and urine (Cikrt et al. 1986, Kopecký et al. 1985 - quoted from IARC 1994). Besides some unidentified metabolites have been detected in the bile of rats (Cikrt et al. 1986).

Male Wistar rats were administered an intravenous dose of 10 mg/kg bw or 50 mg/kg bw of (<sup>14</sup>C)-2-ethylhexyl acrylate. Biliary excretion of radioactivity was followed in 1-3 hour intervals within the first 24 hours after administration. A significant increase in bile flow (243%) was observed. In the 24-hours 2.2% of the dose was eliminated via bile at both doses, most of it (83%) during the first 3 hours. (Cikrt et al. 1986).

Male Wistar rats were administered an intraperitoneal or intravenous dose of 10 mg/kg bw of (<sup>14</sup>C)-2-ethylhexyl acrylate labelled on the vinyl carbons. Within the first 24 hours about 50% of the dose had been excreted in expired air, 7-13% in urine and less than 0.01% in faeces. (Gut et al. 1988).

Male Wistar albino rats were administered an intraperitoneal or oral dose of 100 mg/kg bw of 2-ethylhexyl [2,3-<sup>14</sup>C]-acrylate. Within the first 72 hours more than 90% of the dose had been excreted (78% in expired air, 10% in urine, and 3% in faeces for intraperitoneal application and 50% in expired air, 41% in urine, and 1% in faeces for oral application). (Sapota 1988).

### *Half-life*

Male Wistar rats were administered an intraperitoneal or intravenous dose of 10 mg/kg bw of (<sup>14</sup>C)-2-ethylhexyl acrylate labelled on the vinyl carbons. Elimination of radioactivity from blood was bi-exponential. The plasma half-life for the distribution phase was 60 minutes (i.p.) and 30 minutes (i.v.) for 4 months old and 130 minutes (i.p.) and 115 minutes (i.v.) for 7 months old. For the elimination phase, the half-life was 6 hours (i.p.) and 5 hours (i.v.) for the youngest rats and 14 hours (i.p. and i.v.) for the oldest. (Gut et al. 1988).

Male Wistar albino rats were administered an intraperitoneal dose of 100 mg/kg bw of 2-ethylhexyl [2,3-<sup>14</sup>C]-acrylate. Elimination of radioactivity from blood had a monophasic character. The plasma half-life was about 22 hours. The half-life for excretion was calculated to be about 1½ hour. (Sapota 1988).



### **2.3 Toxicological mechanisms**

No data were found.

## 3 Human toxicity

### 3.1 Short term toxicity

#### *Inhalation*

No data were found.

#### *Oral intake*

No data were found.

#### *Dermal contact*

Seven persons have developed allergic contact dermatitis due to an acrylic based adhesive tape. Patch-testing revealed that all persons reacted to 2-ethylhexyl acrylate. Five of the persons were further tested for cross-sensitisation patterns. They all reacted to 2-ethylbutylacrylate and some of them reacted to other acrylates as well. (Jordan 1975).

No cases of respiratory sensitisation have been reported.

In Finland, 5 cases of occupational contact urticaria caused by 2-ethylhexyl acrylate has been reported from 1990 to 1994 (Kanerva et al. 1996 - quoted from Toxline pre1981-1999).

Generally acrylates are potent contact allergens with polyfunctional acrylates and epoxyacrylates being the strongest and polyfunctional methacrylates and cyanoacrylates being the weakest. A lot of the acrylates cross react. The Danish National Institute of Occupational Health (AMI) has made a list of allergens. It contains about 65 acrylates all causing contact sensitisation. Two of the acrylates (2,3-epoxypropyl-acrylate and methylmethacrylate) also cause respiratory sensitisation. Several epoxy compounds cause respiratory sensitisation so the epoxy-group in 2,3-epoxypropyl-acrylate might be the cause of its allergic effect on the respiratory system. (AMI 1990). In the Nordic countries 23 acrylates were classified for the ability to cause sensitisation by skin contact and were labelled with R43. (Nordisk Ministerråd 1991).

### 3.2 Long term toxicity

No data were found.

### 3.3 Reproductive and developmental effects

No data were found.

### 3.4 Mutagenic and genotoxic effects

No data were found.

### 3.5 Carcinogenic effects

No data were found.

## 4 Toxicity, animal data

### 4.1 Short term toxicity

#### *Inhalation*

The LC<sub>50</sub>-value for mice is greater than 7700 mg/m<sup>3</sup> (BASF 1967 - quoted from IUCLID 1996).

When rats were exposed to a saturated atmosphere (about 1400 mg/m<sup>3</sup>) of 2-ethylhexyl acrylate for 8 hours no mortality occurred (BASF 1958 - quoted from IUCLID 1996).

Alderley Park rats (2 animals of each sex per group) were exposed to 2-ethylhexyl acrylate in ethanol at 375 and 1000 mg/m<sup>3</sup> 6 hours a day, 5 days per week for 2½ week. A reduced body weight gain, lethargy, and dyspnoea were observed in high-dose animals. No changes in blood, urine and pathology were observed. Low-dose animals showed no toxic signs. (Gage 1970 - quoted from IUCLID 1996).

#### *Oral administration*

The reported oral LD<sub>50</sub>-values for 2-ethylhexyl acrylate ranged from 4.4 to 12.8 g/kg for rats (5 values reported), and from 4.4 to greater than 5.0 g/kg for mice (2 values reported). Rabbits have an oral LD<sub>50</sub>-value greater than 3.5 g/kg and the value for cats is greater than 1.8 g/kg (1 value reported for each species). (Studies quoted in IUCLID 1996, Clayton & Clayton 1994, DPIMR 1981, BUA 1994).

Rabbits (1 animal per sex) were fed 2-ethylhexyl acrylate as a 10% emulsion through a tube at a dose of 1774 mg/kg for 6 days (male) or 8 days (female). Four female rabbits were fed a dose of 887 mg/kg for 10 days. The high-dose animals died after 6 or 8 days. A reduced body weight gain, lack of desire to eat, and weak muscle tonus were observed and the gastric mucosa and kidneys were damaged. Low-dose animals only showed momentary lack of desire to eat and a slightly reduced body weight gain. (BASF 1960 - quoted from BUA 1994).

#### *Dermal contact*

The dermal LD<sub>50</sub>-value for rats is greater than 12 g/kg (1 value reported). For rabbits the value is between 7.5 and 16 g/kg (8 values reported), and for the guinea pig it is greater than 8.8 g/kg (2 values reported). (Studies quoted in IUCLID 1996, Clayton and Clayton 1994, DPIMR 1981, BUA 1994).

#### *Skin sensitisation*

Female Dunkin Hartley outbred guinea pigs were induced with intradermal injections of 2-ethylhexyl acrylate in concentrations of 0.5 M or 0.17 M in Freund's complete adjuvant three times during 9 days. Sensitisation was observed when the animals were challenged at day 21, 35 and 49 with 1 M 2-ethylhexyl acrylate applied epicutaneously. At an induction concentration of 0.5 M 6-11 out of 16 animals were sensitised. At an induction concentration of 0.17 M 11-13 out of 16 animals were sensitised. Four control animals were sensitised (3 at day 35 and 1 at day 49). Cross reaction was seen with ethyl acrylate, n-butyl acrylate and hexyl acrylate. (Waegemaekers & van der Walle 1983).

Guinea pigs were induced with 0.1% (w/v) 2-ethylhexyl acrylate applied epicutaneous or intracutaneous 3 times a week for 3 weeks. Sensitisation was observed when the animals were challenged at day 11 after the induction with the same concentration of 2-ethylhexyl acrylate as used for the induction. For the epicutaneous test, 10 out of 10 animals were sensitised. For the intracutaneous test, 7 out of 10 animals were sensitised. (Hunter et al. 1966 - quoted from Nordisk Ministerråd 1991).

In the Polak method, 6 Hartley outbred guinea pigs of either sex were induced with 1 mg 2-ethylhexyl acrylate in Freund's complete adjuvant applied as injections in the footpads and the neck. Sensitisation was observed when the animals were challenged at day 7 after the induction with 1% or 5% 2-ethylhexyl acrylate. (Parker & Turk 1983).

#### *Eye contact*

2-Ethylhexyl acrylate was non-irritating to rabbit eyes in a study done by the Swedish military in accordance to OECD Guidelines 405 (Koch et al. 1985 - quoted from Toxline pre 1981-1999).

2-Ethylhexyl acrylate was irritating to rabbit eyes in a study done by BASF (BASF - quoted from IUCLID 1996).

## **4.2 Long term toxicity**

#### *Inhalation*

Wistar rats (10 animals of each sex per group) were whole-body exposed (OECD-guideline 413) to 2-ethylhexyl acrylate vapours at 75, 225 and 750 mg/m<sup>3</sup> 6 hours a day, 5 days per week for 90 days. No animals died in any dose-group. In mid and high-dose animals, a reduced body weight gain, lethargy and reduced levels for albumin were observed; the olfactory epithelium of the nasal mucosa was degenerated; and female rats had reduced levels of total protein and glucose. Besides high-dose female rats had a higher level than normal of liver enzymes. Low-dose animals showed no toxic signs. (BASF 1989 - quoted from IUCLID 1996 and BUA 1994).

Mice were exposed to 2-ethylhexyl acrylate at 103 mg/m<sup>3</sup> for 4.5 months. Exposure time and interval is not stated in this Russian study. Respiratory tract irritation, dyspnoea, increased level of liver enzymes and reduced diuresis were observed. The study states a limit value of 10 mg/m<sup>3</sup> for inhalation and a limit value of 46 mg/m<sup>3</sup> for the effect on CNS. (Lomonova 1982 - quoted from IUCLID 1996).

#### *Oral administration*

No data were found.

#### *Dermal contact*

There was an apparent increase in the frequency of chronic nephritis in C3H/HeJ mice (68%) treated three times a week for their lifetime with 20 mg 75% (v/v) 2-ethylhexyl acrylate in acetone applied to clipped dorsal skin compared to the negative control (15%). Survival was not affected by the treatment with 2-ethylhexyl acrylate. (DePass et al. 1985).

100 µl of 86.5% 2-ethylhexyl acrylate in acetone applied 3 or 5 times a week for 16 or 68 days to female NMRI mice caused no skin changes in the short term experiment but skin irritation in the 68 day experiment. (BASF 1981 - quoted from IUCLID 1996).

Male NMRI and C3H/HeJ mice (10 animals per group) exposed to doses of 25 µl 21% or 86.5% 2-ethylhexyl acrylate in acetone 3 times a week for 3 months exhibited skin irritation. The NMRI mice were less sensitive than the C3H/HeJ mice. No skin irritation were observed for the NMRI mice given 21% 2-ethylhexyl acrylate. (BASF 1985 - quoted from IUCLID 1996).

In long term (2 years or for life) carcinogenicity studies with 2-ethylhexyl acrylate applied to NMRI or C3H/HeJ mice (80 animals per group) 3 times a week, skin irritation (scaling, scabbing, hyperkeratosis, hyperplasia, crust formation and ulceration) was observed. Survival were not affected by the treatment with 2-ethylhexyl acrylate and no systemic effects were seen. (Mellert et al. 1994, Wenzel-Hartung et al. 1989). The lowest dose administered to the C3H/HeJ mice was 25 µl of a 2.5% (w/w) solution of 2-ethylhexyl acrylate in acetone. Skin irritation was observed at this dose, however, after the 11<sup>th</sup> week of treatment, these lesions were reversible. One group of C3H/HeJ mice was treated with a 43% solution for 24 weeks and thereafter observed for lifetime. Skin lesions were reversible in the 43% group immediately after treatment was stopped. For the higher doses (21% and 86.5%) further skin lesions developed. (Wenzel-Hartung et al. 1989).

Male and female New Zealand white rabbits (2 or 1 animals of each sex) exposed to 1 ml per day of 2-ethylhexyl acrylate for 3 or 12 days developed skin inflammation. After 12 days necroses and ulcerations were also observed. (Hunter et al. 1981 - quoted from IUCLID 1996).

Male and female guinea pigs (5 animals of each sex) exposed to 0.5 ml per day of 2-ethylhexyl acrylate for 12 days developed skin inflammation, necroses and ulcerations. The lesions were worse than the lesions seen in rabbits exposed to the double dose of 2-ethylhexyl acrylate. (Hunter et al. 1981 - quoted from IUCLID 1996).

### **4.3 Reproductive and developmental effects**

2-Ethylhexanol is a metabolite of 2-ethylhexyl acrylate. 2-Ethylhexanol in high doses (above 800 mg/kg b.w.) has caused developmental effects in rats. (Ritter et al. 1987).

### **4.4 Mutagenic and genotoxic effects**

2-Ethylhexyl acrylate was not mutagenic in 4 strains (TA98, TA100, TA1535, and TA1537) of *Salmonella typhimurium* in an Ames test with or without metabolic activation systems (Zeiger et al. 1985).

2-Ethylhexyl acrylate tested in cultured L5178Y mouse lymphoma cells without exogenous activation produced an equivocal result for an increased mutant frequency as well as for induced aberrations. No increase in the number of micronuclei was seen. (Dearfield et al. 1989).

In another experiment the mutation frequency was up to 4.6 times greater than in controls for the highest dose levels of 2-ethylhexyl acrylate added to cultured L5178Y mouse lymphoma cells with metabolic activation. No reproducible increase in mutation frequency was seen without the metabolic activation. (Litton Bionetics 1984 - quoted from HSDB 1999).

2-Ethylhexyl acrylate did not induce a dose-related increase in the hprt mutant frequency in either the suspension or monolayer assay in Chinese hamster ovary cells (Moore et al. 1991).

A cell transformation assay in C3H-10T1/2 cells tested negative with 2-ethylhexyl acrylate (BASF 1982 - quoted from IUCLID 1996).

The sister chromatid exchange assay in CHO cells with and without metabolic activation was slightly positive when tested with 2-ethylhexyl acrylate with metabolic activation (ambiguous result) (BASF 1980 - quoted from IUCLID 1996).

Unscheduled DNA synthesis in primary rat hepatocytes was slightly increased when tested with 2-ethylhexyl acrylate (ambiguous result) (BASF 1980 - quoted from IUCLID 1996).

No chromosome aberrations were observed when mice were given an oral dose of 2.5 g/kg once a day for 1 or 5 days in an *in vivo* cytogenetic assay (BASF- quoted in IUCLID 1996).

#### **4.5 Carcinogenic effects**

In a 2-year carcinogenicity study 25 µl of a 21.5, 43 or 85% (w/w) solution of 2-ethylhexyl acrylate in acetone was applied epicutaneously to the clipped dorsal skin of male NMRI mice (80 per group) three times a week. After about 7 months half of each group was rested for treatment for 2 months and then treated with a promoter for 20 weeks. None of the mice treated with 2-ethylhexyl acrylate alone developed a skin tumour at the application site. One squamous cell papilloma occurred in each of the groups treated with 2-ethylhexyl acrylate and the promoter. Squamous cell carcinomas were observed only in the positive control groups (exposed to 0.015 % benzo[a]pyrene alone or in combination with promoter). (Mellert et al. 1994).

In a lifetime carcinogenicity study 25 µl of a 2.5, 21 or 86.5% (w/w) solution of 2-ethylhexyl acrylate in acetone was applied epicutaneously to the clipped dorsal skin of male C3H/HeJ mice (80 per group) three times a week. Another group was treated with a 43% solution for 24 weeks and thereafter observed for lifetime. Only in the 86.5% and 21% test groups showing chronic irritative skin damage there was a high incidence of neoplastic skin lesions (total of 15 papillomas, 36 carcinomas, and 16 melanomas) with no dose dependency. In contrast, no skin tumours were found in the negative control groups, in the group treated with 2.5% 2-ethylhexyl acrylate for lifetime or in the group treated with 43% 2-ethylhexyl acrylate for about 6 months and then observed for lifetime. (Wenzel-Hartung et al. 1989).

In a lifetime carcinogenicity study 20 mg of a 75% (v/v) solution of 2-ethylhexyl acrylate in acetone was applied epicutaneously to the clipped dorsal skin of 40 male C3H/HeJ mice three times a week. The concentration was chosen as the highest concentration that caused neither grossly observable irritation nor reduced weight gain in a preliminary 2-week study. Two animals had squamous cell carcinomas and four additional animals had squamous cell papillomas all on the treated skin. (DePass et al. 1985).

## 5 Regulations, limit values

<i>Ambient air</i>	Denmark (C-value): -
<i>Drinking water</i>	Denmark: -
<i>Soil</i>	-
<i>OELs</i>	Denmark: -
<i>Classification</i>	2-Ethylhexyl acrylate is classified for irritative effects (Xi;R37/38 - irritating to respiratory system and skin) and for sensitising effects (R43 - may cause sensitisation by skin contact) (MM 1997).
<i>EU</i>	-
<i>IARC/WHO</i>	Ethylhexyl acrylate is not classifiable as to its carcinogenicity to humans (Group 3) (IARC 1994).
<i>US-EPA</i>	-
<i>RD<sub>50</sub></i>	-



## 6 Summary

### *Description*

2-Ethylhexyl acrylate is a colourless liquid with a sharp, musty odour. Its solubility in water is low (0.1g/l). Its vapour pressure is 0.14 mmHg. The odour threshold in air is 0.55-1.36 mg/m<sup>3</sup>.

In Denmark, the principal use of 2-ethylhexyl acrylate is in UV curable inks, lacquers and varnishes.

### *Environment*

2-Ethylhexyl acrylate is not known to occur as a natural compound. It may be released into the environment in fugitive and stack emissions or in wastewater during its production and use.

If released to the atmosphere, 2-ethylhexyl acrylate will react with photochemically produced hydroxyl radicals and ozone with an estimated half-life of 10.3 hours. It may also photolyse in sunlight.

If released to soil and water, 2-ethylhexyl acrylate may biodegrade and it may hydrolyse, especially in an alkaline environment. 2-Ethylhexyl acrylate is not expected to adsorb to sediment or suspended particulate matter in water. It is expected to exhibit moderate mobility in soil. 2-Ethylhexyl acrylate will significantly volatilise from water and near surface soil with an estimated half-life of between 7.3 hours and 2.7 days.

### *Human exposure*

The most probable route of human exposure of 2-ethylhexyl acrylate is by inhalation of contaminated air especially at plants where it is manufactured and used.

### *Toxicokinetics*

In the rat 2-ethylhexyl acrylate is readily absorbed through the gastrointestinal tract and after intraperitoneal application. The plasma radioactivity concentration peaked at 2-3 hours. Following absorption 2-ethylhexyl acrylate is distributed to various organs with the highest concentration occurring in the liver and kidney. 2-Ethylhexyl acrylate is rapidly metabolised and excreted. At high doses (100 mg/kg bw) the decline in concentration in the tissues was slower with levels remaining almost constant for 72 hours in adipose tissue. 2-Ethylhexyl acrylate is believed to undergo carboxylesterase-catalysed hydrolysis to alcohol and acrylic acid, like other acrylate esters. 2-Ethylhexyl acrylate to a minor extent reacts with non-protein SH groups resulting in thioethers and mercapturic acids being excreted in the urine and/or bile. The major route of excretion is the lungs (50-75%) followed by urine (7-41%) and faeces (0.01-3%). The metabolite in the lungs is CO<sub>2</sub>.

### *Human toxicity*

Seven cases of allergic contact dermatitis due to an acrylic based adhesive tape have been reported. Patch-testing revealed that all persons reacted to 2-ethylhexyl acrylate. No cases have been reported of respiratory sensitisation. In Finland 5 people have got contact urticaria due to 2-ethylhexyl acrylate.

### *Animal toxicity*

Single peroral, dermal or inhalatory administration of 2-ethylhexyl acrylate each proved to be only slightly toxic (LC<sub>50</sub>-value for mice is greater than 7700 mg/m<sup>3</sup>; oral LD<sub>50</sub>-values ranged from 1.8 to 12.8 g/kg

for different species; and dermal LD<sub>50</sub>-values ranged from 7.5 to 16 g/kg for different species).

When rats were inhaling about 1400 mg/m<sup>3</sup> of 2-ethylhexyl acrylate for 8 hours no mortality occurred.

A reduced body weight gain, lethargy, and dyspnoea were observed in Alderley Park rats inhaling 2-ethylhexyl acrylate at 1000 mg/m<sup>3</sup> 6 hours a day, 5 days per week for 2½ week. Animals inhaling 375 mg/m<sup>3</sup> for the same exposure period showed no toxic signs.

Skin sensitisation was observed in challenged guinea pigs that had been induced with intradermal injections of 2-ethylhexyl acrylate in concentrations of 0.5 M or 0.17 M in Freund's complete adjuvant three times during 9 days; that had been induced with epicutaneous or intracutaneous application of 2-ethylhexyl acrylate in concentrations of 0.1% (w/v) 3 times a week for 3 weeks; or that in the Polak method had been induced with 1 mg 2-ethylhexyl acrylate in Freund's complete adjuvant applied as injections in the footpads and the neck.

Repeated application to the skin of mice, rabbits and guinea pigs caused skin irritation and subsequent degeneration of the treated areas. C3H mice were more sensitive than NMRI mice. In a lifetime study with 2-ethylhexyl acrylate applied to mice 3 times a week skin irritation was seen. The lowest dose administered was 25 µl of a 2.5% (w/w) solution of 2-ethylhexyl acrylate in acetone. Skin irritation was observed at this dose, however, after the 11<sup>th</sup> week of treatment, these lesions were reversible. For the higher doses (21% and 86.5%) further skin lesions developed.

In one study 2-ethylhexyl acrylate was irritant to the rabbit eye but in another one it was non-irritating.

The olfactory epithelium of the nasal mucosa was degenerated when Wistar rats inhaled 2-ethylhexyl acrylate at 225 and 750 mg/m<sup>3</sup> 6 hours a day, 5 days per week for 90 days. A reduced body weight gain, lethargy and reduced levels for albumin were also observed at these doses. Animals inhaling 75 mg/m<sup>3</sup> for the same exposure period showed no toxic signs.

An apparent increase in the frequency of chronic nephritis was seen in male C3H/HeJ mice treated three times a week for their lifetime with 20 mg 75% (v/v) 2-ethylhexyl acrylate in acetone applied to clipped dorsal skin.

#### *Reproductive and developmental effects*

2-Ethylhexanol is a metabolite of 2-ethylhexyl acrylate. 2-Ethylhexanol in high doses has caused developmental effects in rodents.

#### *Mutagenic and genotoxic effects*

2-Ethylhexyl acrylate was negative in Ames test with and without metabolic activation, in assays in Chinese hamster ovary cells and in a cell transformation assay in C3H-10T1/2 cells. In various *in vitro* studies in cultured L5178Y mouse lymphoma cells, CHO cells and primary rat hepatocytes, 2-ethylhexyl acrylate produced an equivocal result. An *in vivo* cytogenetic assay in mice was negative.

### *Carcinogenicity*

In two dermal carcinogenicity studies performed on C3H/HeJ mice for 2 years or the duration of their natural lives, 2-ethylhexyl acrylate proved to be locally tumourigenic at doses above 21% 2-ethylhexyl acrylate in acetone applied epicutaneously 3 times a week. Skin irritation was seen at the site of application. When the treatment in one group was discontinued after 6 months and observations were kept up for as long as these animals lived, the local skin damage receded almost completely and no skin tumours were observed. In a group receiving 2.5 % 2-ethylhexyl acrylate, skin lesions were reversible after the 11<sup>th</sup> week of treatment and no tumours developed in this group. NMRI mice did not develop skin tumours in a 2-year study equivalent to the study in C3H/HeJ mice.

## 7 Evaluation

The critical effects in humans following exposure to 2-ethylhexyl acrylate are considered to be the skin sensitising and irritative/damaging effects on respiratory tract, skin and eyes. This is based on the following:

In humans, the available data on health effects are limited to seven cases of allergic contact dermatitis after exposure to 2-ethylhexyl acrylate and to some cases of contact urticaria. No cases have been reported of respiratory sensitisation.

In laboratory animals, the main effects observed is skin sensitisation, irritation in the respiratory tract, skin and eye and carcinogenicity.

Long term (90 days) inhalation of 2-ethylhexyl acrylate (225 and 750 mg/m<sup>3</sup>) by Wistar rats degenerated the olfactory epithelium of the nasal mucosa, reduced body weight gain, caused lethargy and induced changes in some biochemical substances. Skin sensitisation and irritation has been observed in several animal experiments as described earlier in this paper. Those concentrations administered in long-term animal trials which no longer led to any local irritative effects were around 2.5% for dermal application and 75 mg/m<sup>3</sup> for inhalation. The two references to eye irritating properties is not mentioning the doses causing the effect/lack of effect on the eye. The different results are therefore likely to be a result of different doses. Since 2-ethylhexyl acrylate is irritating to the skin, it is most likely that it is also irritating to the eye in high enough doses or concentrations.

The carcinogenic effect of 2-ethylhexyl acrylate is considered to be related to its skin irritating effect and not to a genotoxic mechanism. This is based on that 2-ethylhexyl acrylate is negative or has showed equivocal results in different *in vitro* mutagenic assays and no chromosome aberrations were observed in mice in an *in vivo* cytogenetic assay. 2-Ethylhexyl acrylate is not carcinogenic in NMRI mice and the carcinogenic activity of 2-ethylhexyl acrylate in the skin of male C3H/HeJ mice could be detected only in association with a chronic skin irritation. As long as human dermal exposure remains far below levels causing skin irritation or does not persist chronically it is very unlikely that tumours will develop.

With the available studies, a NOAEL cannot be set for skin sensitisation. However, a subchronic inhalation study of good quality exist. This study will be used as the basis for estimating a limit value in air. A level of 75 mg/m<sup>3</sup> is considered as a NOAEL for degeneration of the olfactory epithelium in rats inhaling 2-ethylhexyl acrylate for 6 hours a day, 5 days a week for 90 days.

## 8 Limit value in air

The limit value is calculated based on a NOAEL of 75 mg/m<sup>3</sup> for degeneration of the olfactory epithelium in rats inhaling 2-ethylhexyl acrylate 6 hours a day, 5 days a week for 90 days.

$$LV_{\text{air}} = \frac{\text{NOAEL}}{SF_{\text{I}} \times SF_{\text{II}} \times SF_{\text{III}}} = \frac{75 \times 6/24 \times 5/7 \text{ mg/m}^3}{10 \times 10 \times 10} = 0.01 \text{ mg/ m}^3$$

The safety factor SF<sub>I</sub> is set to 10 assuming that humans are more sensitive than animals. The SF<sub>II</sub> is set to 10 to protect the most sensitive individuals in the population. The SF<sub>III</sub> is set to 10 because: a) the study on which the NOAEL is based is not a chronic study and concern for the development of cancer in the respiratory system exist; b) no data on reproductive toxicity are available; c) 2-ethylhexyl acrylate is known to cause skin sensitisation and can therefore possibly cause respiratory sensitisation as well.

## 9 C-value

A limit value of  $0.01 \text{ mg/m}^3$  has been calculated. For substances having acute or subchronic effects, but for which activity over a certain period of time is necessary before the harmful effect occurs, the C-value is set at the limit value (MST 1990). A C-value of  $0.01 \text{ mg/m}^3$  and placing in Main Group 2, is proposed.

2-Ethylhexyl acrylate has a low odour threshold in air ( $0.55\text{-}1.36 \text{ mg/m}^3$ ). However, the proposed limit value of  $0.01 \text{ mg/m}^3$  is considered to take into account the discomfort from odour.

*C-value*

$0.01 \text{ mg/m}^3$ , Main Group 2.

## 10 References

- AMI (1990). Allergi- og overfølsomhedsfremkaldende stoffer i arbejdsmiljøet. AMI-rapport 33.
- BUA (1994). 2-Ethylhexyl acrylate (December 1991). Beatergremium für umweltrelevante Alstoffe (BUA) 88, Gesellschaft Deutscher Chemiker, p. 1-55.
- Cikrt M, Vodicka P, Sapota A, Gut I, Stiborová A and Kopecký J (1986). Biliary excretion and organ distribution of  $^{14}\text{C}$  radioactivity after  $^{14}\text{C}$ -2-ethylhexyl acrylate administration in rats. *J Hyg Epidemiol Microbiol Immunol* **30**, 365-370.
- Clayton GD and Clayton FE (1994). Acrylates. In: Patty's Industrial Hygiene and Toxicology, 4<sup>th</sup> ed. New York, John Wiley Sons, vol. 2D, 2999-3007.
- DPIMR (1981). 2-Ethylhexyl acrylate. In: Dangerous Properties of Industrial Materials Report, vol. 1, 57-59.
- Dearfield KL, Millis CS, Harrington-Brock K, Doerr CL and Moore MM (1989). Analysis of the genotoxicity of nine acrylate/methacrylate compounds in L5178Y mouse lymphoma cells. *Mutagenesis* **4**, 381-393.
- DePass LR, Maronpot RR and Weil CS (1985). Dermal oncogenicity bioassays of monofunctional and multifunctional acrylates and acrylate-based oligomers. *J Toxicol Environ Health* **16**, 55-60.
- Gut I, Vodicka P, Cikrt M, Sapota A and Kavan I (1988). Distribution and elimination of ( $^{14}\text{C}$ )-2-ethylhexyl acrylate radioactivity in rats. *Arch Toxicol* **62**, 346-350.
- HSDB (1999). 2-Ethylhexyl acrylate. In: Hazardous Substances Data Base.
- IARC (1994). 2-Ethylhexyl acrylate. In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, vol. 60, 475-487.
- ICSC (1993). 2-Ethylhexyl acrylate. In: International Chemical Safety cards (WHO/IPCS/ILO), ICSC number: 0478, <http://www.cdc.gov/niosh/ipcneng/neng0478.html>.
- IUCLID (1996). 2-Ethylhexyl acrylate. In: International Uniform Chemical Information Database. Existing Chemicals 1996. ECB, JRC, Ispra.
- Jordan WP (1975). Cross-sensitization patterns in acrylate allergies. *Cont Derm* **1**, 13-15.

- Mellert W, Kühborth B, Gemhardt C and Munk R (1994). 2-year carcinogenicity study in the male NMRI mouse with 2-ethylhexyl acrylate by epicutaneous administration. *Fd Chem Toxic* **32**, 233-237.
- MM (1997). The Statutory Order from the Ministry of the Environment no. 829 of November 6, 1997, on the List of Chemical Substances.
- Moore MM, Parker L, Huston J, Harrington-Brock K and Dearfield KL (1991). Comparison of mutagenicity results for nine compounds evaluated at the hprt locus in the standard and suspension CHO assays. *Mutagenesis* **6**, 77-85.
- Nordisk Ministerråd (1991). Review over 2-ethylhexylacrylate's (EHA) allergene effekter. In: Kriteriedokumenter fra et nordisk allergiprojekt 51, 135-137.
- Parker D and Turk JL (1983). Contact sensitivity to acrylate compounds in guinea pigs. *Cont Derm* **9**, 55-60.
- Ritter EJ, Scott WJ, Randall JL and Ritter JM (1987). Teratogenicity of di(2-ethylhexyl)phthalate, 2-ethylhexanol, 2-ethylhexanoic acid, and valproic acid, and potentiation by caffeine. *Teratology* **35**, 41-46.
- RTECS (1999). Acrylic acid, 2-ethylhexyl ester. In: Registry of Toxic Effects of Chemical Substances.
- Ruth JH (1986). Odor thresholds and irritation levels of several chemical substances: a review. *Am Ind Hyg Assoc J* **47**, A142-A151.
- Samimi B and Falbo L (1982). Monitoring of workers exposure to low levels of airborne monomers in a polystyrene production plant. *Am Ind Hyg Assoc J* **43**, 858-862.
- Sapota A (1988). The disposition of [2,3-<sup>14</sup>C]-methyl and [2,3-<sup>14</sup>C]-2-ethylhexyl acrylate in male Wistar albino rats. *Arch Toxicol* **62**, 181-184.
- Toxline (pre 1981-1999). 2-Ethylhexyl acrylate. In: Toxline database.
- Vodicka P, Gut I and Frantík E (1990). Effects of inhaled acrylic acid derivatives in rats. *Toxicology* **65**, 209-221.
- Waegemaekers TH and van der Walle HB (1983). The sensitizing potential of 2-ethylhexyl acrylate in the guinea pig. *Cont Derm* **9**, 372-376.
- Wenzel-Hartung RP, Brune H and Klimisch HJ (1989). Dermal oncogenicity study of 2-ethylhexyl acrylate by epicutaneous application in male C3H/HeJ mice. *J Cancer Res Clin Oncol* **115**, 543-549.
- Zeiger E, Haworth S, Mortelmans K and Speck W (1985). Mutagenicity testing of di(2-ethylhexyl)phthalate and related chemicals in Salmonella. *Environ Mutag* **7**, 213-232.





**Evaluation of health hazards  
by exposure to**

***Propylene carbonate***

**and estimation of a limit value in air.**

**Vibe Beltoft  
Elsa Nielsen**


**The Institute of Food Safety and Toxicology  
Danish Veterinary and Food Administration**

# 1 General description

## 1.1 Identity

Molecular formula:  $C_4H_6O_3$

Structural formula:



Molecular weight: 102.09

CAS-no.: 108-32-7

Synonyms: 4-methyl-1,3-dioxolan-2-one; dipropylene carbonate; 1,2-propanediolcarbonate; 1,2-PDC; cyclic methylethylene carbonate; cyclic propylene carbonate; cyclic 1,2-propylene carbonate; 1,2-propylene carbonate; propylene glycol cyclic carbonate; 4-methyl-2-oxo-1,3-dioxolane; carbonic acid, cyclic propylene ester.

## 1.2 Physical / chemical properties

Description: Propylene carbonate is a colourless and odourless non-viscous liquid.

Purity: -

Melting point: -48.8 - -49.2 °C

Boiling point: 241.7 - 243.4 °C

Density: 1.189; 1.2069 g/ml (at 20°C)

Vapour pressure: 0.03 mmHg (4 Pa) at 20°C

Concentration of saturated vapours: 40 ppm (165 mg/m<sup>3</sup>) (calculated)

Vapour density: -

Conversion factor: 1 ppm = 4.17 mg/m<sup>3</sup> 20°C  
1 mg/m<sup>3</sup> = 0.236 ppm 1 atm

Flash point: 135°C (open cup); 130-132°C

Flammable limits: -

Autoignition temp.: 510°C

Solubility:	Water: 83 g/l (at 20°C). Soluble in alcohol, ether, acetone, benzene, chloroform, ethyl acetate, carbon tetrachloride.
logP <sub>octanol/water</sub> :	-
Henry's constant:	-
pK <sub>a</sub> -value:	-
Stability:	-
Incompatibilities:	Incompatible with strong oxidising agents, acid, bases, and reducing agents.
Odour threshold, air:	-
References:	CIR (1987), EPA (1998), HSDB (1998).

### 1.3 Production and use

Propylene carbonate is produced through the thermal cracking of saturated hydrocarbons. It can also be produced by the reaction of propylene oxide with carbon dioxide over a tetraethyl/ammonium bromide catalyst. (EPA 1998).

Propylene carbonate is used in CO<sub>2</sub> recovery, in lithium batteries, in solvent extraction, plasticiser, organic synthesis, natural gas purification, synthetic fibre spinning solvent, and for the detection of N-containing drugs and their salts. (HSDB 1998).

Propylene carbonate is also used in painting and paint-stripping, to extraction of metals, and as a component of cooling agents and brake fluids. (EPA 1998).

It is also used in cosmetic products as a polar solvent at concentrations ranging from ≤ 0.1 to 5%. In some products, up to 20% is used. (CIR 1987).

### 1.4 Environmental occurrence

No data were found.

### 1.5 Environmental fate

*Air*

No data were found.

*Water*

Propylene carbonate may decompose in aqueous solutions with the transient formation of propylene oxide. Based on the available physical and chemical properties, evaporation from water would be slow. (EPA 1998).

*Soil*

Leaching to water may occur, however, no data were available on soil to air or water to air mobility. Based on the available physical and chemical properties, evaporation from soil would be slow. (EPA 1998).

*Bioaccumulation*

No data were found.

**1.6 Human exposure**

Humans are exposed to propylene carbonate as cosmetic ingredient (up to 5%), and during work as a e.g. paint-stripping agent. (CIR 1987, EPA 1998).

## 2 Toxicokinetics

### 2.1 Absorption, distribution

*Inhalation*

No data were found

*Oral intake*

No data were found

*Dermal contact*

A procedure to measure the steady-state rate of permeation of commercial solvents through living human skin was used on human female skin. The skin was removed from healthy females during plastic surgery of the breast. The samples were thinned by removing the dermal tissue from the epidermis and then stretched to a thickness of 300 to 600  $\mu\text{m}$ . The permeability rate of propylene carbonate was reported to be  $0.7 \text{ g/m}^2\text{hour}$  compared to a permeability rate for water of  $24 \text{ g/m}^2\text{h}$  indicating that propylene carbonate is not readily absorbed through the skin. (Ursin et al. 1995 - quoted from EPA 1998).

### 2.2 Elimination

No data were found.

### 2.3 Toxicological mechanisms

No data were found.

## 3 Human toxicity

### 3.1 Short term toxicity

No data on short term toxicity are available except for studies on irritative effects.

In clinical studies, subjects were exposed to a wide range of cosmetic products containing from 0.5 to 10% propylene carbonate. In most of the studies, no skin irritation or sensitisation was noted. However, in one study (Hill Top Research 1977 - quoted from CIR 1987) of an antiperspirant (containing 2% propylene carbonate) using a modified Draize procedure, four subjects out of 51 developed skin erythema on intact sites and another four subjects developed erythema on abraded sites during the induction phase. In one study, moderate skin irritation was reported in subjects exposed to 20% solution of propylene carbonate. Occasionally other symptoms, e.g. hyperpigmentation, dryness, oedema and vesicles of the skin have been reported. (CIR 1987).

When five subjects were exposed to undiluted propylene carbonate applied to scarified skin once daily for three days, moderate skin irritation was observed; no evidence of phototoxicity was noted (CIR 1987).

### 3.2 Long term toxicity

No data were found.

### 3.3 Reproductive and developmental effects

No data were found.

### 3.4 Mutagenic and genotoxic effects

No data were found.

### 3.5 Carcinogenic effects

No data were found.

## 4 Toxicity, animal data

### 4.1 Short term toxicity

#### *Inhalation*

“Concentrated vapours” (concentration not stated) for 8 hours was not lethal to six rats during a 14 days observation period. (Smyth et al. 1954 - quoted from CIR 1987).

Dogs, guinea pigs, and rats were exposed to an aerosol of propylene carbonate at a concentration of 2800 mg/m<sup>3</sup> 6 hours/day for 5 days/week for 21 days. The rats developed rhinorrhea and diarrhoea; no other toxicological effects were reported. (Jefferson Chemical Company, Inc. - quoted from CIR 1987).

#### *Oral administration*

Propylene carbonate was given by oral intubation in logarithmic doses to groups of five rats. Animals were observed for 14 days following the single oral dose. The LD<sub>50</sub>-value was reported to be 29.1 g/kg. (CIR 1987).

In mice, the oral LD<sub>50</sub>-value was reported to be 20.7 g/kg; no other data was reported (Jefferson Chemical Company, Inc. - quoted from CIR 1987).

Five male and female rats were administered undiluted propylene carbonate at a dose of 5 g/kg by oral gavage. They were observed for 14 days. Salivation was noted immediately after the single dose. No deaths and no lesions were observed at terminal necropsy. (Pharmakon Research International 1985 - quoted from CIR 1987).

#### *Dermal contact irritation*

Undiluted propylene carbonate was applied to the intact and abraded, clipped skin of rabbits (three males and three females). Skin responses were assessed at 24 and 72 hours after treatment. Very slight to well defined erythema and very slight oedema were noted at the 24 hours evaluation. All treated sites were normal at the 72 hours evaluation. The results indicated slight skin irritation. (Pharmakon Research International 1985 - quoted from CIR 1987).

#### *Eye irritation*

Undiluted propylene carbonate (0.1 ml, pH 8.82) was instilled into the right eye of three male and three female albino rabbits. Ocular irritation was reported to be only minimally; five had irritation of the conjunctivae only and one had irritation of the cornea, iris, and conjunctiva. (Pharmakon Research International 1985 - quoted from CIR 1987).

No ocular irritation was noted in six rabbits exposed to 10.5 or 17.5% propylene carbonate. (Kuramoto et al. 1972 - quoted from CIR 1987).

Instillation of 0.5 ml propylene carbonate into the conjunctival sac of the eyes of rabbits produced marked erythema of the conjunctivae, vascularisation of the sclera, and oedema of the lids and nictitating membrane within 24 hours; all eyes appeared normal by the 7<sup>th</sup> day. (Jefferson Chemical Company, Inc. - quoted from CIR 1987).



## 4.2 Long term toxicity

### *Inhalation*

Rats (15/sex/group) were exposed to 100, 500, or 1000 mg/m<sup>3</sup> propylene carbonate as aerosol for 90 days. No significant signs of toxicity were noted, except for some periocular swelling in the high and mid-dose groups. No systemic toxicity was reported.

An additional 20 rats per group were studied to investigate acute and subchronic neurotoxicity. For the acute study, rats received a single 6-hour exposure to propylene carbonate aerosol; no behavioural alterations were noted in any exposure groups at 1 hour and 24 hours after exposure. Standard neurobehavioral tests and motor activity were examined after 6 and 13 weeks; no behavioural alterations were noted in any of these exposure groups.

(Huntsman Corporation - quoted in EPA 1998).

### *Oral administration*

Rats were given 1000, 3000, 5000 mg/kg/day propylene carbonate by gavage for 90 days. A recovery group was followed further from day 90 to day 118. No consistent dose-related findings were reported following necropsy or histopathological examination. (Huntsman Corporation - quoted in EPA 1998).

### *Dermal contact*

To investigate dermal carcinogenicity, 50 µl propylene carbonate was applied twice a week to the shaved backs of 50 male mice for 104 weeks. A total of 10.4 ml was applied to each animal during the study. No deaths were observed, nor were any consistent body weight changes or significant dermal effects noted during the course of the study. (Huntsman Corporation - quoted in EPA 1998).

## 4.3 Reproductive and developmental effects

Twenty-seven dams (Sprague-Dawley rats) per group were orally exposed by gavage to 1000, 3000, and 5000 mg/kg/day propylene carbonate on days 6 through 15 of gestation. No developmental toxicity was observed at any dose. Maternal toxicity (decreased body weight gain and food consumption) was observed in high-dose dams. (Huntsman Corporation - quoted in EPA 1998).

## 4.4 Mutagenic and genotoxic effects

Propylene carbonate was evaluated for mutagenicity in *Salmonella typhimurium*, strains TA1535, TA1537, TA1538, TA98, TA100 with and without metabolic activation by liver homogenate. Doses of 50 to 5000 µg/plate were used. In the case of TA100, propylene carbonate showed some minor activity with and without activation at five doses, however, a dose-response relationship was not observed. (CIR 1987).

Propylene carbonate at five doses up to 4000 µg/plate was negative for genotoxicity in rat hepatocyte primary culture (CIR 1987).

#### 4.5 Carcinogenic effects

To investigate dermal carcinogenicity, 50 µl propylene carbonate was applied twice a week to the shaved backs of 50 male mice for 104 weeks. A total of 10.4 ml was applied to each animal during the study. No tumours were noted during the course of the study. (Huntsman Corporation - quoted in EPA 1998).

## 5 Regulations, limit values

<i>Ambient air</i>	Denmark (C-value): -
<i>Drinking water</i>	Denmark: -
<i>Soil</i>	-
<i>OELs</i>	Denmark: -
<i>Classification</i>	Propylene carbonate is classified for irritative effects (Xi;R36 - irritating to eyes) (MM 1997).
<i>Cosmetics</i>	As propylene carbonate is widely used in cosmetic products at concentrations from $\leq 0.1\%$ to 5%, it was concluded (based on clinical studies and animal studies) by the CIR panel (CIR 1987) that propylene carbonate is safe as a cosmetic ingredient in the present practices of use and concentrations.
<i>EU</i>	-
<i>IARC/WHO</i>	-
<i>US-EPA</i>	-
<i>RD<sub>50</sub></i>	-

## 6 Summary

<i>Description</i>	Propylene carbonate is an odourless, clear liquid with a low vapour pressure (0.03 mmHg) and a high water solubility (83 g/l) at room temperature.
<i>Environment</i>	Only limited data are available. Based on the physical and chemical properties, evaporation from soil to water and air is considered to be slow.
<i>Toxicokinetics</i>	One study has reported that propylene carbonate is not readily absorbed through the skin. No other data have been found.
<i>Human toxicity</i>	No data on systemic toxicity have been found. In clinical studies, a 20% solution of propylene carbonate and undiluted propylene carbonate caused moderate skin irritation, whereas 5 and 10% aqueous solutions produced no skin irritation or sensitisation. However, in one study, subjects (4/51) developed skin erythema on intact sites and other four subjects developed erythema on abraded sites during the induction phase (2% solutions).
<i>Animal toxicity</i>	No deaths were observed in rats exposed to “concentrated vapours” for 8 hours. Dogs, guinea pigs, and rats exposed to propylene carbonate (aerosol) at 2800 mg/m <sup>3</sup> 6 hours/day for 5 days/week for 21 days developed rhinorrhea and diarrhoea; no other toxicological effects were reported. LD <sub>50</sub> -values was reported to be around 29 g/kg for rats and 20 g/kg for mice. Slight skin irritation were indicated in rabbits after undiluted propylene carbonate was applied to the intact skin, whereas marked irritation was observed following instillation in the eyes of rabbits. No systemic effects were observed in rats exposed at concentrations of 100, 500 and 1000 mg/m <sup>3</sup> propylene carbonate (aerosol) for 90 days; however, some periocular swelling was noted at 500 and 1000 mg/m <sup>3</sup> ; thus, a NOAEL of 100 mg/m <sup>3</sup> is considered in this study. Likewise, no effects were seen in rats following oral administration at doses up to 5000 mg/kg/day for 90 days or in mice following dermal application for 104 weeks.
<i>Reproductive and developmental effects</i>	No human data have been found. No developmental toxicity was observed in rats following oral doses of 1000, 3000 and 5000 mg/kg/day during gestation days 6 through 15; maternal toxicity (decreased body weight gain and food consumption) was noted at 5000 mg/kg.
<i>Mutagenic and genotoxic effects</i>	Propylene carbonate was negative when tested in <i>Salmonella typhimurium</i> (strains TA1535, TA1537, TA1538, TA98) with and without metabolic activation whereas strain TA100 showed minor activity although not in a dose related manner. Propylene carbonate was negative in rat hepatocyte primary culture.
<i>Carcinogenicity</i>	No human data have found. In a 2-year dermal mice study, no tumours were observed.

## 7 Evaluation

The available data on health effects of propylene carbonate in humans are limited to data on irritative effects. Following application to the skin of undiluted propylene carbonate (one study) or of a 20% solution (one study), a moderate skin irritation was observed; however, no irritative effects were observed following application of solutions containing up to 10% propylene carbonate. One study using a modified Draize procedure has reported that 4/51 subjects developed skin erythema on intact sites and other four subjects developed erythema on abraded sites during the induction phase (2% propylene carbonate).

Propylene carbonate is of low acute toxicity in experimental animal following a single oral administration; no data have been found for inhalation exposure.

Following repeated inhalation exposure to propylene carbonate as aerosol, no systemic effects were observed following 21 days (dogs, guinea pigs, and rats - 2800 mg/m<sup>3</sup>) or 90 days (rats - up 1000 mg/m<sup>3</sup>); local effects in form of rhinorrhea and diarrhoea (21-day study) and some periocular swelling (90-day study) were reported. Likewise, no effects were seen in rats following oral administration (up to 5000 mg/kg/day) for 90 days or in mice following dermal application for 104 weeks. As diarrhoea was not reported in the oral study, the relevance of this finding is uncertain.

No reproductive toxicity studies have been found. In the only developmental study, no developmental toxicity including teratogenicity was observed in rats even when tested at dose levels giving rise to maternal toxicity.

The mutagenicity and genotoxicity tests available do not indicate that propylene carbonate is a genotoxic substance. No tumours were observed in the dermal carcinogenicity study on mice, the only study available.

The available studies indicate that exposure to propylene carbonate does not result in systemic toxicity even when tested at high dose levels by inhalation or oral administration. Thus, the critical effects following exposure to propylene carbonate are considered to be the local effects observed in the inhalation studies, effects which are probably related to the irritative properties of propylene carbonate. For the estimation of a limit value in air, a NOAEL of 100 mg/m<sup>3</sup> is considered for local effects (periocular swelling) observed in the 90-day rat study.

## 8 Limit value in air

The limit value is calculated based on a NOAEL of 100 mg/m<sup>3</sup> for local effects (periocular swelling) in rats exposed to propylene carbonate for 90 days.

$$\begin{aligned} LV_{\text{air}} &= \frac{\text{NOAEL}}{SF_{\text{I}} \times SF_{\text{II}} \times SF_{\text{III}}} = \frac{100 \text{ mg/m}^3}{10 \times 10 \times 1} \\ &= 1 \text{ mg/m}^3 \end{aligned}$$

The safety factor SF<sub>I</sub> is set to 10 assuming that humans are more sensitive than animals. The SF<sub>II</sub> is set to 10 to protect the most sensitive individuals in the population. The SF<sub>III</sub> is set to 1 because of using a NOAEL for local effects and as no systemic effects have been observed even following administration of high doses.

## 9 C-value

A limit value of 1 mg/m<sup>3</sup> has been calculated. For substances having acute or subchronic effects, but for which activity over a certain period of time is necessary before the harmful effect occurs, the C-value is set at the limit value (MST 1990). A C-value of 1 mg/m<sup>3</sup> and placing in Main Group 2 is proposed.

*C-value*

1 mg/m<sup>3</sup>, Main Group 2.

# 10 References

EPA (1998). Environmental profile for propylene carbonate. EPA/600/R-98/068. National risk management research laboratory office of research and development. U.S. environmental protection agency. Cincinnati.

CIR (1987). Final report on the safety assessment of propylene carbonate (1987). *J Amer Coll Toxicol* **6**, 23-51.

HSDB (1998). Propylene carbonate. In: Hazardous Substances Data Base.

MM (1997). The Statutory Order from the Ministry of the Environment no. 829 of November 6, 1997, on the List of Chemical Substances.

MST (1990). Begrænsning af luftforurening fra virksomheder. Vejledning fra Miljøstyrelsen nr. 6 1990.



**Evaluation of health hazards  
by exposure to**

***Quaternary ammonium  
compounds***

***(Cationic surfactants)***

**and estimation of a limit value in air.**

**Inger Thorup**

**The Institute of Food Safety and Toxicology  
Danish Veterinary and Food Administration**

# 1 General description

## 1.1 Identity


Quaternary ammonium compounds (QACs) are cationic surfactants. They are synthetic organically tetrasubstituted ammonium compounds, where the R substituents are alkyl or heterocyclic radicals. A common characteristic of these synthetic compounds is that they have one long-chain hydrophobic alkyl group. The products used in the technical field are normally not distinct individual compounds, but mixtures of homologues, in which the average chain length and the distribution of chain lengths in the lipophilic parts of the molecules may vary according to the starting materials used. The most well investigated compound is benzalkonium chloride.

In 1988, EPA suggested the QACs clustered into four groups, so that the toxicity studies would be facilitated by selecting one representative from each group for testing (Merianos 1991).

Below is given the structural formula for one representative of each of the four groups:

### Group I: Straight-chain alkyl or hydroxyalkyl QACs


(e.g. CAS no.124-03-8, Hexadecyl ethyl dimethyl ammonium bromide; CAS no. 1119-97-7, Tetradecyl trimethyl ammonium bromide; CAS no. 57-09-0, Hexadecyl trimethyl ammonium bromide; CAS no. 112-03-8, Octadecyl trimethyl ammonium chloride; CAS no. 1120-02-1, Octadecyl trimethyl ammonium bromide); CAS no. 1119-94-4, Dodecyl trimethyl ammonium bromide.)



Hexadecyl trimethyl ammonium bromide (CTAB)


### Group II: Alkyl dimethyl benzyl ammonium compounds

(e.g. CAS no. 139-08-2, Tetradecyl dimethyl benzyl ammonium chloride (Benzalkonium chloride); CAS no. 122-18-9, Hexadecyl dimethyl benzyl ammonium chloride.)




Tetradecyl dimethyl benzyl ammonium chloride (benzalkonium chloride)

Group III: Alkyl [di- and tri- chlorobenzyl] dimethyl ammonium compounds



Tetradecyl dimethyl dichlorobenzyl ammonium chloride

Group IV: Heterocyclic ammonium compounds



1-Hexadecylpyridinium chloride (cetylpyridinium chloride)

## 1.2 Physical / chemical properties

QACs are white, crystalline powders. Low molecular weight QACs are very soluble in water, but slightly or not at all soluble in solvents such as ether, petrol and benzene. As the molecular weight and chain lengths increase, the solubility in polar solvents (e.g. water) decreases and the solubility in non-polar solvents increases.

References: Gloxhuber (1974), Gosselin (1984), Kirk-Othmer (1985), Merianos (1991).

## 1.3 Production and use

QACs are synthesised industrially by alkylation of tertiary amines with alkyl halides or other alkylating species.

QACs are used as antiseptics, bactericides, fungicides, sanitisers, and softeners, but are also used in deodorants and as conditioning agents in hair cosmetics. The compounds are normally applied in concentrations between 0.01 and 1%. Concentrations in the low range are used in pharmaceutical products as topical antiseptics (skin, conjunctivae and mucous membranes). Benzalkonium chloride is a common used preservative in ophthalmic and nasal solutions.

In general, QACs within the field of antiseptics etc. contain alkyl chain lengths in the range C<sub>8</sub> to C<sub>16</sub> as these show good antimicrobial activities. For the use as softeners and hair conditioning agents chain lengths be-

tween C<sub>16</sub> to C<sub>18</sub> are used. The QACs are most effective against micro-organisms at neutral or slightly alkaline pH and become virtually inactive below pH 3.5. They are incompatible with anionic detergents such as soap, and demonstrate a high degree of binding to non-ionic surfactants.

References: Gosselin (1984), Kirk-Othmer (1985), Merianos (1991), MST (1991).

#### 1.4 Environmental occurrence

QACs are synthetic compounds and therefore not naturally occurring substances.

Levels of 1-5 mg QACs/litre in the water influx at sewage plants have been measured in Europe and USA (MST 1991).

#### 1.5 Environmental fate

A major part of the QACs is discharged into wastewater and removed in the biological processes of sewage treatment plant. A 90% reduction of the QACs in the water phase of sludge has been reported and alkyl di-/trimethyl ammonium and alkyl dimethyl benzyl ammonium compounds seem almost completely degraded in sewage sludge.

However, the aerobic and anaerobic biodegradability of QACs is not well investigated. Only sparse data are available concerning stability, solubility and biodegradability. In general, it seems that the biodegradability decreases with increasing numbers of alkyl chains:  $R(\text{CH}_3)_3\text{N}^+ > R_2(\text{CH}_3)_2\text{N}^+ > R_3(\text{CH}_3)\text{N}^+$ . Within each category the biodegradability seems inversely proportional to the alkyl chain length. Heterocyclic QACs are less degradable than the non-cyclic.

Investigations have shown that bioaccumulation of considerable dimensions will probably not take place. (MST 1991).

#### 1.6 Human Exposure

The general population are exposed to QACs directly through their use in disinfectants, hair conditioning agents and fabric softening agents, and indirectly through food stuffs due to the use to clean food contact surfaces.

## 2 Toxicokinetics

### 2.1 Absorption, distribution and elimination

#### *Oral intake*

Rats received orally  $^{14}\text{C}$ -labeled hexadecyl trimethyl ammonium bromide (CTAB, group I). About 80% of the dose of radioactivity was found in the gastrointestinal tract 8 hours after the administration, only small amounts were found in the blood plasma and about 2% of the administered radioactivity was excreted in the bile during the first 12 hours after treatment. The low levels of radioactivity in the plasma and bile, together with the large amount of radioactivity found in the gastrointestinal tract indicated poor intestinal absorption of CTAB. Only small amounts of radioactivity were found in the liver, kidneys, spleen, heart, lung and skeletal muscles. Within three days of ingestion 92% of the radioactivity was excreted via the faeces and 1% via urine. (Isomaa 1975a).

#### *Intraperitoneal application*

Intraperitoneal injections of  $^{14}\text{C}$ -labeled CTAB to bile-duct cannulated rats showed that after 24 hours 36% of the radioactivity was excreted in the bile and 1% in the urine. The study indicated that CTAB was subjected to metabolic transformation, but the metabolites were not identified. (Isomaa 1975a).

After i.p. injections to pregnant rats small amounts of the compound could be detected in placenta and foetus (Anon. 1976).

#### *Dermal, mucosal and eye application*

Benzalkonium chloride was not detected in either venous blood or breast milk from woman using vaginal tampons containing 60 mg benzalkonium chloride (Bleau 1983 - quoted from Anon. 1989).

Following the instillation of a  $\text{C}^{14}$  benzalkonium chloride solution onto the corneal surface of rabbits, radioactivity was detected in the corneal epithelium, endothelium and stroma, and in conjunctivae. No radioactive material was found in the aqueous humour or any other tissues, including the blood (Green 1986 - quoted from Anon. 1989).

Although the absorption of QACs through normal skin probably is of less importance (Cutler & Drobeck 1970, Gosselin 1984), studies with excised guinea pig skin have shown that the permeability constants strongly depends on the exposure time and type of skin (Gloxhuber 1974).

### 2.2 Toxicological mechanisms

The cationic surface active compounds are in general more toxic than the anionic and non-ionic surfactants. The positively-charged cationic portion is the functional part of the molecule and the local irritation effects of QACs appear to result from the quaternary ammonium cation.

Due to their relative ability to solubilise phospholipids and cholesterol in lipid membranes, QACs affect cell permeability which may lead to cell death. Further QACs denature proteins as cationic materials precipitate protein and are accompanied by generalised tissue irritation.

It has been suggested that the shown decrease in acute toxicity of QACs with chain lengths above C<sub>16</sub> is due to decreased water solubility (Cutler & Drobeck 1970, Gloxhuber 1974, Gosselin 1984, Effendy 1995).

In general it appears that QACs with a single long-chain alkyl groups are more toxic and irritating than those with two such substitutions. Only the first mentioned are useful as germicides/detergents (Gosselin 1984).

The straight chain aliphatic QACs have been shown to release histamine from minced guinea pig lung tissue (Cutler & Drobeck 1970). However, studies with benzalkonium chloride have shown that the effect on histamine release depends on the concentration of the solution. When cell suspensions (11% mast cells) from rats were exposed to low concentrations, a decrease in histamine release was seen. When exposed to high concentrations the opposite result was obtained (Anon. 1989).

In addition, QACs may show curare-like properties, a muscular paralysis with no involvement of the central nervous system. This is most often associated with lethal doses (Cutler & Drobeck 1970, Merianos 1991).

## 3 Human toxicity

The toxicity of QACs in general is not well established, although several human fatalities have been ascribed to them. Far from all of the compounds have been put through toxicological investigation and specific investigations are used to characterise the toxicological properties of the QACs. As mentioned before, the QACs has been clustered into four groups (Merianos 1991), so that the toxicity would be facilitated by selecting one member from each group for testing.

The major part of the present data refer to investigation on benzalkonium chloride/alkyl dimethyl benzyl ammonium chloride which belong to group II. In the literature the generic term alkyl dimethyl benzyl ammonium chloride is often used as a general term for benzalkonium chloride.

### 3.1 Short term/single exposure

At least 10 human fatalities (9 adults and one child) implicating QACs are medically recorded as resulting from alkyl dimethyl benzyl ammonium chloride (C<sub>8</sub>-C<sub>18</sub>) solutions of 10 to 15% that were introduced into the victims via oral ingestion, intramuscular, intravenous or intrauterine instillation (Gleason 1969 - quoted from Merianos 1991).

#### *Inhalation*

Five deep breaths of benzalkonium chloride (4 mg/ml in 0.9% sodium chloride, nebulised) caused constrictions of the airways in asthmatic persons. The mechanism of this effect is unclear, but it was not considered by the investigators to be an allergic response. (Miszkiel 1988).

#### *Oral intake*

Ingestion of 100-400 mg/kg b.w. of alkyl dimethyl benzyl ammonium chloride (10-15% solutions) caused rapid death within a few minutes to three hours in five persons. Superficial necrosis of mucous membranes was seen in the upper alimentary tract and erosion, ulceration and petechial haemorrhages were seen throughout the small intestine. Severe changes were seen in the liver, kidneys and heart. Even in the case of prompt death lesions were seen in these organs. In addition glottic and pulmonary oedema was reported. (Cutler & Drobeck 1970, Gosselin 1984).

In humans poisoning paralysis is not a well established phenomenon. However, curare-like paralysis was reported in three persons poisoned with dimethyl benzyl ammonium chloride (benzalkonium chloride). (Gosselin 1984).

#### *Dermal application skin irritation*

From human testing of different QACs the generalised conclusion is obtained that all the compounds investigated to date exhibit similar toxicological properties.

It has been concluded that the maximum concentration that did not produce irritating effect on intact skin is 0.1%. Irritation became manifest in the 1-10% range. Concentrations below 0.1% have caused irritation in persons with contact dermatitis or broken skin. (Anon. 1989, BIBRA 1989, Cutler & Drobeck 1970, Merianos 1991).

### *Sensitisation*

Topical mucosal application of QACs may produce sensitisation. Reports on case stories and patch test have shown that compounds such as benzalkonium chloride (group II), cetalkonium chloride (group II) and cetrimide (group I) may possibly act as sensitisers (Anon. 1989, BIBRA 1989, Cronin 1980, Cutler & Drobeck 1970, Merianos 1991). However, in general it is suggested that QACs have a low potential for sensitising man (Cronin 1980).

In several studies patients from dermatological clinics have been patch tested with 0.1% benzalkonium chloride (according to standard international procedures). It was shown that the compound was able to induce skin sensitisation in about 0.5-5.5 % of the patients. (Camarasa 1979 - quoted from Anon. 1989, Fuchs et al. 1993, Perrenoud et al. 1994, Schnuch et al.1998).

In patch studies carried out in the general population and in healthy volunteers, no sensitivity to 0,1 % benzalkonium chloride was detected (BIBRA 1989, Lovell 1992 – quoted from Anon. 1989).

It is difficult to distinguish between an allergic and an irritative skin reaction due to the inherent skin irritating effect of QACs.

### *Mucous membranes and eye*

A 0.1% benzalkonium chloride instilled into the eye produced burning and stinging reactions. In general, a 0.02% solution seems without irritating effect. A few cases of unpleasant reactions have been reported at this concentration, however only conjunctival redness and not corneal damage has been described. 0.01% did not cause any damage. (BIBRA 1989, Anon. 1989).

Intrauterine instillation of alkyl dimethyl benzyl ammonium chloride in the range of 5-15 mg /kg/b.w. (10-15% solutions) has lead to death (Gosselin 1984).

### *Intramuscular or intravenous administration*

Intramuscular or intravenous administration of 5-15 mg alkyl dimethyl benzyl ammonium chloride /kg/b.w. (10-15% solutions) caused death. In total five deaths are reported due to intramuscular, intravenous or intrauterine administration. Three of the persons who received intravenous injections died within 21-46 hours. Another person survived for 15 days (Gosselin 1984).

## **3.2 Long term/repeated exposure**

### *Inhalation*

A group of 196 farmers (with or without respiratory symptoms) were evaluated for the relationship between exposure to QACs (unspecified, exposure levels not given) and respiratory disorders by testing for lung function and bronchial responsiveness to histamine. After histamine provocation statistically significant associations were found between the prevalence of mild bronchial responsiveness (including asthma-like symptoms) and the use of QACs as disinfectant. The association seems even stronger in people without respiratory symptoms. (Vogelzang et al. 1997).



*Oral intake*

No data have been found.

*Dermal application*

No data have been found.

### **3.3 Reproductive / developmental effects**

No data have been found.

### **3.4 Genotoxic effects**

No data have been found.

### **3.5 Carcinogenic effects**

No data have been found.

## 4 Toxicity, animal data

The toxicological data available for most of the QACs are limited (see 3 - Human toxicity). However, studies have been performed on some of the widely used compounds. The most investigated QACs belong to group II as particularly benzalkonium chlorides have been studied.

### 4.1 Short term/single exposure

The acute toxicity of QACs varies with the compound and, especially, the route of administration. For some substances the LD<sub>50</sub> value is several hundreds times lower by the i.p. or i.v. than the oral route, whereas toxicities between the congeners only differ in the range of two to five times.

At least some QACs are significantly more toxic in 50% dimethyl sulfoxide than in plain water when given orally (Gloxhuber 1974, Merianos 1991, Gosselin 1984).

Probably all common QAC derivatives produce similar toxic reactions, but as tested in laboratory animals the oral mean lethal dose varies with the compound between the approximate limits given below (Merianos 1991, Gosselin 1984).

#### *Inhalation*

Wistar rats were exposed to an alkyl dimethyl ethyl benzyl ammonium compound at a concentration of 5.4 mg/litre (maximum attainable) for one hour. This concentration led to 100% death. (Levenson 1965-quoted from Cutler & Drobeck 1970).

Recently, a whole-body inhalation study on cetylpyridinium chloride has been reported. This is a heterocyclic QAC belonging to group IV. Groups of five rats per sex were exposed to air containing 0, 0.05, 0.07, 0.13 and 0.29 mg cetylpyridinium chloride dust/l for four hours (equal to 50, 70, 130 and 290 mg dust/m<sup>3</sup>). The particle size was less than 5 µm. The LC<sub>50</sub> was 0.09 mg/l (90 mg/m<sup>3</sup>) with upper and lower 95% confidence limits at 0.13 and 0.07 mg/l respectively. Deaths occurred in all treated groups (2/10, 1/10, 8/10 and 10/10). No deaths were seen among controls and all the deaths occurred within 4 days of exposure. Nasal discharge and chromodacryorrhoea (red discoloration around the nares) was found in all exposed groups and during the first week transient laboured breathing/respiratory difficulty (most pronounced at the higher exposure levels) was seen. The remaining animals were killed after 14 days. Besides lesions in the eyes (see below), no gross lesions attributed to the treatment were seen in these animals. Histopathological examination of lungs and other major organs were not carried out. (Lin 1991). The author has calculated that the total cetylpyridinium chloride exposure at the LC<sub>50</sub> level (0.09 mg/l) was about 4-8 mg/kg b.w. and based upon this it was inferred that cetylpyridinium chloride could be more toxic by inhalation exposure than by oral or dermal exposure.

#### *Oral administration* *LD<sub>50</sub>*

LD<sub>50</sub> values for QACs have been reported within the range of 250-1000 mg/kg for rats, 150-1000 mg/kg for mice, 150-300 mg/kg for guinea pigs and about 500 mg/kg b.w. for rabbits and dogs (Cutler & Drobeck 1970,

Glohuber 1974, Anon. 1976). The ranges observed reflect differences in the study designs of these rather old experiments as well as differences between the various QACs.

The oral route of administration was characterised by delayed deaths, gastrointestinal lesions and respiratory and central nervous system depression. It was also found that given into a full stomach, the QACs lead to lower mortality and fewer gastrointestinal symptoms. This supports the suggestion of an irritating effect. (Cutler & Drobeck 1970, Glohuber 1974, Merianos 1991, Gosselin 1984, BIBRA 1989).

In an attempt to elucidate the relationship between structure and toxicity of QACs, various homologues alkyl dimethyl benzyl ammonium chloride (C<sub>8</sub>-C<sub>19</sub>) were investigated with respect to LD<sub>50</sub> in mice. The results indicated that increasing chain length beyond C<sub>16</sub> decreased the acute toxicity markedly and that even numbered members appeared to be more toxic than those with odd numbered carbon chains. It was suggested that the decrease in toxicity above C<sub>16</sub> was due to decreased water solubility. (Cutler & Drobeck 1970).

#### *Dermal application* *LD<sub>50</sub>*

Only a very few LD<sub>50</sub> data are available. For benzalkonium unspecified (group II) a LD<sub>50</sub> at about 1500 mg/kg b.w. for rats has been reported. In mice a LD<sub>50</sub> value at 1600 mg/kg b.w. for octadecyl trimethyl ammonium chloride (group I) and in rabbits a LD<sub>50</sub> at 7700 mg/kg b.w. for cetylpyridinium chloride (group IV) have been obtained.

CTAB (group I) given subcutaneously to rabbits and guinea pigs lead to a LD<sub>50</sub> at about 100 mg/kg. Unspecified alkyl dimethyl benzyl ammonium chloride (group II) applied subcutaneously gave rise to values in the range of 60 (mice) to 400 (rats). (BIBRA 1989, RTECS 1998).

0.1, 1.5, 6.5 and 50% solutions of benzalkonium chloride were applied on the fur (0.05 ml and then rubbed in) of two strains of mice. Each dilution was applied to 8 mice. 29 of 96 mice receiving 6.5 and 50% solutions (approximately 160 and 1250 mg/kg b.w./day) died within 72 hours after the application. Weight reduction was seen in the 6.5 and 50% groups, but not at lower levels. Necropsy of animals which died revealed discoloration of the subcutis on application site and absence of content in the gastrointestinal tract. The cause of death was not apparent. (Serrano 1972 - quoted from Anon. 1989).

#### *skin irritation*

From animal testing (rabbits, guinea pigs, rats and mice) of different QACs within groups I and II the generalised conclusion is obtained that all the QACs investigated to date exhibit similar skin irritating properties. In general, the maximum concentration that did not produce effect on intact skin is 0.1%. Solutions of 0.3-5% induces reactions ranging from skin irritation (erythema) to necrosis. (Gosselin 1984, BIBRA 1989, Merianos 1991).

#### *Sensitisation*

Various protocols involving repeated dermal or intradermal applications of benzalkonium chloride and challenge with 0.01-0.3% solutions have shown that benzalkonium chloride is able to induce sensitisation in guinea pigs and mice (Anon. 1989, BIBRA 1989). Older studies performed on other QACs did not reveal any signs of sensitising effect (Cutler & Drobeck 1970).

## *Mucous membranes and eye*

Various studies concerning toxic effect of benzalkonium chloride to the eye have been performed. Instillation of different concentrations of benzalkonium chloride solutions in the rabbit eye have revealed that microscopic changes in the corneal epithelium can be induced at levels 0.01% or more. 0.001% is without damaging effect. (Anon. 1989).

Examination of five groups I or II QACs showed that 0.063-0.125% was the "threshold irritant concentration" range. (Cutler & Drobeck 1970).

Investigation of two QACs -alkyl dimethyl benzyl ammonium chloride and cetylpyridinium chloride- showed that instillation of a 330 ppm (0.033%) solution was the maximum concentration which did not produce irritation in rabbit eyes (Whitehall 1945 - quoted from Merianos 1991).

Eye irritation due to airborne cetylpyridinium chloride (group IV) has been reported once (see 4.1, inhalation above). Groups of five rats per sex were exposed to air containing 0, 0.05, 0.07, 0.13 and 0.29 mg cetylpyridinium chloride dust/l for four hours (equal to 50, 70, 130 and 290 mg dust/m<sup>3</sup>). Eye irritation was found in one or more animals per sex in all groups, except the controls. Lesions of the cornea, iris and/or conjunctiva were found in 4/10, 4/10, 6/10 and 6/10, respectively. All the ocular lesions were reversible (Lin 1991). In general, the longer chain alkyl trimethyl ammonium compounds are less irritating to the eye than the shorter chain homologues (C<sub>18</sub><C<sub>12</sub>) and the dialkyl dimethyl ammonium compounds are less irritating than the corresponding mono alkyl trimethyl ammonium compounds.

Other tests for mucous membrane irritation occasionally applied to study the QACs include a penile irritation test. Seven group I QACs were tested (alkyl trimethyl ammonium compounds) in such assay. Irritating effect were seen after application of a 1-10% solutions. (Cutler & Drobeck 1970).

## *Others*

Benzalkonium chloride or benzethonium chloride (group II) was instilled in the middle ear of guinea pigs. A single application of a 0.1% the respective solutions were placed in the tympanic cavity for 10-60 minutes. After two or 9 weeks the animals were killed. For both compounds severe lesions were seen in both the middle and inner ear. The extent of the damages were related to both the duration of exposure and the length of survival after the exposure. (Aursnes 1982).

A curare-like paralysis of skeletal muscles have been ascribed to QACs, specifically benzalkonium chloride and cetyl pyrimidinium chloride. Parenteral injections in rats, rabbits and dogs have resulted in prompt but transient limb paralysis and sometimes fatal paresis of the respiratory muscles. This effect seems to be transient. (Gosselin 1984).

## **4.2 Long term/repeated exposure**

### *Inhalation*

An inhalation toxicity study of an aerosolised hair conditioner containing an effective benzalkonium chloride concentration at 0.1% has been carried out in rats and hamsters. 12 CD rats and 12 golden hamsters were exposed to 9.9 mg conditioner/m<sup>3</sup> five days a week, four hours/day, for

14 weeks (9.9 mg conditioner corresponds to 9.9 µg benzalkonium chloride/m<sup>3</sup>). Body weights, haematological and biochemistry data were recorded, and gross and histopathological examination were conducted. No changes related to inhalation of the benzalkonium chloride conditioner were seen in any of the species. (CFTA 1979 - quoted from Anon. 1989).

*Oral administration  
rat*

The most widely investigated group is the alkyl dimethyl benzyl ammonium chlorides, particularly benzalkonium chloride. Many long term studies have been carried out, however, they are all of a very old date and do not meet the requirements of today's quality guidelines.

Osborn-Mendel rats were fed 0.063, 0.125, 0.25 and 0.5% alkyl dimethyl benzyl ammonium chloride (group II) in the diet for two years. The measured toxicity parameters were growth rate, food consumption, mortality, and gross and microscopic (at least ten tissues) pathological examination. Suppression of growth occurred even at the lowest concentration (about 63 mg/kg b.w./day). For the remaining parameters toxic effects were seen at the 0.25% level. At about this level (250 mg/kg b.w./day) pathologic changes were reported including diarrhoea and bloating of the abdomen, brown syrupy material in the intestine, distension of the coecum and foci of haemorrhagic necrosis in the gastro-intestinal tract. All rats at the 0.5% level died within 10 weeks. (Fitzhugh 1948 – quoted from Cutler & Drobeck 1970 and BIBRA 1989).

In another two years study, however, using a larger number of animals (12/sex), levels of 0.015, 0.031, 0.062, 0.125, 0.25 and 0.5% alkyl dimethyl benzyl ammonium chloride in the diet were tested. This study revealed that alkyl dimethyl benzyl ammonium chloride at 0.125% (125 mg/kg b.w./day) in the diet did not affect the growth, food consumption, blood picture or histopathology of the treated animals. At the 0.5% level only 50% of the animals survived 50 days. The pathological findings at this level were in agreement with Fitzhugh (1948) in that diarrhoea, brown viscid contents in the upper intestinal tract and acute gastritis were observed. Histopathological investigation revealed mucosal necrosis of the gastrointestinal tract. (Alfredson 1951 - quoted from Cutler & Drobeck 1970).

In these long-term studies the alkyl dimethyl benzyl ammonium chloride were fed in the diet. To obviate the difficulties concerning calculation of the exact doses administered to the animals, studies with benzalkonium chloride given by gavage were carried out. Rats were given the compound at 50 and 100 mg/kg b.w./day for 12 weeks with water or milk as vehicle. The compound was well tolerated at 50 mg/kg b.w./day, but depression of weight gain was seen at 100 mg/kg b.w./day when water was used as vehicle. (Coulston 1961 - quoted from Cutler & Drobeck 1970). It is not clear if tissue examination was performed in this study.

In a rat study doses of 5, 12.5 and 25 mg benzalkonium chloride /kg b.w./day given by gavage for two years lead to decrease in body weight at the highest dose level and increased cell growth in the gastric mucosa (probably at all dose levels) (Shelanski 1949 - quoted from Cutler & Drobeck 1970 and BIBRA 1989).

CTAB (group I) was offered to 10 SD rats of each sexes in concentrations of 0.007, 0.014 and 0.032% in drinking water for one year. These concentrations were calculated to deliver doses of approximately 10, 20 and 45 mg/kg b.w./day. The compound was well tolerated at the two lowest dose levels. At the highest dose level reduction in body weight, wetting and discoloration of the fur in the ventral region, decreased relative liver weight and increased relative coecum weight were seen. No compound related haematological or gross pathologic changes were seen and no microscopic alterations were found in the wall of stomach and small intestine of treated rats. No other tissues were histopathological examined. (Isomaa 1976).

#### *dog*

Dogs fed alkyl dimethyl benzyl ammonium chloride in the diet for 15 weeks at levels of 0.031, 0.062, 0.125, 0.25, 0.5 and 1.0% showed that 0.125% (approximately 30 mg/kg b.w./day) was the level without toxic effect. At the 0.25% level decreased body weight and food consumption were seen. Dogs fed the 0.5 and 1% levels died. As in the rats, the pathological changes were restricted to the gastrointestinal tract and included haemorrhage and necrosis in the gastrointestinal mucosa. (Alfredson 1951 - quoted from Cutler & Drobeck 1970).

In another study dogs (6 animals/dose) were given doses of 12.5, 25 and 50 mg benzalkonium chloride/kg b.w./day by gavage for 52 weeks with water or milk as vehicle. The benzalkonium chloride was given as a 10% solution. Deaths occurred among dogs at the two highest dose levels, but only when water was used as vehicle. The toxic effects seen at these levels - salivation, emesis and enteritis - were most intense in the dogs given the compound in water. When water was used as vehicle, intestinal congestion and inflammation was seen even in the dogs receiving 12.5 mg/kg b.w./day. These observations were, however, regarded as minor changes. (Coulston 1961 - quoted from Anon. 1989).

#### *guinea pig*

Groups of 20 guinea pigs were given 5, 12.5 or 25 mg alkyl dimethyl benzyl ammonium chloride by gavage for one year. No overt adverse effects or cellular changes in the major organs (not further specified) were seen. (Shelanski 1949 - quoted from Anon. 1989).

The above mentioned repeated toxicity studies do not cover all the studies carried out on group I and II QACs, but include the data which seems most pertinent. For the remaining studies not described above, the reported non-toxic (unspecified) levels are within the same range -or even higher- than those stated above. (Cutler & Drobeck 1970).

#### *Dermal application*

Application (probably uncovered) of benzalkonium chloride at 10 mg/kg b.w./day or more five times per week for three months to rats caused changes in the blood picture, liver and kidney damage and changes in certain organ weights (Berezovskaya 1978 - quoted from BIBRA 1989).

In a dermal study involving 100 female Swiss mice and ten New Zealand rabbits (both males and females), half of the mice and rabbits were treated with 8.5% benzalkonium chloride and the remaining half with 17% for about 80 weeks. An untreated group consisting of 100 mice and 19 rabbits served as controls. The solutions were applied uncovered twice a week (0.02 ml) on shaved dorsal skin (mice) or ear (rabbit). The

highest dose level corresponds to approximately 85 mg/kg b.w./day for mice and 0.85 mg/kg/day for rabbits. Complete necropsy was performed on each animal. Skin samples and lesions in the lung, liver, kidneys were examined microscopically. Benzalkonium chloride caused ulceration, inflammation and scarring at the application site at both dose levels. No effects were seen on survival. The study indicated lack of systemic toxicity. (Stenbäck 1977).

### 4.3 Reproductive / developmental effects

The toxicological data available are primarily related to benzalkonium salts. Only a few studies on other relevant QACs have been found.

#### *Oral intake*

There were no overt adverse effects on reproduction in groups of 15 rats and 10 guinea pigs given up to 25 mg benzalkonium chloride/kg b.w./day by gavage for two generations (Shelanski 1948 - quoted from BIBRA 1989).

Pregnant rats given up to 50 mg benzalkonium chloride/kg/day by gavage from days 6-15 of pregnancy showed no evidence of foetal malformations or decrease in litter size (FDRL 1977 - quoted from BIBRA 1989).

A brief review reported maternal and embryo toxicity (unspecified) when pregnant rabbits were fed 30 mg/kg b.w./day or more of an unspecified benzalkonium salt by gavage on days 7-19 of pregnancy. No malformations were seen. (CEC 1987 - quoted from BIBRA 1989).

#### *Dermal application*

Benzalkonium chloride (0.5 ml) in concentrations up to 6.6% was applied (uncovered) to the shaved skin of rats on days 6-15 of pregnancy (6.6% corresponds to approximately 150 mg /kg/day). The doses induced local adverse maternal reaction (skin reactions), but not systemic toxicity. No effects on litter size, post-implantation loss, litter and mean foetal weights were seen. No signs of embryotoxicity or foetal abnormalities. (Palmer et al. 1983).

Dermal exposure to up to 120 mg /kg/day of an unspecified benzalkonium salt on days 6-15 of pregnancy apparently caused no adverse effects on the foetus in rats. No further details available. (CEC 1987 - quoted from BIBRA 1989).

Dimethyl distearyl ammonium chloride (group I) (0.5 ml) in concentrations up to 9.9% or 0.5 ml trimethyl stearyl ammonium chloride in concentrations up to 2.5% was applied (uncovered) to the shaved skin of rats on days 6-15 of pregnancy (2.5 and 9.9% corresponds to approximately 60 and 250 mg /kg/day, respectively). The doses induced local adverse maternal reaction (skin reactions), but not systemic toxicity. No effects on litter size, post-implantation loss, litter and mean foetal weights were seen. No signs of embryotoxicity or foetal abnormalities. (Palmer et al. 1983).

#### *Mucous membranes*

Single doses of 0, 25, 50, 100 and 200 mg benzalkonium chloride/kg b.w. were instilled into the vagina of pregnant rats. No adverse effects on pregnancy outcome at the lowest dose level. At 50 mg/kg b.w. and

above, there were decreases in the number of live pups per litter and in litter size and weight. No visceral anomalies were seen, however abnormal bone development (sternal defects), increases in early embryo/foetal death (resorptions), reduced foetal growth and slight decreases in pregnancy rate were seen at 100 mg/kg b.w. In all rats given 100 mg/kg b.w. or more vaginal inflammation was seen at necropsy. (Buttar 1985 - quoted from BIBRA 1989).

#### *Intraperitoneal application*

I.p. administration of 10.5 or 35 mg CTAB /kg b.w. to pregnant mice as a single dose increased the incidence of dead implantations and malformations, principally cleft palate and minor skeletal defects in the skull and sternum. At the high dose CTAB increased foetal mortality. As QACs are able to alter the cell permeability it was suggested by the authors, that the embryotoxic and teratogenic effects of CTAB was due to a disturbance of the functional integrity of the placenta. (Isomaa & Ekman 1975b).

### 4.4 Genotoxic effects

Primarily benzalkonium chloride, but also other QACs have been investigated for mutagenicity in microbial test systems.

In Ames tests using *Salmonella typhimurium* with and without metabolic activation no signs of mutagenicity has been observed. Negative results were also obtained in *E. coli* reversion and *B. subtilis* rec assays. However, for benzalkonium chloride also positive and equivocal results were seen in the *B. subtilis* rec assays. In an *E. coli* DNA polymerase assay benzalkonium chloride induced repairable DNA damage, which points towards a genetic damage. (Yam 1984, BIBRA 1989, Anon. 1989).

QACs have been tested in hamster and mouse cell-transformation tests with negative results (Yam 1984, BIBRA 1989, Anon. 1989).

In vivo (i.p., micronucleus test) and/or in vitro tests (mouse and hamster cell cultures) carried out with unspecified benzalkonium salts did not lead to sister chromatid exchanges or any chromosomal aberrations (BIBRA 1989, NTP – quoted from Toxline, 1995-1998).

### 4.5 Carcinogenic effects

A few oral and dermal carcinogenicity studies on representative QACs (from groups I and II) are available. However, they are of an earlier date and do not meet the requirements of today's quality guidelines.

#### *Oral intake*

In a two years study rats (12-24/group) were given an alkyl dimethyl benzyl ammonium chloride in dietary levels of 0.015 to 0.5%. Only the highest level showed signs of toxic effect. The incidence of neoplasms among the treated groups was not significantly different from that observed in the control group. Only a limited number of organs were examined. (Alfredson 1951 – quoted from Cutler & Drobeck 1970 and BIBRA 1989).

#### *Dermal contact*



The tumorigenicity of benzalkonium chloride was evaluated in a dermal study involving 100 female Swiss mice and ten New Zealand rabbits (both males and females). Half of the mice and rabbits were treated with 8.5% benzalkonium chloride and the remaining half with 17% for about 80 weeks. An untreated group consisting of 100 mice and 19 rabbits served as controls. The solutions were applied uncovered twice a week (0.02 ml) on shaved dorsal skin (mice) or ear (rabbit). Complete necropsy was performed on each animal. Skin samples, grossly observed tumours, and other lesions in the lung, liver, kidneys were examined microscopically. Neither local skin tumours or systemic tumours were induced. (Stenbäck 1977).

In a well performed NTP study (1995) benzethonium chloride (group II) was investigated in rats and mice. Groups of 60 animals of each sex and species were topically administered up to 1.5 mg benzethonium chloride/kg b.w. 5 days/week for 103 weeks. The doses were administered in ethanol. There were no evidence of carcinogenic activity of benzethonium chloride in neither rats nor mice. (NTP - quoted from Toxline, 1995-1998).

## 5 Regulations, limit values

<i>Ambient air</i>	-
<i>Drinking water</i>	-
<i>Soil</i>	-
<i>OELs</i>	-
<i>Classification</i>	QACs in the category benzyl-C <sub>8-18</sub> -alkyldimethyl chloride are classified for acute toxicity (Xn;R21/22 - harmful in contact with skin or if swallowed), for corrosive properties (C;R34 - causes burns); and for environmental toxicity (N;R50 - dangerous for the environment; very toxic to aquatic organisms) (MM 1999).
<i>Cosmetics</i>	Denmark: The content of alkyl (C <sub>8</sub> -C <sub>18</sub> ) dimethyl benzyl ammonium chloride and alkyl trimethyl ammonium chloride/bromide in cosmetics must not exceed 0.1% (MEM 1998).
<i>IARC/WHO</i>	-
<i>USA</i>	FDA has concluded for some QACs, that the food additive regulations should be amended to provide for the safe of use on food equipment and food contact surfaces, if the solution does not exceed 200 ppm. In this instance, safe use does not require potable water rinse (Federal Register 1969 & 1974 - quoted from Merianos 1991).

## 6 Summary

### *Description and use*

Quaternary ammonium compounds (QACs) are cationic surfactants. They are synthetic organically tetrasubstituted ammonium compounds, where the R substituents are alkyl or heterocyclic radicals.

A common characteristic of these synthetic compounds is that one of the R's is a long-chain hydrophobic aliphatic residue. The most well investigated compound is benzalkonium chloride.

QACs are used as antiseptics, bactericides, fungicides, sanitisers, and softeners, but are also used in deodorants and as conditioning agents in hair cosmetics. Benzalkonium chloride is a common used preservative in ophthalmic and nasal solutions. The compounds are normally applied in concentrations between 0.01 and 1%.

### *Environment*

QACs are synthetic compounds and therefore not naturally occurring substances. A major part of the QACs is discharged into wastewater and removed in the biological processes of sewage treatment plant. A 90% reduction of the QACs in the water phase of sludge has been reported and alkyl di/trimethyl ammonium and alkyl dimethyl benzyl ammonium compounds seem almost completely degraded in sewage sludge.

Investigations indicate that bioaccumulation of considerable dimensions will not take place.

The general population are exposed to QACs directly through their use in disinfectants, hair conditioning agents and fabric softening agents, and indirectly through food stuffs due to the use as sanitising food contact surfaces.

### *Toxicokinetics*

Studies in rats have indicated poor intestinal absorption of QACs. For CTAB 92% of the radioactivity was excreted via the faeces and 1% via urine within three days of ingestion.

### *Toxicity*

The mammalian toxicity of QACs in general is not well established and far from all of the compounds have been put through toxicological investigations.

The major part of the present data refer to investigations on benzalkonium chloride/alkyl dimethyl benzyl ammonium chloride.

### *Human toxicity*

A few deep breaths benzalkonium chloride (4 mg/ml in 0.9% sodium chloride, nebulised) has caused constrictions of the airways in asthmatic persons.

A group of 196 farmers were evaluated for the relationship between exposure to QACs and respiratory disorders. Associations were found between the prevalence of mild bronchial responsiveness and the use of QACs as disinfectant.

Human fatalities implicating QACs are recorded as resulting from alkyl dimethyl benzyl ammonium chloride (C<sub>8</sub>-C<sub>18</sub>) solutions of 10 to 15% (100-400 mg/kg b.w.). Erosion, ulceration and necrosis of mucous membranes was seen in the alimentary tract. Severe changes were seen in the liver, kidneys and heart.

From human dermal testing of different QACs it is concluded that all the compounds investigated to date exhibit similar toxicological properties. The maximum concentration that did not produce irritating effect on in-

tact skin is 0.1%. Irritation became manifest in the 1-10% range. Concentrations below 0.1% have caused irritation in persons with contact dermatitis or broken skin. Concerning eye and mucosa, the level which did not cause any damage is 0.01%.

It cannot be excluded that topical mucosal application of certain QACs may produce sensitisation. 0.1 % benzalkonium chloride has been shown to lead to positive skin reaction, but in general it is suggested that QACs have a low potential for sensitising man.

### *Animal toxicity*

Exposure to a dimethyl ethyl benzyl ammonium compound for one hour in concentrations of 5.4 mg/l air lead to 100% dead. In a study rats were exposed to air containing 0, 0.05, 0.07, 0.13 and 0.29 mg cetylpyridinium chloride dust/l for four hours (equal to 50, 70, 130 and 290 mg dust/m<sup>3</sup>) and the LC<sub>50</sub> was estimated to 0.09 mg/l (90 mg/m<sup>3</sup>). Deaths within 4 days of exposure occurred in all treated groups. Eye irritation, nasal discharge and discoloration around the nares and transient laboured breathing/respiratory difficulty was seen in all exposed groups.

The oral LD<sub>50</sub> values for QACs have been reported within the ranges of 250-1000 mg/kg for rats, 150-1000 mg/kg for mice, 150-300 mg/kg for guinea pigs and about 500 mg/kg b.w. for rabbits and dogs. The administration lead to deaths, gastrointestinal lesions and respiratory and central nervous system depression. Only a very few dermal LD<sub>50</sub> data are available and the reported values are in the ranges of 1500-7700 mg/kg b.w. for mice, rats and rabbits.

From animal testing (rabbits, guinea pigs, rats and mice) of different QACs within group I and II it can be concluded that all the QACs investigated to date exhibit similar skin irritating properties. The maximum concentration that does not produce effect on intact skin is 0.1%. Solutions of 0.3-5% induces reactions ranging from skin irritation to necrosis. Studies have shown that benzalkonium chloride is able to induce sensitisation in guinea pigs and mice.

Many studies concerning toxic effect of benzalkonium chloride to the eye have been performed. Instillation of different concentrations of benzalkonium chloride solutions in the rabbit eye have revealed that microscopic changes in the corneal epithelium can be induced at levels 0.01% or more. 0.001% is without damaging effect. Eye irritation may also be induced via exposure to QACs in the air.

A 14 weeks inhalation study with an aerosolised hair conditioner containing 0.1% benzalkonium chloride (corresponding to 9.9 µg benzalkonium chloride/m<sup>3</sup>) has been carried out in rats and hamsters. No changes related to inhalation of the benzalkonium chloride conditioner were seen in any of the species.

Long term studies in rats (one and two years duration) showed that QACs in doses as low as 0.032% in drinking water (45 mg/kg b.w./day) or 0.063% in the diet (63 mg/kg b.w./day) may affect the growth of rats and cause slight gastro-intestinal disturbances. In dogs severe gastro-intestinal lesions were seen after administration of 0.25% QAC in the diet (60 mg/kg b.w./day) for 15 weeks. Concentrations at 0.5% lead to deaths among both rats and dogs. The effects observed is primarily of local nature due to irritation of surface tissues. Based upon the available studies a NOAEL at about 0.01% in drinking water/diet can be established (roughly corresponding to 15 mg/kg b.w.). Long term dermal studies in rats showed that application of a 8.5% benzalkonium chloride

solution twice a week lead to local skin inflammation and ulceration. No systemic toxic effect was observed.

*Reproductive and developmental effects*

No developmental toxicity was observed in oral studies causing local, but not systemic, maternal toxicity. Toxic effect was observed when QACs have been applied locally near the developing foetus (i.p. application or instillation into vagina). This could be due to a disturbance of the functional integrity of the placenta.

*Genotoxicity*

The results of the genotoxicity tests were in the vast majority of the cases negative, indicating that QACs have negligible potential to cause genetic damage.

*Carcinogenicity*

The results of the carcinogenicity tests were negative, indicating that QACs have no carcinogenic potential.

## 7 Evaluation

As the QACs are solid substances (which are used in form of solutions) the exposure in form of vapour is irrelevant whereas dust as well as aerosol exposure is relevant. No data with respect to dust exposure is available and for aerosol exposure, only one relevant animal study has been carried out.

The toxicity profile of QACs is primarily based upon data from studies with benzalkonium chloride. Other QACs have only been more or less sparsely investigated. However, it seems that the various QACs exhibit similar toxicological properties.

Oral, dermal and few inhalation toxicity studies on representative QACs are available. However, they are of an earlier date and do not meet the requirements of today's quality guidelines.

The studies have shown that QACs may induce adverse effect, including death, in humans as well as animals. From the available studies it can be concluded that the critical toxic effect of QACs apparently can be ascribed to the local irritating effects on surface tissues (skin, gastrointestinal mucosa, eye, and respiratory system). These effects of QACs can be induced at levels not causing systemic effect. Therefore, the threshold for induction of oral toxic effect seems more related to the concentration of the solution than the daily amount of compound ingested. Studies have shown that 0.001% solutions are without adverse effect even on the most sensitive membranes (eye).

It has been shown that benzalkonium chloride is able to induce sensitisation in guinea pigs and mice at concentrations not leading to skin irritation. In humans, it has been difficult to distinguish between an allergic and an irritative skin reaction due to the inherent skin irritating effect of QACs. However, it is suggested that QACs have a low potential for sensitising man (Andersen 1999).

Only a few studies reflect of QACs after inhalation. In a human study, a group of farmers were investigated for a possible relationship between exposure to QACs and respiratory disorders. Associations were found between the prevalence of mild bronchial responsiveness and the use of QACs as disinfectant. The design of the study does not allow the use for setting a N/LOAEL.

The most pertinent study for setting a N/LOAEL seems to be the four hours rat study on cetylpyrimidinium chloride in dust form. A NOAEL cannot be estimated from this experiment as effects (death as well as irritating effect) were seen even at the lowest dose level at 0.05 mg/l. This is only about 6 times lower than the dose level, which caused 100% death. Cetylpyrimidinium chloride seems to cause adverse effects at dose levels similar to other QACs after application on surfaces and after repeated oral intake. Based upon calculations from the cetylpyrimidinium chloride inhalation study it could be inferred that the compound is more toxic by inhalation exposure than by oral or dermal exposure. This may be the case for other QACs too.

A repeated animal inhalation study performed with a hair conditioner containing a very low concentration of benzalkonium chloride (9.9  $\mu\text{g}/\text{m}^3$ ) was without adverse effect.

The results from the reprotoxicity studies do not indicate developmental toxicity. Effects have only been observed when QACs have been applied locally near the developing foetus (i.p. or instillation into vagina). This could be due to a disturbance of the functional integrity of the placenta.

The results of the genotoxicity tests were in the majority of the cases negative, indicating that QACs have negligible potential to cause genetic damage. This is in accordance with the results from the carcinogenicity studies, although these do not meet today's quality guidelines.

Based on the available data, the critical effect in humans following exposure to QACs is considered to be the irritative effect on skin, mucosal membranes and eye and respiratory system. The effect may be induced following exposure to QACs in solutions or as aerosols. For the purpose of estimating a limit value in air, an exposure level of 50 mg cetylpyrimidinium chloride/ $\text{m}^3$  (as aerosols, particle size less than 5  $\mu\text{m}$ ) is considered a LOAEL for death and irritative effects in rats.

## 8 Limit value in air

### *Limit value in air*

The limit value is calculated based on an acute inhalation study in rats (cetylpyrimidinium chloride as aerosols, particle size less than 5  $\mu\text{m}$ ). A NOAEL could not be established as effect was seen even at the lowest dose level of 50  $\text{mg}/\text{m}^3$ . At this concentration irritative effect and even death was seen.

$$\begin{aligned} \text{LV}_{\text{air}} &= \frac{\text{LOAEL}}{\text{SF}_I \times \text{SF}_{II} \times \text{SF}_{III}} = \frac{50 \text{ mg}/\text{m}^3}{10 \times 10 \times 100} \\ &= 0.005 \text{ mg}/\text{m}^3 \end{aligned}$$

The safety factor  $\text{SF}_I$  is set to 10 assuming that humans are more sensitive than animals. The  $\text{SF}_{II}$  is set to 10 to protect the most sensitive individuals in the population. The  $\text{SF}_{III}$  is set to 100 since deaths were recorded even at the lowest dose level and the calculations were based upon a four hour exposure study.



## 9 C-value

A limit value of  $0.005 \text{ mg/m}^3$  has been calculated for the sum of QACs. For substances having acute or subchronic effects, but for which activity over a certain period of time is necessary before the harmful effect occurs, the C-value is set at the limit value. A C-value of  $0.005 \text{ mg/m}^3$  and placing in Main Group 2 is proposed (MST 1992).

*C-value*

$0.005 \text{ mg/m}^3$  (sum of QACs), Main Group 2.

# 10 References

Andersen KE. Personal communication, May 1999.

Anon. (1989). Final Report on the Safety Assessment of Benzalkonium Chloride. *J Am Coll Toxicol* **8**, 589-625.

Anon. (1976). Raad van Europa Werkgroep Cosmetica: Alkyltrimethylammoniumbromide; Alkyltrimethylammoniumchloride;. Dialkyldimethylammoniumchloride; Alkyldimethyl benzylammoniumchloride.

Aursnes J (1982). Ototoxic effect of quaternary ammonium compounds. *Acta Otolaryngol* **93**, 421-433.

BIBRA Working Group (1989). Benzalkonium chloride. Toxicity profile. The British Industrial Biological Research Association.

Cronin E (1980). *Cont Derm*, 692-695. Churchill Livingstone.

Cutler RA and Drobeck HP (1970). Toxicology of Cationic Surfactants. In: *Cationic Surfactants*. Vol. 4 (Chap. 15). Jungermann E (Ed.) Marcel Dekker, Inc., New York.

Effendy I and Maibach HI (1995). Surfactants and experimental irritant contact dermatitis. *Cont dermat* **33**, 217-225.

Fuchs T, Meinert A, Aberer W, Bahmer FA, Peters KP, Lischka GG, Schulze Dirks A, Enders F and Frosch PJ (1993). [Benzalkonium chloride- a relevant contact allergen or irritant? Results of a multicenter study of the German Contact Allergy Group] In German. *Hautarzt* **44**, 699-702.

Gosselin RE, Smith RP and Hodge HC (1984). *Clinical Toxicology of Commercial Products*. 5<sup>th</sup> ed. Baltimore: Williams and Wilkins.

Glohuber C (1974). Review articles. Toxicological Properties of Surfactants. *Arch Toxicol* **32**, 245-270.

HSDB (through 1998). Tetradecylbenzyl-dimethyl-ammonium-chloride. Alkyl-dimethyl-benzyl-ammonium-chloride In: *Hazardous Substances Database*.

Isomaa B, Reuter J and Djupsund BM (1976). The Subacute and Chronic Toxicity of Cetyltrimethylammonium Bromide (CTAB), a Cationic Surfactant, in the Rat. *Arch Toxicol* **35**, 91-96.

Isomaa B (1975a). Absorption, distribution and excretion of [<sup>14</sup>C]CTAB, a quaternary ammonium surfactant, in the rat. *Fd Cosmet Toxicol* **13**, 231-237.

Isomaa B and Ekman K (1975b). Embryotoxic and teratogenic effects of CTAB, a cationic surfactant, in the mouse. *Fd Cosmet Toxicol* **13**, 331-334 .

Kirk-Othmer (1985). Quaternary ammonium compounds. In: *Concise Encyclopedia of Chemical Technology*. John Wiley & Sons. A Wiley-Interscience Publication, 162-63.

Lin GHY (1991). Acute inhalation toxicity of Cetylpyridinium chloride. *Fd Chem Toxic* **29**, 851-854.

Lægemiddelkataloget. København 1996. Danmarks Apotekerforening, Foreningen af danske Medicinfabrikker og Medicinindustriforeningen. ISSN 0105-287X.

MEM (1998). Bekendtgørelse om kosmetiske produkter. Miljø- og Energiministeriets bekendtgørelse nr. 303 af 18. maj 1998.

Merianos JJ (1991). Quaternary Ammonium Antimicrobial Compounds. In: *Disinfection, Sterilisation, and Preservation (Chap. 13)*. Block S. (Ed.) Fourth edition. Lea & Febiger, USA.

Miskiel KA, Beasley R, Rafferty P and Holgate ST (1988). The contribution of histamine release to bronchoconstriction provoked by inhaled benzalkonium chloride in asthma. *Br J Clin Pharmacol* **25**, 157-163.

MM (1999). Danish Environment and Energy Ministry Standing Order No. 510 af 18th.June, 1999.

MST (1992). Industrial Air Pollution Control Guidelines. Vejledning fra Miljøstyrelsen nr. 9 1992.

MST (1991). Overfladeaktive stoffer - spredning og effekter i miljøet. Miljøprojekt nr. 166. Miljøstyrelsen.

Palmer AK, Bottomley AM, Edwards JA and Clark R (1983). Absence of embryotoxic effects in rats with three quaternary ammonium compounds (cationic surfactants). *Toxicology* **26**, 313-315.

Perrenoud D, Bircher A, Hunziker T, Suter H, Bruckner Tuderman L, Stager J, Thurlimann W, Schmid P Suard A and Hunziker N (1994). Frequency of sensitization to 13 common preservatives in Switzerland. Swiss Contact Dermatitis Research Group. *Cont Derm* **30**, 276-9.

Preller L, Doekes G, Heederik D, Vermeulen R, Vogelzang PF and Boleij JS (1996). Disinfectant use as a risk factor for atopic sensitization and symptoms consistent with asthma: an epidemiological study. *Eur Resp J*. **9**, 1407-13.

RTECS (1998). Hexadecyl trimethyl ammonium bromide. In the data base: Registry of Toxic Effects of Chemical Substances.

Schnuch A, Geier J, Uter W and Frosch PJ (1998). Patch testing with preservatives, antimicrobials and industrial biocides. Results from a

multicentre study. *Br J Dermatol* **138**, 467-76.

Stenbäck F (1977). Local and Systemic Effects of Commonly Used Cutaneous Agents: Lifetime Studies of 16 Compounds in Mice and Rabbits. *Acta Pharmacol Toxicol* **41**, 417-431.

Toxline data base:1995-1998/09.

Vogelzang PFJ, van der Gulden JWJ, Preller L, Tielen MJM, van Schayck CP and Folgering H (1997). Bronchial hyperresponsiveness and exposure in pig farmers. *Int Arch Occup Environ Health* **70**, 327-333.

Yam J, Booman KA, Broddle W, Geiger L, Heinze JE, Lin YJ, McCarthy K, Reiss S, Sawin V, Sedlak RI, Slesinski RS and Wright GA (1984). Surfactants: A survey of short-term genotoxicity testing. *Fd Chem Toxicol* **22**, 761-769.



**Evaluation of health hazards  
by exposure to**

***Triglycidyl isocyanurate***

**and estimation of a limit value in air.**

**Pia Berthelsen**

**The Institute of Food Safety and Toxicology  
Danish Veterinary and Food Administration**


# 1 General description

Commercial (technical) grade TGIC is a mixture of two optical stereoisomers, alpha and beta, which have different physicochemical properties. There are two main technical grades of TGIC. These are Araldite PT 810 (also known as TK 10622), and TEPIC. (NOHSC 1994).

## 1.1 Identity

Molecular formula:  $C_{12}H_{15}N_3O_6$

Structural formula:



Molecular weight: 297.3

CAS-no.: 2451-62-9

Synonyms: Glycidylisocyanurate  
Isocyanuric acid triglycidyl ester  
N,N',N''- Triglycidylisocyanurate  
Teroxirone ( $\alpha$ -TGIC)  
s-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris  
(2,3-epoxypropyl)  
TGT  
1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris  
(oxiranylmethyl)  
Tris (2,3-epoxypropyl) isocyanurate  
1,3,5-Tris (2,3-epoxypropyl)-s-triazine-  
2,4,6(1H,3H,5H)-trione  
1,3,5-Triglycidylisocyanurate  
1,3,5-Triglycidylisocyanuric acid  
1,3,5-Tris (oxiranylmethyl)-1,3,5-triazine-  
2,4,6(1H,3H,5H)-trione

## 1.2 Physical / chemical properties

Description: White, granular solids with no discernible odour.

Purity: 90% (TEPIC)  
>97% (Araldite PT 810, TK 10622)

Melting point:	90-125°C (TEPIC) 95°C (Araldite PT 810, TK 10622) 105°C ( $\alpha$ -TGIC) 156°C ( $\beta$ -TGIC)
Boiling point:	-
Density:	1.42 g/ml (TEPIC) 1.46 g/ml (Araldite PT 810, TK 10622)
Vapour pressure:	$0.05 \times 10^{-6}$ mmHg (7.2 $\mu$ Pa) at 20°C (Araldite PT 810, TK 10622)
Concentration of saturated vapours:	-
Vapour density:	-
Conversion factor:	-
Flash point:	>170°C (TEPIC)
Flammable limits:	-
Autoignition temp.:	>200°C (TEPIC)
Solubility:	water: 9 g/l (TEPIC at 25°C) 10 g/l ( $\alpha$ -TGIC at 20°C) 0.5 g/l ( $\beta$ -TGIC at 20°C) epichlorohydrin: <220 g/l (Araldite PT 810 at 25°C) DMSO: >100 g/l at 20°C methanol: 73 g/l (Araldite PT 810 at 25°C) < 1 g/l at 20°C toluene: 30 g/l (Araldite PT 810 at 25°C) < 1 g/l at 20°C isopropanol: 10 g/l (Araldite PT 810 at 25°C) 95 % ethanol: < 1 g/l at 20°C acetone: < 1 g/l at 20°C
$\log P_{\text{octanol/water}}$ :	- 0.8 (TEPIC)
Henry's constant:	-
pK <sub>a</sub> -value:	-
Stability:	TGIC contains three epoxide groups which give alkylating and cross-linking properties to the chemical. TGIC, in its molten state, reacts easily with various functional groups like amines, carboxylic acids, carboxylic acid anhydrides, phenols, thiols and alcohols in the presence of catalysts or promoters. It can be polymerised by



catalysts. Molten TGIC may undergo hazardous autopolymerisation after heating to >120°C for more than 12 hours.

Incompatibilities: -

Odour threshold, air: -


Particle size distribution: Technical grade granules (TEPIC):  
0.003% <10 µm,  
0.12% <150 µm,  
99.6% > 400 µm.

Powder coatings:  
99.7% <105 µm,  
6.2% <9.56 µm,  
2.3% <7 µm

References: Atassi et al. (1980), Chemfinder (1999),  
NOHSC (1994), NTP (1991), RTECS (1999),  
WHO (1998).

### 1.3 Production and use

TGIC is produced from epichlorohydrin and isocyanuric acid using sodium hydrate and methanol (Nishioka et al. 1988). No production of TGIC occurs in Denmark.



Epichlorohydrin

Isocyanuric acid

TGIC has been used as a curing agent for polyester resins in weather-resistant powder coatings in Europe for about 20 years. In Denmark TGIC has an extended use in powder coatings. A powder coating contains up to 10 % TGIC. It is sprayed directly onto metal objects by an electrostatic process. Powder coated objects include office and garden steel furniture, car parts, metal fencing, window and door frames, shelving, electrical equipment, and domestic appliances such as refrigerators, washing machines and ovens. (NOHSC 1994). TGIC is also used in electrical insulation materials, resin moulding systems, laminated sheetings, printed circuits, tools, inks, adhesives, lining materials, stabilisers for plastics and amine captures (Nishioka et al. 1988).

The alpha isomer of TGIC was used as an experimental anti-tumour agent under the names of Teroxirone, alpha-TGT, and Henkels compound. Clinical use of the alpha isomer was not pursued. (NOHSC 1994).

#### **1.4 Environmental occurrence**

Environmental exposure to TGIC resulting from normal use in spray painting workplaces is expected to be low. Plants that formulate TGIC powder coatings do release some TGIC to the atmosphere and sewer. One Australian plant has estimated that it annually releases 26 kg to the atmosphere, 15 kg to sewer, and 7.5 tonnes to landfill. (NOHSC 1994).

#### **1.5 Environmental fate**

As TGIC is an epoxide, any residues which enter the environment are expected to be rapidly degraded, either through microbial action or abiotic hydrolysis. (NOHSC 1994). However, when tested in a modified Sturm test, TGIC is not readily biodegradable (Ciba-Geigy Ltd. 1988 - quoted in NOHSC 1994). The result is likely to reflect complete primary degradation, with slow opening of the triazine ring restricting the rate of complete mineralisation. (NOHSC 1994).

#### *Bioaccumulation*

The reactivity of TGIC precludes any possibility of bioaccumulation (NOHSC 1994).

#### **1.6 Human exposure**

No data were found.

## 2 Toxicokinetics

### 2.1 Absorption, distribution

#### *Inhalation*

Only 0.003 per cent of technical grade TGIC is < 10 µm and only 2.3 per cent of TGIC powder coatings is < 7 µm. The particles in this same powder coating were all < 130 µm and therefore have the potential to be inhaled. (NOHSC 1994). No toxicokinetic inhalation studies have been performed.

#### *Oral intake*

When <sup>14</sup>C-labelled α-TGIC was administered to rabbits by stomach tube, no parent drug was detected in plasma. Plasma concentration of metabolites were lower compared to those observed following i.v. administration. (Ames et al. 1984).

In a study in mice at least 17% of the administered dose was absorbed within 24 hours. TGIC was distributed to the liver, stomach and testes (the only tissues studied). Eight hours after treatment no free TGIC was detected. (Ciba-Geigy 1990 - quoted in WHO 1998).

#### *Dermal contact*

Absorption is probably low following dermal contact indicated by a high LD<sub>50</sub> value (NOHSC 1994).

### 2.2 Elimination

#### *Metabolism*

TGIC metabolism seem to involve hydrolysis catalysed by microsomal epoxide hydrolase. In a recently conducted study, induction of epoxide hydrolase activity in rat livers was associated with increased hydrolysis of TGIC. However, this study only examined oral and intraperitoneal administration and did not consider dermal and inhalational exposure. (Ciba-Geigy Ltd 1993 - quoted in NOHSC 1994).

α-TGIC was metabolised *in vitro* by rat liver, but not lung, microsomal preparations by an NADPH-independent pathway. Epoxide hydrolysis metabolites were detected in the microsomal incubations, and cyclohexene oxide, a known inhibitor of microsomal epoxide hydrolases, inhibited α-TGIC metabolism. (Ames et al. 1984).

Epoxide hydrolase activity in some human tissues may be higher than in rodent tissues (Seidegard et al. 1986, Schmidt & Loeser 1985, Glat & Oesch 1987, Pacifici et al. 1988 - all quoted in NOHSC 1994). There is considerable variation in epoxide hydrolase activity between tissues and also significant (approximately 100-fold) interindividual variation of epoxide hydrolase activity in humans (Mertes et al. 1985 - quoted in NOHSC 1994).

#### *Excretion*

When <sup>14</sup>C-labelled α-TGIC was administered to rabbits by stomach tube, no parent drug was detected in plasma. Twenty-four-hour urinary recovery of radioactivity was about 30%. (Ames et al. 1984).

When humans were given i.v. administration of  $\alpha$ -TGIC in doses up to 500 mg/m<sup>2</sup> (= 15 mg/kg bw, calculated by using a standard weight of 60 kg and a standard surface area of 1.85 m<sup>2</sup>), less than 1 %  $\alpha$ -TGIC is recovered in 24-hour urine. (Ames et al. 1984). In a phase I anticancer clinical trial with  $\alpha$ -TGIC, i.v. infusion of 2000 mg/m<sup>2</sup> (= 62 mg/kg bw, calculated) administered over 2-3 hours was measured during the study to correspond to a plasma concentration of about 1 $\mu$ g/ml (Piccart et al. 1981).

When <sup>14</sup>C-labelled  $\alpha$ -TGIC is administered to rabbits by i.v. infusion, twenty-four-hour urinary recovery of parent drug is < 1%, while urinary recovery of <sup>14</sup>C total radioactivity is 60 to 70%. (Ames et al. 1984).

#### *Half-life*

Rapid plasma elimination ( $t_{1/2}$  < 5min.) and total body clearance (about 5 litres/min.) are observed following i.v. administration of  $\alpha$ -TGIC to humans in doses up to 500 mg/m<sup>2</sup> (= 15 mg/kg, calculated). When <sup>14</sup>C-labelled  $\alpha$ -TGIC is administered to rabbits by i.v. infusion, plasma disappearance of parent drug is very rapid ( $t_{1/2}$  < 5min.), while metabolites in the plasma are eliminated at a much slower rate ( $t_{1/2}$  > 60 min.). (Ames et al. 1984).

### **2.3 Toxicological mechanisms**

The cytotoxicity of TGIC is probably related to the alkylating capacity of the epoxide moieties (Ames et al. 1984).  $\alpha$ -TGIC was shown to alkylate a model compound 4-(p-nitrobenzyl)pyridine. E. coli strains defective in UV repair function were much more sensitive to  $\alpha$ -TGIC than were the nondefective strains, suggesting that DNA may be the target of drug action. However, no *in vitro* interaction between  $\alpha$ -TGIC and DNA or its components could be detected under physiological conditions by using a variety of biochemical and physicochemical techniques. (Wu & Le Pecq 1983). Two *in vivo* studies have demonstrated that TGIC is capable of covalently binding to DNA in mouse liver, stomach and testis tissues following oral administration and in rat liver tissue following intraperitoneal or oral administration. (Both quoted in NOHSC 1994).

## 3 Human toxicity

### 3.1 Short term toxicity

<i>Inhalation</i>	No data were found.
<i>Oral intake</i>	No data were found.
<i>Dermal contact</i>	No data were found.
<i>Intravenous application</i>	In human clinical trials $\alpha$ -TGIC was administered intravenously to cancer patients at doses up to 2700 mg/m <sup>2</sup> (= 83 mg/kg b.w., calculated) using a variety of dosing regimens. The dose-limiting factor was local thrombophlebitis which was noted down to about 200 mg/m <sup>2</sup> (= 6 mg/kg b.w., calculated). Its severity seemed to increase with higher doses and was most pronounced in patients previously treated with $\alpha$ -TGIC. At high doses $\alpha$ -TGIC induced leukopenia which resulted in life-threatening infections at doses of 2400 and 2700 mg/m <sup>2</sup> (= 74 and 83 mg/kg b.w., calculated). Myelosuppression in patients given more than 1500 mg/m <sup>2</sup> (= 46 mg/kg b.w., calculated) was observed in one of the trials where $\alpha$ -TGIC was more concentrated. Other toxic effects were mild to moderate and consisted of nausea, vomiting and hair loss. Nausea and vomiting was seen in one patient already at a dose of 33 mg/m <sup>2</sup> (= 1 mg/kg b.w., calculated). (Dombernowsky et al. 1983, Neidhart et al. 1984, Piccart et al. 1981, Rubin et al. 1987).

### 3.2 Long term toxicity

<i>Inhalation</i>	TGIC has caused occupational asthma in a healthy 36-year old non-smoking man who worked mainly as a spray painter, using a powder paint containing 4% TGIC. Before the examinations he had been painting 5-8 hours daily for about 7 years. He was diagnosed with contact dermatitis as well as occupational asthma. (Piirilä et al. 1997).
<i>Oral intake</i>	No data were found.
<i>Dermal contact</i>	Allergic contact dermatitis due to exposure to TGIC is the main reported human health effect. Sixteen case reports exist in the literature. Patch tests confirmed that TGIC was the causative agent of the skin problems. (Craven et al. 1999, Dooms-Goossens et al. 1989, Foulds & Koh 1992, Jolanki et al. 1994, Mathias 1988, McFadden & Rygroft 1993, Munro & Lawrence 1992, Nishioka et al. 1988, Wigger-Alberti et al. 1997). Workers may become sensitised to TGIC from short-term exposure (less than 12 months) to the chemical in the production (Nishioka et al. 1988; 1 person) or the manufacture (Foulds & Koh 1992, Munro & Lawrence 1992, Wigger-Alberti et al. 1997; 9 persons) of it and during use of TGIC-containing powder paints (Dooms-Goossens et al. 1989, Mathias 1988, McFadden and Rygroft 1993, Piirilä et al. 1997; 4 persons). A chemist (Craven et al. 1999) and a silk-screen painter (Jolanki et al. 1994) working in the manufacture of circuit boards developed allergic

dermal reactions to TGIC as well as to epoxy resins and acrylates after 12-15 years of exposure.

In the early nineties, the level of TGIC dust was monitored at several workplaces where TGIC was used throughout Australia. Different work practices significantly affected the level of exposure that was found to be from <0.001 to 6.5 mg/m<sup>3</sup>. Health effects in workers exposed to TGIC included allergic dermatitis which was confirmed with patch tests, aggravated asthma, nasal, eye and throat irritation, skin rash and nose bleed. Of 232 spray painters in Sydney, 11 had suffered health problems, mostly skin rashes, as a result of using TGIC powder coatings. (NOHSC 1994).

*Epidemiological studies*

No data were found.

**3.3 Reproductive and developmental effects**

No data were found.

**3.4 Mutagenic and genotoxic effects**

No data were found.

**3.5 Carcinogenic effects**

No data were found.

## 4 Toxicity, animal data

### 4.1 Short term toxicity

#### *Inhalation*

Two single, four-hour nose-only inhalation exposure studies in 10 rats of each sex per dose using technical grade TGIC revealed a  $LC_{50}$  of 300- >650  $mg/m^3$ . A whole body exposure study in 5 male mice resulted in a  $LC_{50}$  of 2000  $mg/m^3$ . More than 60% of the TGIC particles were within the respirable range (<7 $\mu m$ ). No animals died when 2 rats of each sex were exposed nose-only for 30 minutes to technical grade TGIC at an atmospheric level of 3200  $mg/m^3$ . (All quoted in NOHSC 1994).

Groups of 12 male CD-1 mice were exposed nose-only to atmospheres containing 0, 10, 40 or 140  $mg/m^3$  of technical grade TGIC for six hours/day for five days. More than 79% of the TGIC particles were less than 4  $\mu m$  and therefore respirable. Two animals from each group were killed six hours after the final exposure to assess cytotoxicity. Approximately 400 metaphase germ cells were scored per animal. Cytotoxicity in germ cells was not increased in any of the treated groups indicating a lack of effect of TGIC on germ cell survival even at the two highest doses where high mortality of the rest of the mice were observed. The surviving animals were observed over a 17 day recovery period. Clinical signs of toxicity, increased body weight losses and high mortality were observed in the intermediate and high dose groups. The clinical signs included hunched posture, piloerection, lethargy and dyspnoea. Dead animals had lung damage. Besides pathology for animals dosed with 140  $mg/m^3$  included pale livers, pale kidneys, and congestion of the small intestine. In the low dose group only one animal died and the death was unrelated to treatment. One animal had slightly reddened lungs in the low dose group. (Safepharm Laboratories Ltd. 1991 - quoted in NOHSC 1994).

A nose-only five day inhalational chromosomal aberration study was conducted in which groups of 10 male CD-1 mice were exposed to technical grade TGIC (dose of 7.8  $mg/m^3$ ) or 10% TGIC powder coating (dose of 95.3 or 255.3  $mg/m^3$ ) for 6 hours/day. The inhaled dust particles were for the main part respirable. There were no deaths during the study. The only adverse clinical signs noted were confined to one animal exposed to 255.3  $mg/m^3$  of 10% TGIC powder coating on day four. This animal displayed hunched posture and piloerection. Bodyweight gain was unaffected in all groups. For the groups inhaling TGIC, cytotoxicity in spermatogonial cells was not significantly increased at the doses tested. (Safepharm Laboratories Ltd. 1992 - quoted in NOHSC 1994).

In an inhalational chromosomal aberration study, groups of 10 male CD-1 mice were whole body exposed to technical grade TGIC at concentrations of 0, 2.5, 10 and 50  $mg/m^3$  for 6 hours/day for five days. The particle size range of TGIC was 2.5 to 3.5  $\mu m$ . No deaths occurred and no adverse clinical signs were observed in the TGIC-treated animals. Body weight losses occurred in all groups. The study suggests that TGIC was cytotoxic to spermatogonial cells at doses of 10 and 50  $mg/m^3$  because of a low number of animals in these groups with a sufficient number of

scorable cells for chromosome aberrations. However, the cytotoxic ratios were not calculated. (Bushy Run Research Center 1992 - quoted in NOHSC 1994).

#### *Oral administration*

Five animals of each sex per dose were given technical grade TGIC and observed for 14 days to establish acute oral LD<sub>50</sub>. For rats LD<sub>50</sub> was <100-950 mg/kg (4 studies). For hamsters LD<sub>50</sub> was 1670 mg/kg (1 study). (All quoted in NOHSC 1994).

For seven consecutive days 10 CFE rats per sex per dose were fed 0, 54 or 216 mg/kg b.w./day (males) or 0, 43, or 172 mg/kg b.w./day (females) of technical grade TGIC dissolved in dimethylsulfoxide (DMSO) by gavage. Gross pathology was recorded for the lungs, kidney, liver, stomach, and intestines. Renal tubular, gastric and duodenal damage was observed in both sexes in the high dose groups. In the low dose groups renal tubular damage also occurred. (Shell Research Ltd. 1971 - quoted in NOHSC 1994 and WHO 1998).

A chromosomal aberration study was conducted in which a group of 10 male CD-1 mice were orally administered 115.0 mg/kg of technical grade TGIC for 5 days. There were no deaths during the study. Adverse clinical signs were noted in all animals treated with TGIC on day five. These animals displayed hunched posture and piloerection. Bodyweight gain was unaffected. TGIC significantly increased cytotoxicity in spermatogonial cells. (Safeparm Laboratories Ltd. 1992 - quoted in NOHSC 1994).

#### *Dermal contact*

In three acute dermal toxicity studies in 3-5 rats per sex per dose technical grade TGIC (in carboxymethylcellulose or arachid oil) was applied to intact shaven skin prior to the application of a semi-occlusive dressing. After 24 hours the skin was washed clean and the animals were observed for 14 days. LD<sub>50</sub> was >2000 mg/kg. (All quoted in NOHSC 1994).

Very slight erythema and oedema were observed in five studies of acute skin irritation in rabbits. In each study, three rabbits of each sex were exposed for 24 hours to technical grade TGIC in the form of 0.5 ml as a 50% solution in polypropylene glycol or 0.5 g powder moistened with distilled water. The rabbits were observed for at least 72 hours. (All quoted in NOHSC 1994).

In two studies, skin sensitisation was observed in 4 out of 20 (half of each sex) or 12 out of 20 guinea pigs induced with technical grade TGIC and challenged two weeks later. For the induction in the first study, adjuvant was injected intradermally in the neck area and 40 mg TGIC was applied topically over the injection site and occluded for 24 hours. One week later, 120 mg of TGIC (in vaseline) was applied occlusively to the injection site for 48 hours. In the second study, the induction was carried out by injecting 0.5 mg of TGIC in arachid oil and 0.5 mg of TGIC in adjuvant intradermally to the shoulder area of each animal. One week later 100-150 mg of TGIC in arachid oil was applied topically to the injection site and held under an occlusive wrap for 48 hours. For the challenge, 20 mg (first study) or 50-100 mg (second study) of TGIC (in arachid oil for the second study) was applied occlusively for 24 hours to the



flank. A positive response was seen as slight to moderate erythema and/or oedema. (Both quoted in NOHSC 1994).

#### *Eye contact*

Severe eye reactions (moderate to severe corneal opacity, redness, chemosis and discharge) were noted in all treated, unwashed eyes in two out of three studies in which 3 rabbits of each sex in each study had 0.1 g of technical grade TGIC placed in the conjunctival sac of the left eye. The untreated right eye served as control. In three of the six rabbits in each study, the treated eye was flushed with saline. Eyes were assessed for irritation at 24, 48, 72 hours and four and seven days post-treatment. (All quoted in NOHSC 1994).

### **4.2 Long term toxicity**

No data were found.

### **4.3 Reproductive and developmental effects**

In a dominant lethal test, technical grade TGIC (in arachid oil) was administered by single gavage at doses of 0, 160 and 480 mg/kg b.w. to groups of 20 male Tif MAGf(SPF) mice. These mice were mated over three periods of 6 days to 40 female mice per dose group. The female mice were replaced at the end of each period. Females were killed on day 14 of gestation and the numbers of live and dead foetuses and foetal resorptions were noted. Females mated to males given 480 mg/kg of TGIC during the first period showed a significant increase in the number of embryonic deaths, compared with the negative control. No increase was seen in the females mated in the second and third periods at the same dose, nor in the females in the other treated groups. (Ciba-Geiga Ltd. 1986 - quoted in NOHSC 1994).

In a second dominant lethal test, technical grade TGIC (in peanut oil) was administered by single gavage at doses of 0, 138, 275 and 550 mg/kg b.w. to groups of 20 male ICR mice. These mice were mated over three periods of 5 days to 40 female mice per dose group. The female mice were replaced at the end of each period. No significant difference was observed in the number of embryonic deaths in test groups compared to the negative control. (Hazleton Laboratories America Inc. 1989 - quoted in NOHSC 1994).

In a third dominant lethal test, 10% TGIC in powder coating (doses of 0, 100, 1000, or 1700 mg/m<sup>3</sup>) was administered by whole body inhalational exposure to dust for six hours per day for five consecutive days to 30 male CD-1 mice per group. Following treatment each male was mated to two virgin females for eight weekly periods with the females being replaced at the end of each period. No increase in embryonic deaths was observed except in the positive control group and therefore TGIC did not induce heritable dominant lethal mutations under the conditions of the experiments. (Bushy Run Research Center 1991 - quoted in NOHSC 1994).

In a fourth dominant lethal test, technical grade TGIC (doses of 0, 2.5, 10, or 50 mg/m<sup>3</sup>) was administered by whole body inhalational exposure to dust for six hours per day for five consecutive days to 30 male CD-1 mice per group. Following treatment each male was mated to two virgin females for eight weekly periods with the females being replaced at the end of each period. TGIC did not induce heritable dominant lethal mutations. There was a slight increase in the number of non-viable implants and early resorptions in the third mating week, but this was not statistically significant. The study showed reduced fertility in males at 10 and 50 mg/m<sup>3</sup> as seen by reduced number of males impregnating females in some of the mating weeks and a non-significant ten percent reduction in testes weight in the 50 mg/m<sup>3</sup> group. The reductions in fertility were consistent with an effect on mature sperm, maturing spermatids and Type B spermatogonia at the 50 mg/m<sup>3</sup> level and with Type B spermatogonia at the 10 mg/m<sup>3</sup> level. (Bushy Run Research Center 1992 - quoted in NOHSC 1994).

In a 13-week toxicity/fertility study, groups of 10 male rats were given diets containing 0, 10, 30, or 100 ppm (0, 0.5, 1.5 or 5 mg/kg b.w., calculated) TGIC. This study followed a preliminary 19-day range-finding investigation in which signs of toxicity were observed in animals administered diets containing 160 or 640 ppm TGIC. In the full study after 64 days of treatment, each male was placed with two females until mating occurred. The females were then allocated to two subgroups (caesarean or normal delivery) on day 19 of pregnancy. Females from the caesarean group were killed on day 20 of pregnancy and the ovaries and uterus examined. The other group was allowed to deliver normally and the pups were examined for clinical signs and development. Between 22 and 25 days postpartum, the females in the normal delivery group were sacrificed and examined. In males at autopsy, all organs were examined in the high-dose and control groups. No exposure-related clinical effects or death were observed. Body weight gain was slightly lower over the first 6 weeks in animals from the 100 ppm test group. A dose-related reduction in the number of spermatozoa was noted but the spermatozoa viability was unchanged. No exposure-related infertility was noted in males, and no effects on embryonic and pup development were observed in the offspring. The highest concentration used in this study was not a maximum tolerated dose. (CIT 1995 - quoted in WHO 1998).

#### **4.4 Mutagenic and genotoxic effects**

##### *In vitro tests*

Technical grade TGIC (dissolved in DMSO) was positive in two Ames tests using five strains (TA1535, TA1538, TA1537, TA98 and TA100) of *Salmonella typhimurium* when tested both with and without metabolic activation systems. (Hazleton 1987, Ciba-Geiga Ltd. 1982 - both quoted in NOHSC 1994).

When tested in mammalian cells, technical grade TGIC (dissolved in DMSO) was positive in the mouse lymphoma assay with and without metabolic activation systems, in chromosome aberration and sister chromatid exchange tests in Chinese hamster ovary cells with and without metabolic activation systems, and for unscheduled DNA synthesis in rat hepatocytes. Technical grade TGIC dissolved in DMSO also tested posi-

tive in a chromosome aberration assay in Chinese hamster lung cells without metabolic activation systems but was negative with metabolic activation. A reduction in the response to treatment was noted in the mouse lymphoma assay and in the two assays in Chinese hamster ovary cells when metabolic activation was present. TGIC was negative in two cell transformation assays in mouse embryo fibroblasts. (Loveday et al. 1990, Sofuni et al. 1990, NOHSC 1994).

In human cells, technical grade TGIC tested negative in a chromosomal aberrations assay in human lymphocyte cultures (TGIC doses between 0.063 and 10 µg/ml) and for unscheduled DNA synthesis in human fibroblast cultures (TGIC doses between 2.7 and 400 µg/ml) without metabolic activation systems. (Ciba-Geigy Ltd. 1985, Ciba-Geigy Ltd. 1988 - both quoted in NOHSC 1994).

#### *In vivo tests*

Technical grade TGIC was shown to be clastogenic in a nucleus anomaly test in Chinese hamsters. TGIC (in arachid oil) was administered by gavage to groups of three animals of each sex at dose levels of 0, 140, 280 or 560 mg/kg b.w./day for two days. The animals were sacrificed 24 hours after the second dose and femoral bone marrow samples were taken. One thousand bone marrow cells were scored per animal. Nuclear anomalies for the intermediate and high dose groups were significantly different from the negative control. (Ciba-Geigy Ltd. 1983 - quoted in NOHSC 1994).

Two studies were conducted to determine the ability of technical grade TGIC to induce sister chromatid exchanges (SCEs) in the bone marrow cells of Chinese hamsters. In each study, TGIC was suspended in arachid oil and administered by gavage. Twenty-five cells per animal were scored for SCEs. In one study, four animals of each sex per dose were treated with TGIC at dose levels of 0, 35, 70 and 140 mg/kg b.w.. In this study, no increases in the number of SCEs were observed. In the second study, groups of two animals per sex were treated with TGIC at doses of 0, 140, 280 and 560 mg/kg b.w. and a dose-related positive effect was observed. (Ciba-Geigy Ltd. 1984, Ciba-Geigy Ltd. 1983 - both quoted in NOHSC 1994).

Four oral and four inhalational studies have been conducted to determine chromosomal aberrations in mouse germ cells in animals exposed to technical grade TGIC *in vivo*. (Ciba-Geigy Ltd. 1986, Hazleton Laboratories America Inc. 1989, Hazleton Microtest 1991a, Hazleton Microtest 1991b, Bushy Run Research Center 1992, Bushy Run Research Center 1991, Safepharm Laboratories Ltd. 1992, Hazleton Microtest 1993 - all quoted in NOHSC 1994):

In three chromosomal aberration studies, male mice were dosed orally with TGIC by gavage on five consecutive days in doses ranging between 0 and 350 mg/kg b.w. Chromosomal aberrations in the spermatogonia were observed in a dose-related manner starting at about 30 mg/kg b.w. Cytotoxicity was first observed at 57.5 mg/kg b.w. (Ciba-Geigy Ltd. 1986, Hazleton Laboratories America Inc. 1989, Hazleton Microtest 1991a - all quoted in NOHSC 1994).

In another chromosomal aberration study, groups of 15 male mice were given TGIC (in arachid oil) by gavage at dose levels of 0, 32 or 96 mg/kg b.w. on days 0, 2, 3, 5 and 9. Animals were killed 3 days after the final dose and tested for chromosomal aberrations in their spermatocytes. The results of this study were negative. (Hazleton Microtest 1991b - quoted in NOHSC 1994).

In an inhalational chromosomal aberration study, groups of 10 male CD-1 mice were whole body exposed to technical grade TGIC at concentrations of 0, 2.5, 10 and 50 mg/m<sup>3</sup> for 6 hours/day for five days. The particle size range of TGIC was 2.5 to 3.5 µm. Animals were killed six hours after the end of the last exposure. The results of this study were inconclusive mainly because statistical analysis could not include the 10 and 50 mg/m<sup>3</sup> groups due to a small number of animals in these groups with a sufficient number of scorable cells (>50 per animal). No statistically significant aberrations were found in the 2.5 mg/m<sup>3</sup> group. The study suggests TGIC was cytotoxic to spermatogonial cells at doses of 10 and 50 mg/m<sup>3</sup>. However, the cytotoxic ratios were not calculated. (Bushy Run Research Center 1992 - quoted in NOHSC 1994).

In a second inhalational chromosomal aberration study, groups of 10 CD-1 male mice were whole body exposed to atmospheres containing 0, 100, 1000 or 1700 mg/m<sup>3</sup> powder coating containing 10 % TGIC for 6 hours/day for five days. The animals were killed six hours after the last exposure period. The test material significantly increased the number of chromosomal aberrations in spermatogonial cells of the animals exposed to 1700 mg/m<sup>3</sup> powder coating but as for the above mentioned study, the number of animals with enough scorable cells was very low. (Bushy Run Research Center 1991- quoted in NOHSC 1994).

A nose-only five day inhalational chromosomal aberration study was conducted in which groups of 10 male CD-1 mice were exposed to technical grade TGIC (dose of 7.8 mg/m<sup>3</sup>) or 10% TGIC powder coating (dose of 95.3 or 255.3 mg/m<sup>3</sup>) for 6 hours/day for 5 days. Oral administration (dose of 115.0 mg/kg b.w.) of technical grade TGIC was included in this study for comparison. The animals were killed six hours after the final exposure to the test material. The inhaled dust particles were for the main part respirable. For the groups inhaling TGIC, cytotoxicity and chromosomal damage in spermatogonial cells was not significantly increased at the doses tested. Oral administration of TGIC, 115 mg/kg b.w., significantly increased both cytotoxicity and total chromosomal aberrations in spermatogonial cells. (Safeparm Laboratories Ltd 1992 - quoted in NOHSC 1994).

In a similar chromosomal aberration study, groups of six B6D2F1 male mice were exposed for 6 hours/day to powder coating containing 4.6% TGIC. The mice were exposed to atmospheres containing from 0 to 2000 mg/m<sup>3</sup> of powder coating. A statistically significant increase in the number of spermatogonial cells with chromosomal aberrations was observed in animals exposed to the highest concentration - 2000 mg/m<sup>3</sup>. However, the increase was mainly due to chromosome damage in a single animal. (Hazleton Microtest 1993 - quoted in NOHSC 1994).

An *in vivo* study on TGIC's ability to alkylate mouse liver, stomach and testis DNA demonstrated that TGIC is capable of covalently binding to DNA in these tissues following oral administration. Radiolabelled TGIC, in either aqueous solution or in oil, was administered by gavage to at least two male Tif:MAGf(SPF) mice per group at doses of 5, 17 and 200 mg/kg b.w. DNA was isolated at three, eight or 24 hours from the liver, stomach and testes and measured for radioactivity levels. Dose-dependent increases in TGIC-DNA adduct formation were observed. (Ciba-Geigy Ltd. 1990 - quoted in NOHSC 1994).

Another *in vivo* alkylating study was conducted in rats to assess the binding of technical grade TGIC to liver DNA. Two to four male Tif:RAIf(SPF) rats were pre-treated with trans-stilbene oxide (TSO) to induce epoxide hydrolase (EH) and glutathione S-transferase activities. Six days later these animals as well as untreated animals were intraperitoneally or orally administered 20 mg/kg b.w. radiolabelled TGIC. Twenty-four hours later the animals were killed and the livers excised. The results of this study indicated that increased microsomal EH activity was associated with increased hydrolysis of TGIC and a corresponding decrease in TGIC-DNA adduct formation in the rat liver. The study demonstrated that TGIC does bind to DNA *in vivo* in rats. However, the binding values were relatively low suggesting that only a small proportion of administered TGIC binds to DNA in the rat liver. (Ciba-Geigy Ltd. 1993 - quoted in NOHSC 1994).

TGIC was negative in the mouse spot test. This test system permits the detection of mutational events in the melanoblasts of embryos exposed *in utero* to a chemical. The mutational events resulting from the expression of recessive genes involved in coat colour determination are observed as spots in the fur of young mice. Technical grade TGIC was administered at doses of 13.5, 27.0 and 54.0 mg/kg b.w. in a single intraperitoneal injection to 96 female pregnant mice (C57 Bl/6) per group on the 10th day after conception. (Ciba-Geigy Ltd. 1986 - quoted in NOHSC 1994).

#### **4.5 Carcinogenic effects**

2.5% TGIC did not promote skin tumour formation in CF-1 mice painted twice weekly for 26 weeks. Four groups of 24 mice of each sex had a tumour initiating agent applied dermally to their shaved backs. Three weeks later (and twice weekly for the next 26 weeks), these mice were painted with either 2.5% TGIC, 2.5% of a tumour promoting agent, solvent or received no secondary treatment. After 27 weeks, the mice were killed and the skin from the treated areas was examined microscopically. Only mice who received the tumour promoting agent developed skin tumours. Of those mice exposed to TGIC, one female showed severe acanthosis and two males showed ulceration. (Shell research Ltd. 1971 - quoted in NOHSC 1994).

The final results of a chronic toxicity/carcinogenicity bioassay in rats conducted by the Centre Internationale de Toxicologie (CIT) in France were not available in 1998 (WHO 1998).

## 5 Regulations, limit values

<i>Ambient air</i>	Oklahoma, USA, has a maximum acceptable ambient concentration (MAAC) for TGIC of 0.5 µg/m <sup>3</sup> (OAPCR 1999).
<i>Drinking water</i>	-
<i>Soil</i>	-
<i>OELs</i>	American Conference of Governmental Industrial Hygienists has set a threshold limit value of 0.05 mg/m <sup>3</sup> (TWA) (ACGIH 1997 - quoted in Toxline pre 1981-1999).  Australia has a provisional occupational exposure limit of 0.08 mg/m <sup>3</sup> (TWA) (NOHSC 1994).
<i>Classification</i>	TGIC is classified for acute toxic effects (T;R23/25 - toxic by inhalation and if swallowed), for local effects (Xi;R41 - risk of serious damage to eyes), for sensitising properties (Xi;R43 - may cause sensitisation by skin contact), for effects following repeated exposure (Xn;R48/22 - harmful: danger of serious damage to health by prolonged exposure if swallowed), for mutagenic properties (Mut2;R46 - may cause heritable genetic damage), and for environmental effects (N;R52/53 - harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment). (MM 1997).
<i>EU</i>	-
<i>IARC/WHO</i>	-
<i>US-EPA</i>	-
<i>RD<sub>50</sub></i>	-

## 6 Summary

### *Description*

Commercial (technical) grade TGIC is a mixture of two optical stereoisomers, alpha and beta, which have different physicochemical properties. It is a white powder or granule with no discernible odour. TGIC's solubility in water is relatively low (9 g/l).

The main use of TGIC is as a three-dimensional cross-linking or curing agent in polyester powder coatings (paints) where it constitute up to 10%. The alpha isomer of TGIC has been used as an experimental anti-tumour agent.

### *Environment*

Environmental exposure to TGIC resulting from normal use in spray painting workplaces is expected to be low. Plants that formulate TGIC powder coatings do release some TGIC to the atmosphere and sewer. As TGIC is an epoxide, any residues which enter the environment are expected to be rapidly degraded, either through microbial action or abiotic hydrolysis. Hydrolysis proceeds more rapidly in the marine environment because of more rapid ring opening by chloride ions. TGIC is not expected to accumulate in soil or sediment because of high mobility. The reactivity of TGIC precludes any possibility of bioaccumulation.

### *Human exposure*

No data were found.

### *Toxicokinetics*

No toxicokinetic inhalation studies have been performed. If inhaled, most commercial TGIC particles are too big for reaching the lower bronchioles and alveolar regions of the lungs and will be deposited in the upper respiratory tract. TGIC is partially absorbed after oral administration to mice and rabbits. Absorption is probably low following dermal contact indicated by a high LD<sub>50</sub>-value. In mice in a oral study, TGIC was distributed to the liver, stomach and testes (the only tissues studied).

Clinical trials with  $\alpha$ -TGIC in humans and studies in rabbits (intravenous administration) indicated that TGIC is rapidly eliminated from plasma with a half-life less than 5 minutes and a total body clearance at about 5 litres/minute. Less than 1%  $\alpha$ -TGIC was recovered in 24-hour urine. Metabolites in the plasma were eliminated at a much slower rate ( $t_{1/2}$  > 60 minutes). Twenty-four-hour urinary recovery of <sup>14</sup>C total radioactivity was 60 to 70%.

TGIC metabolism seems to involve hydrolysis catalysed by microsomal epoxide hydrolase in the liver as indicated by both an *in vitro* and an *in vivo* study in rats. In the *in vitro* study, epoxide hydrolysis metabolites were detected in the microsomal incubations.

### *Human toxicity*

Allergic contact dermatitis due to exposure to TGIC is the main reported human health effect. Sixteen case reports, in which patch tests confirmed that TGIC was the causative agent of the skin problems, exist in the literature. Workers may become sensitised to TGIC from short-term exposure (less than 12 months) to the chemical. Other health effects in workers exposed to TGIC include aggravated asthma, nasal, eye and throat irritation, skin rash and nose bleed. TGIC has caused occupational asthma

in a healthy 36-year old non-smoking man who worked mainly as a spray painter, using a powder paint containing 4% TGIC. Before the examinations, he had been painting 5-8 hours daily for about 7 years.

In human clinical trials,  $\alpha$ -TGIC was administered intravenously to cancer patients at very high doses. The dose-limiting factor was local thrombophlebitis. Leukopenia and myelosuppression was seen at the highest doses. Other toxic effects were mild to moderate and consisted of nausea, vomiting and hair loss.

#### *Animal toxicity*

Acute toxicity studies in animals have shown that TGIC is toxic by the oral ( $LD_{50}$  of <100-950 mg/kg for rats and  $LD_{50}$  of 1670 mg/kg for hamsters) and inhalational ( $LC_{50}$  of 300->650 mg/m<sup>3</sup> for rats and  $LC_{50}$  of 2000 mg/m<sup>3</sup> for mice) routes but has low acute dermal ( $LD_{50}$  of >2000 mg/kg for rats) toxicity.

TGIC causes serious eye effects in rabbits following instillation. Skin sensitisation was observed in guinea pigs. Very slight erythema and oedema were observed in studies of acute skin irritation in rabbits.

In a short term (6 hours/day for 5 days) nose-only inhalational study, mice were exposed to atmospheres containing 0, 10, 40 or 140 mg/m<sup>3</sup> TGIC. Clinical signs of toxicity, increased body weight losses and high mortality were observed in the intermediate and high dose groups. The clinical signs included hunched posture, piloerection, lethargy and dyspnoea. Dead animals had lung damage. Besides pathology for animals dosed with 140 mg/m<sup>3</sup> included pale livers, pale kidneys, and congestion of the small intestine. One animal had slightly reddened lungs in the low dose group. In another similar study, body weight gain was unaffected, no deaths occurred, and no adverse clinical signs were observed at a concentration of 7.8 mg/m<sup>3</sup>.

When rats were fed 0, 54 or 216 mg/kg b.w./day (males) or 0, 43, or 172 mg/kg b.w./day (females) of TGIC by gavage for 7 consecutive days, gross pathology was recorded for the lungs, kidney, liver, stomach, and intestines in both sexes in dosed animals. Renal, gastric and duodenal damage was observed in both sexes in the high dose groups.

In a 13-week toxicity/fertility study, male rats were given diets containing 0, 10, 30, or 100 mg/kg TGIC. This study followed a preliminary 19-day range-finding investigation in which signs of toxicity were observed in animals administered diets containing 160 or 640 mg/kg TGIC. In the 13-week study, no exposure-related clinical effects or death were observed. Body weight gain was slightly lower over the first 6 weeks in animals from the 100 mg/kg test group.

#### *Reproductive and developmental effects*

In the 13-week toxicity/fertility study, a dose-related reduction in the number of spermatozoa was noted in the male rats but the spermatozoa viability was unchanged. No exposure-related infertility was noted in males, and no effects on embryonic and pup development were observed in the offspring.

A dominant lethal test showed reduced fertility in male mice inhaling 10 and 50 mg/m<sup>3</sup> of TGIC. No increase in embryonic deaths was observed



in two dominant lethal studies where male mice inhaled up to 170 mg/m<sup>3</sup> of TGIC for 6 hours/day for 5 consecutive days before mating the females. In a dominant lethal study with oral administration of TGIC, a dose of 480 mg/kg b.w. caused a significant increase in the number of embryonic deaths in females mated to the intoxicated males within the first week. This observation was not confirmed in a similar study where TGIC was given in doses up to 550 mg/kg b.w.

#### *Mutagenic and genotoxic effects*

TGIC is classified for mutagenic properties. The mutagenic and genotoxic effect of TGIC has been investigated in a wide range of *in vitro* and *in vivo* assays.

*In vitro* TGIC was positive both with and without metabolic activation systems in Ames test, in the mouse lymphoma assay, and in chromosome aberration and sister chromatid exchange tests in Chinese hamster ovary cells. A reduction in the response to treatment was noted in the mouse lymphoma assay and in the two assays in Chinese hamster ovary cells when metabolic activation was present. TGIC also tested positive in a chromosome aberration assay in Chinese hamster lung cells without metabolic activation systems but was negative with metabolic activation. TGIC was positive for unscheduled DNA synthesis in rat hepatocytes. TGIC was negative in two cell transformation assays in mouse embryo fibroblasts.

In human cells *in vitro*, TGIC tested negative in a chromosomal aberrations assay in lymphocytes and for unscheduled DNA synthesis in fibroblasts.

*In vivo*, TGIC was shown to be clastogenic in a nucleus anomaly test in Chinese hamsters when they were administered oral doses above 280 mg/kg b.w./day for two days. TGIC also induced dose-related sister chromatid exchanges (SCEs) in the bone marrow cells of Chinese hamsters exposed orally to doses above 140 mg/kg b.w. Chromosomal aberrations in the spermatogonia were observed in a dose-related manner starting at about 30 mg/kg b.w. when male mice were exposed orally to TGIC for 5 days.

TGIC in a dose of 7.8 mg/m<sup>3</sup> did not induce chromosomal damage in spermatogonial cells in mice exposed by nose-only inhalation for 6 hours/day for 5 days. Chromosomal aberrations were observed in male mice exposed nose-only to 2000 mg/m<sup>3</sup> of powder coating containing 4.6% TGIC (that is 92 mg/m<sup>3</sup> of TGIC). An *in vivo* inhalational study in mice exposed to TGIC in concentrations between 0 and 50 mg/m<sup>3</sup> for 6 hours/day for 5 days was inconclusive regarding chromosomal aberrations in spermatogonia possibly because of cell cytotoxicity above 10 mg/m<sup>3</sup>. Chromosomal aberrations were observed at a concentration of 170 mg/m<sup>3</sup> (10% TGIC in powder coating at 1700 mg/m<sup>3</sup>) but the number of scorable cells were very low.

Chromosomal aberrations in the spermatocytes were not observed in male mice given TGIC by gavage at doses up to 96 mg/kg b.w. for 5 days.

TGIC was negative in the mouse spot test following single intraperitoneal doses up to 54 mg/kg b.w.

The cytotoxicity of TGIC is probably related to the alkylating capacity of the epoxide moieties. Two *in vivo* studies have demonstrated that TGIC is capable of covalently binding to DNA in mouse liver, stomach and testis tissues following oral administration of doses between 5 and 200 mg/kg b.w. and in rat liver tissue following intraperitoneal or oral administration of 20 mg/kg b.w.

#### *Carcinogenicity*

2.5% TGIC did not promote skin tumour formation in CF-1 mice painted twice weekly for 26 weeks.

The final results of a chronic toxicity/carcinogenicity bioassay in rats conducted by the Centre Internationale de Toxicologie (CIT) in France were not available in 1998.

## 7 Evaluation

The critical effects in humans following exposure to TGIC is considered to be the possibly mutagenic effect and the skin sensitisation and asthma that it causes. This is based on the following:

In humans, the available data on health effects after exposure to TGIC in the air are limited to 16 case reports of allergic contact dermatitis, one report of occupational asthma and Australian surveys of health effects in workers exposed to TGIC. Workers may be exposed to TGIC in concentrations of up to  $6.5 \text{ mg/m}^3$ . Health effects include aggravated asthma, nasal, eye and throat irritation, skin rash and nose bleed.

In humans,  $\alpha$ -TGIC in the systemic circulation (given intravenously) in high doses induced leukopenia which resulted in life-threatening infections at plasma concentrations above  $1.2 \text{ }\mu\text{g/ml}$ . Other toxic effects were mild to moderate and consisted of nausea, vomiting and hair loss. In rats exposed orally to TGIC, gross pathology was recorded for the lungs, kidney, liver, stomach, and intestines. These studies show that systemic effects of TGIC are seen above certain dose levels but it is a question to what extent TGIC is absorbed after inhalation.

No toxicokinetic inhalation studies have been performed. If inhaled, most commercial TGIC particles are too big for reaching the lower bronchioles and alveolar regions of the lungs and will be deposited in the upper respiratory tract. Short term inhalation studies in rats and mice with respirable TGIC resulted mainly in lung damage indicating that the absorption of TGIC following inhalation probably is low. Pale livers, pale kidneys, and congestion of the small intestine seen in mice inhaling  $140 \text{ mg/m}^3$  short-term could be a side-effect of the heavily damaged lungs and not a direct toxic effect of TGIC since no cytotoxicity was observed in tested germ cells. Speaking against the low absorption is some *in vivo* inhalational genotoxicity studies in mice. A dose of  $7.8 \text{ mg/m}^3$  of TGIC did not induce chromosomal damage in spermatogonial cells but aberrations were observed in mice inhaling powder coating containing TGIC equivalent to  $92 \text{ mg/m}^3$ . The question is whether TGIC was the toxic substance in the powder coating but some genotoxic substance in the powder coating must have been absorbed.

It is a cause of concern that several *in vitro* and *in vivo* genotoxicity studies are positive and TGIC seems to be a direct-acting mutagen. *In vitro*, TGIC tested positive in both gene mutation and clastogenic assays. *In vivo*, TGIC is not causing gene mutations as shown in the mouse spot test. Regarding a clastogenic effect, both positive and negative results exist. TGIC alkylates DNA but apparently it is not very potent. A 26 week study where mice were painted twice weekly with TGIC did not result in tumour formation. So far no results from long term toxicity/carcinogenicity studies have been published.

A long term carcinogenicity study would be valuable in assessing whether the genotoxic effect of TGIC can lead to cancer. But just as im-

portant is it to get established to what extent technical grade TGIC is absorbed when inhaled.

We know very little of which doses that are causing sensitisation. At the moment, the best study to base a NOAEL on is therefore a short term (6 hours/day for 5 days) nose-only inhalational study. In one such study, one mouse exposed to  $10 \text{ mg/m}^3$  of TGIC had slightly reddened lungs but in another similar study with 10 mice, body weight gain was unaffected, no deaths occurred and no adverse clinical signs were observed at  $7.8 \text{ mg/m}^3$ . No cytotoxicity and chromosomal aberrations in spermatogonial cells were noted at this dose either. For the purpose of estimating a limit value in air, a level of  $8 \text{ mg/m}^3$  is therefore considered as a NOAEL for irritative effects and chromosomal aberrations in spermatogonial cells in mice inhaling TGIC short term.

## 8 Limit value in air

The limit value is calculated based on a NOAEL of 8 mg/m<sup>3</sup> for irritative effects and chromosomal aberrations in spermatogonial cells in mice exposed to TGIC 6 hours/day for 5 days.

$$\begin{aligned}LV_{\text{air}} &= \frac{\text{NOAEL}}{\text{SF}_I \times \text{SF}_{II} \times \text{SF}_{III}} = \frac{8 \times 6/24 \times 5/7 \text{ mg/m}^3}{10 \times 10 \times 100} \\ &= 0.0001 \text{ mg/m}^3\end{aligned}$$

The safety factor SF<sub>I</sub> is set to 10 assuming that humans are more sensitive than animals. The SF<sub>II</sub> is set to 10 to protect the most sensitive individuals in the population. The SF<sub>III</sub> is set to 100 taking into account the quality of the study (few animals, only one dose level, poorly reported, short-term study) and because TGIC is a known genotoxic substance in *in vitro* and *in vivo* studies and it is still an open question whether chronic exposure will cause cancer. Finally, a NOAEL for asthma is not established and therefore cannot be considered for use in calculating the limit value.

## 9 C-value

A limit value of 0.0001 mg/m<sup>3</sup> has been calculated. For substances having acute or subchronic effects, but for which activity over a certain period of time is necessary before the harmful effect occurs, the C-value is set at the limit value (MST 1990). A C-value of 0.0001 mg/m<sup>3</sup> and placing in Main Group 1 is proposed. Placing in Main Group 1 is proposed because TGIC is a mutagenic substance which probably may cause cancer following chronic exposure.

*C-value*

0.0001 mg/m<sup>3</sup>, Main Group 1.

## 10 References

- Ames MM, Kovach JS and Rubin J (1984). Pharmacological characterization of Teroxine, a triepoxide antitumor agent, in rats, rabbits, and humans. *Cancer Res* **44**, 4151-4156.
- Atassi G, Spreafico F, Dumont P, Nayer P and Klastersky J (1980). Antitumoral effect in mice of a new triepoxide derivative: 1,3,5-triglycidyl-s-triazinetrione (NSC 296934). *Eur J Cancer* **16**, 1561-1567.
- Chemfinder (1999). 1,3,5-Triglycidyl Isocyanurate. In: Chemfinder data base. [Http://www.chemfinder.com](http://www.chemfinder.com)
- Craven NM, Bhushan M and Beck MH (1999). Sensitization to triglycidyl isocyanurate, epoxy resins and acrylates in a developmental chemist. *Cont Derm* **40**, 54-55.
- Dombernowsky P, Lund B and Hansen HH (1983). Phase I study of  $\alpha$ -1,3,5-triglycidyl-s-triazinetrione (NSC 296934). *Cancer Chemother Pharmacol* **11**, 59-61.
- Dooms-Goossens A, Bedert R, Vandaele M and Degreef H (1989). Airborne contact dermatitis due to triglycidylisocyanurate. *Cont Derm* **21**, 202-203.
- Foulds IS and Koh D (1992). Allergic contact dermatitis from resin hardeners during the manufacture of thermosetting coating paints. *Cont Derm* **26**, 87-90.
- Jolanki R, Kanerva L, Estlander T and Tarvainen K (1994). Concomitant sensitization to triglycidyl isocyanurate, diaminodiphenylmethane and 2-hydroxyethyl methacrylate from silk-screen printing coatings in the manufacture of circuit boards. *Cont Derm* **30**, 12-15.
- Loveday KS, Anderson BE, Resnick MA and Zeiger E (1990). Chromosome aberration and sister chromatid exchange tests in Chinese hamster ovary cells in vitro. V: Results with 46 chemicals. *Environ Mol Mutagen* **16**, 272-303.
- Mathias CGT (1988). Allergic contact dermatitis from triglycidyl isocyanurate in polyester paint pigments. *Cont Derm* **19**, 67-68.
- McFadden JP and Rygroft JG (1993). Occupational contact dermatitis from triglycidyl isocyanurate in a powder paint sprayer. *Cont Derm* **28**, 251.
- MM (1997). The Statuary Order from the Ministry of the Environment no. 829 of November 6, 1997, on the List of Chemical Substances.

Munro CS and Lawrence CM (1992). Occupational contact dermatitis from triglycidyl isocyanurate in a powder paint factory. *Cont Derm* **26**, 59.

Neidhart JA, Derocher D, Grever MR, Kraut EH and Malspeis L (1984). Phase I trial of teroxirone. *Cancer Treat Rep* **68**, 1115-1119.

NOHSC (1994). Triglycidylisocyanurate (TGIC). National Industrial Chemicals notification and Assessment Scheme (NICNAS). National Occupational Health and Safety Commission (Worksafe Australia). [Http://www.worksafe.gov.au/worksafe/fulltext/toc/h3-38.htm](http://www.worksafe.gov.au/worksafe/fulltext/toc/h3-38.htm)

NOHSC (1998). Triglycidylisocyanurate (TGIC). List of designated hazardous substances. National Occupational Health and Safety Commission (Worksafe Australia). [Http://www.worksafe.gov.au/cgi-bin/wsresult.exe?txtID=2537](http://www.worksafe.gov.au/cgi-bin/wsresult.exe?txtID=2537)

Nishioka K, Ogasawara M and Asagami C (1988). Occupational contact allergy to triglycidyl isocyanurate (TGIC, Tepic<sup>®</sup>). *Cont Derm* **19**, 379-380.

NTP(1991). Tris (2,3-epoxypropyl) isocyanurate. In: NTP chemical Health and Safety Data. [Http://ntp-db.niehs.nih.gov/NTP\\_Reports/NTP\\_Chem\\_H&S/NTP\\_Chem2/Radian2451-62-9.txt](http://ntp-db.niehs.nih.gov/NTP_Reports/NTP_Chem_H&S/NTP_Chem2/Radian2451-62-9.txt)

OAPCR (1999). 1,3,5-Triglycidyl isocyanurate. In: Oklahoma Air Pollution Control Rules. [Http://www.deq.state.ok.us/air1/toxdis.html](http://www.deq.state.ok.us/air1/toxdis.html)

Piccart M, Rozenzweig M, Dodion P, Cumps E, Crespeigne N, Makaroff O, Atassi G, Kisner D and Kenis Y (1981). Phase I clinical trial with alpha 1,3,5-triglycidyl-s-triazinetriene (NSC 296934). *Eur J Cancer Clin Oncol* **17**, 1263-1266.

Piirilä P, Estlander T, Keskinen H, Jolanki R, Laakkonen A, Pfäffli P, Tupasela O, Tuppurainen M and Nordman H (1997). Occupational asthma caused by triglycidyl isocyanurate (TGIC). *Clin Exp Allergy* **27**, 510-514.

RTECS (1999). S-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2,3-epoxypropyl)-. In: Registry of Toxic Effects of Chemical Substances.

Rubin J, Kovach JS, Ames MM, Moertel CG, Creagan ET and O'Connell MJ (1987). Phase I study of two schedules of teroxirone. *Cancer Treat Rep* **71**, 489-492.

Sofuni T, Matsuoka A, Sawada M, Ishadate M, Zeiger E and Shelby MD (1990). A comparison of chromosome aberration induction by 25 compounds tested by two Chinese hamster cell (CHL and CHO) systems in culture. *Mutat Res* **241**, 175-213.

Toxline (pre 1981-1999). Triglycidylisocyanurate. In: Toxline database.



Wigger-Alberti W, Hofmann M and Elsner P (1997). Contact dermatitis caused by triglycidyl isocyanurate. *Am J Cont Derm* **8**, 106-107.

WHO (1998). Triglycidyl Isocyanurate. Concise International Chemical Assessment Document, no. 8. World Health Organisation, International Programme on Chemical Safety, Geneva.

Wu FYH and Le Pecq JB (1983). Mechanistic studies of a novel anti-tumor drug,  $\alpha$ -1,3,5-triglycidyl-s-triazinetriene. Antitumor and cytotoxic effects. *Mol Pharmacol* **23**, 182-189.




# 1 General description

## 1.1 Identity

Molecular formula: C<sub>15</sub>H<sub>24</sub>O<sub>6</sub>

Structural formula:



Molecular weight: 300.39

CAS-no.: 42978-66-5

Synonyms: Acrylic acid, propylenebis(oxypropylene) ester;  
2-Propenoic acid, (1-methyl-1,2-diethanediyl)-  
bis(oxy(methyl-2,1-ethanediyl)) ester;  
Tripropyleneglycol diacrylate;  
TPGDA;  
TRPGDA.

## 1.2 Physical / chemical properties

Description: Pale, yellow tinted liquid with a mild odour.

Purity: Technical product: 80% pure monomer with > 18% oligomer (Nylander-French & French 1998).

Melting point: -

Boiling point: -

Density: 1.030 g/ml (at 20°C)

Vapour pressure: < 0.01 mmHg (< 1.33 Pa) at 20°C  
0.0106 mmHg (1.41 Pa) at 25°C

Concentration of saturated vapours: 14 ppm (175 mg/m<sup>3</sup> (calculated) at 20°C and 760 mmHg)

Vapour density: -

Conversion factor: 1 ppm = 12.5 mg/m<sup>3</sup> 20°C  
1 mg/m<sup>3</sup> = 0.080 ppm 1 atm

Flash point: > 110°C, closed cup

Flammable limits: -

Autoignition temp.:	-
Solubility:	Insoluble in water. Soluble in many organic solvents.
logP <sub>octanol/water</sub> :	-
Henry's constant:	-
pK <sub>a</sub> -value:	-
Stability:	-
Incompatibilities:	-
Odour threshold, air:	-
References:	RTECS (1999), Nylander-French & French (1998), Mortensen (1991).

### 1.3 Production and use

No data were found on production.

Tripropyleneglycol diacrylate is used in a variety of UV curable inks, lacquers and varnishes (surface coatings). A lacquer contains 56.4% TPGDA monomer (Tice et al. 1997). Surface coating materials in Sweden normally contain 10 - 30% TPGDA (Nylander-French et al. 1994).

### 1.4 Environmental occurrence

No data were found

### 1.5 Environmental fate

No data were found

### 1.6 Human exposure

No data on human exposure have been found. However, the general population may be exposed to tripropyleneglycol diacrylate by inhalation of contaminated air and through contact with TPGDA containing products.

## 2 Toxicokinetics

### 2.1 Absorption, distribution

*Inhalation*

No data were found.

*Oral intake*

No data were found.

*Dermal contact*

No data were found, but systemic effects have been observed following dermal application indicating that absorption through the skin takes place (Celanese Corporation - quoted from Mortensen 1991)

### 2.2 Elimination

*Metabolism*

The major route of detoxification of acrylates is their conjugation with glutathione via the Michaëlis addition reaction or glutathione-S-transferase. Conjugation of acrylates by glutathione is expected to be proportional to the number of functional acrylate groups. The available data suggest that the acrylates most likely act on the site of contact, conjugate available glutathione, and are hydrolysed by carboxylesterases. (Tice et al. 1997).

*Excretion*

No data have been found.

*Half-life*

No data have been found.

### 2.3 Toxicological mechanisms

Based on the chemical structure and molecular reactivity, acrylates have the potential to interact with biomolecules, including nucleic acids and nucleoproteins and thus to induce DNA damage, being limited in the biological activity only by the physico-chemical properties and access to biological systems (Tice et al. 1997).

## 3 Human toxicity

### 3.1 Short term toxicity

#### *Inhalation*

No data were found

#### *Oral intake*

No data were found

#### *Dermal contact*

Acrylates are generally potent contact allergens. Polyfunctional acrylates and epoxyacrylates are the most potent ones, whereas the polyfunctional methacrylates and cyanoacrylates are much weaker. Many of the acrylates cross-react.

The list of allergens contain some 60 acrylates which all cause contact sensitisation (National Institute of Occupational Health 1990). In the Nordic countries, 23 acrylates are considered contact allergens and a classification with R43 (may cause sensitisation by skin contact) has been agreed (Nordic Council of Ministers 1991).

One American woman working with silk screening of computer discs with UV curable inks developed acute allergic contact dermatitis on hands and forearms. Patch testing revealed a number of strong reactions to epoxy resins and many multifunctional epoxy resins. The only material listed on the safety data sheet to which she reacted was tripropyleneglycol diacrylate. The other positive reactions likely represent cross-reactions. (Skotnicki & Pratt 1998 - quoted from TOXLINE PLUS 1998).

Occupational allergic contact dermatitis due to tripropyleneglycol diacrylate exposure was observed in a male silk screen maker in Belgium (Goossens et al. 1998).

Fingertip paraesthesia and occupational allergic contact dermatitis caused by acrylics (one of which was tripropyleneglycol diacrylate) occurred in a dental nurse in Finland. (Kanerva et al. 1998 – quoted from TOXLINE PLUS 1998).

Three out of 59 workers exposed to polyfunctional acrylic monomers (including tripropyleneglycol diacrylate) in 5 Swedish furniture companies developed severe acute toxic skin reactions due to insufficient product knowledge and lack of introduction routines, handling directions and protective equipment. A follow-up period of three years upon implementation of new routines revealed no further cases of acute toxic eczema in the five companies. (Voog & Jansson 1992).

Based on 10 years of patch testing with the (meth)acrylate series, Kanerva et al. (1997) put a low score (ranked 22 of 24) on tripropyleneglycol diacrylate with respect to its sensitising capacity.

### 3.2 Long term toxicity

No data were found.

### **3.3 Reproductive and developmental effects**

No data were found.

### **3.4 Mutagenic and genotoxic effects**

No data were found.

### **3.5 Carcinogenic effects**

No data were found.

## 4 Toxicity, animal data

### 4.1 Short term toxicity

#### *Inhalation*

No data were found.

#### *Oral administration*

An LD<sub>50</sub>-value after oral administration of a single dose of tripropylene glycol diacrylate (TPGDA) to rats of 6200 mg/kg has been reported (NTIS - quoted from RTECS 1999).

#### *Dermal contact*

An LD<sub>50</sub>-value after single dermal application of TPGDA to rabbit skin of > 2000 mg/kg has been reported (Celanese Corporation - quoted from RTECS 1999).

A study on repeated dermal exposure was performed. Rabbits were painted with 500 mg/kg b.w. TPGDA 5 days a week for 2 weeks. The observation period was 4 week after the last application. This repeated exposure led to systemic toxicity, including convulsions, tremors and ataxia. The test methods and results are not further described and the data are unpublished. (Celanese Corporation - quoted from Andrews & Clary 1986).

#### *Irritation skin*

TPGDA was tested for skin irritation after a single application to rabbits. The rabbits were examined 24 hours, 72 hours and 7 days after the application. The irritation was scored as moderately irritating both after 24 and 72 hours. At day 7, a delayed skin effect was observed. For most of the animals, skin necrosis and eschar formation were noted. The delayed effects were assigned to category I (refers to corrosion). The dose was not stated. The test method is not described further and the data are unpublished. (Celanese Corporation - quoted from Andrews & Clary 1986).

#### *eye*

When TPGDA was tested for eye irritation in rabbits, it was scored as category IV (slight irritation) after 72 hours. The test method is not described further and the data are unpublished. (Celanese Corporation - quoted from Andrews & Clary 1986).

#### *Sensitisation*

TPGDA (purity not specified) was tested for sensitising capacity in guinea pigs using the Guinea Pig Maximization Test (GPMT). Groups of exposed and control animals consisted of 15 albino Dunkin-Hartley strain guinea pigs. For intradermal induction was used 1% TPGDA in olive oil:acetone (9:1), and for the topical induction was used a solution of 25% TPGDA in petrolatum. The challenge concentration was 0.2% TPGDA in petrolatum. The optimal test concentration was determined in a preliminary test. Of the guinea pigs treated with TPGDA, 11 of 15 (73%) became sensitised, which indicates that TPGDA is a strong sensitizer. (Björkner 1984).

The same study shows that other multifunctional acrylates such as 1,4-butanediol diacrylate, diethyleneglycol diacrylate, tetraethyleneglycol diacrylate and neopentylglycol diacrylate cross-react with TPGDA. (Björkner 1984).



The same test performed with acetone as vehicle show that the vehicle influences the allergic response to a very large extent. Of 15 animals tested, none was positive if acetone was used (11 of 15 were positive when petrolatum was used). The discrepancy between the results is due to a polymerisation process of the acrylates in acetone. Petrolatum prevents polymerisation of acrylic monomers. (Björkner & Niklasson 1984).

TPGDA stabilised with 500 ppm hydroquinone methylether was tested for sensitising properties in the Guinea Pigs Maximization Test (GPMT). The group of treated animals consisted of 10 male and 10 female and the control group of 5 male and 5 female Dunkin Hartley guinea pigs. On day 1, 0.1 ml of the test substance, in the presence of Freund's adjuvant, was administered by intradermal route at a concentration of 0.5% in paraffin oil. On day 9, 0.5 ml of the test substance was applied by cutaneous route and kept on the application site for 48 hours. After a period of 15 days without treatment, a 0.5 ml challenge cutaneous application of the vehicle (left flank) and 0.5 ml of the test substance (right flank) at a concentration of 25% in paraffin oil was performed in all animals. The substances were held in place by means of an occlusive dressing for 24 hours. The cutaneous reactions were evaluated at the challenge application site, 24 and 48 hours after removal of the dressing. After the last scoring, the animals were sacrificed. No behavioural abnormalities, or cutaneous reactions were observed in any animal from the control or treated groups.

It was concluded that under the experimental conditions and according to the maximization method of Magnusson and Kligman, no cutaneous reactions related to a sensitisation potential of TPGDA were observed in the guinea pig.

(C.I.T. unpublished study 1989).

An identical study was performed by the same laboratory using exactly the same substance (TPGDA with 500 ppm hydroquinone methylether as stabiliser), same number of animals and same procedure, only was the concentration used for intradermal induction by day 1, 1% TPGDA in paraffin oil and the concentration used for the cutaneous induction on day 9, was 10% in paraffin oil. In this study, no behavioural abnormalities were observed in the animals throughout the study. Minimal to barely perceptible cutaneous reactions (very slight erythema) were noted 24 hours after removal of the dressing from the cutaneous challenge application, on the right flank (test substance) in 4 out of 10 males and in 2 out of 10 females in the treated group.

It was again concluded that under the experimental conditions and according to the maximization method of Magnusson and Kligman, no cutaneous reactions related to a sensitisation potential of TPGDA were observed in the guinea pig.

(C.I.T. unpublished study 1989).

Photomer 4061 (TPGDA with unspecified purity) was tested in the GMPT for sensitising properties using 10 and 5 female Dunkin Hartley guinea pigs as treated and control group, respectively. Six additional animals were used for the preliminary (dose finding) investigations. Alembicol D - a product of coconut oil was used as solvent. Based on the preliminary investigations, the following concentrations of Photomer 4061 were chosen: for the induction intradermal injection, 0.5% v/v in

Alembicol D; for the induction topical application, - 25% v/v in Alembicol D; and for the topical challenge, 10% (anterior) or 5% (posterior) v/v in Alembicol D. Intradermal induction was performed on day 1 with 0.1 ml of each of 50% Freund's complete adjuvant, 0.5% v/v Photomer 4061 in Alembic D and 0.5% v/v Photomer 4061 in 50:50 Freund's complete adjuvant and Alembic D (control animals received the same but without Photomer 4061). One week later, the treated animals were inducted topically with 0.4 ml 25% v/v Photomer 4061 in Alembic D (controls with Alembic D alone) held on place for 48 hours with an occlusive dressing. Two weeks after this, all animals were challenged with 0.2 ml 10% and 5% v/v Photomer 4061 in Alembic D for 24 hours and the challenge sites were evaluated 24, 48 and 72 hours after removal of the patches. In this study, Photomer 4061 produced evidence of skin sensitisation (delayed contact hypersensitivity) in 8 of the 10 tested animals (2 were inconclusive). (Huntingdon Research Centre unpublished study 1993).

TPGDA was shown to induce contact sensitivity in Guinea pigs using the Polak method. In the test, 6 outbred Hartley guinea pigs were used. For intradermal induction, the guinea pigs received 1 mg TPGDA dissolved in ethanol:saline (1:4) and Freund's complete adjuvant (FCA). Seven days later, the skin tests were performed with 0.2 ml of a solution (0.5% or 1% TPGDA in acetone:olive oil (4:1)) being applied to the skin. The test concentrations were 5% of the maximum concentration, which gave no irritation. The skin tests were repeated weekly up to 12 weeks. The time for the first positive skin reaction was at day 28. The number of sensitised animals was not mentioned. (Parker & Turk 1983).

## 4.2 Long term toxicity

### *Inhalation*

No data were found.

### *Oral administration*

No data were found.

### *Dermal contact*

Rats were tested in a 90-day dermal test with TPGDA at dose levels of 20, 67, or 200 mg/kg b.w. for 5 days a week. Doses up to and including 67 mg/kg b.w. did not give rise to any systemic effects and is thus a NO-AEL for systemic effects. All 3 doses led to skin irritation early in the study. The skin appeared to acclimatise and after 3 weeks, the severity of the irritation declined. There was no sign of irritation during the last few weeks of the study in rats treated with 20 mg/kg. The test methods and results are not further described and the data are unpublished. (Celanese Corporation - quoted from Andrews & Clary 1986).

## 4.3 Reproductive and developmental effects

TPGDA was screened for teratogenic potential by repeated dermal exposure. Twenty pregnant rats were given a daily dermal dose of 250 mg/kg b.w. during day 6 to 15 of pregnancy. The dose level was based on results from a preliminary dermal maternal toxicity screening. TPGDA was not found to be teratogenic or foetotoxic based on maternal observations, including number of implantations, number of live and dead foetuses, number of early and late resorptions, and number of corpora lutea, as

well as external, skeletal and visceral evaluation of foetuses for malformations. No further details of the test methods are described and the data are unpublished. (Celanese Corporation - quoted from Andrews & Clary 1986).

#### 4.4 Mutagenic and genotoxic effects

TPGDA has been tested for mutagenicity in bacteria (Ames test) with and without metabolic activation; no mutagenic potential was found. The test method and results are not further described and the data are unpublished. (Celanese Corporation - quoted from Andrews & Clary 1986).

In another test with mammalian cells *in vitro*, the mouse lymphoma cell mutagenicity assay, a positive mutagenic response was found both with and without metabolic activation. The test method and results are not further described and the data are unpublished. (Celanese Corporation - quoted from Andrews & Clary 1986).

TPGDA or Lacquer A (an ultraviolet radiation curable lacquer containing 56.4% TPGDA as the active ingredient) were applied dermally to Tg.AC mice - 3 times a week for 20 weeks. Peripheral blood leukocytes were evaluated for DNA damage (single-strand breaks, alkali labile sites, and DNA crosslinking) at week 4, 8, 12, 16, and 20 by using the alkaline (pH:13) single cell gel (SCG) assay. Peripheral blood polychromatic erythrocytes (PCE) and normochromatic erythrocytes (NCE) were evaluated for the presence of micronuclei at week 20. The extent of DNA migration in leukocytes and the frequency of micronucleated erythrocytes were not significantly altered by treatment with TPGDA when administered alone or in Lacquer A, at doses that induced cell proliferation in keratinocytes. The absence of genotoxicity in these two cell populations suggests that these acrylates are not genotoxic or that they are not absorbed when applied dermally. However, a significant dose-dependent increase in the percentage of PCE relative to the vehicle control was present in mice treated with TPGDA, while a dose-dependent, but non-significant, increase in the percentage of PCE was observed in mice treated with Lacquer A. This observed rate of erythropoiesis may reflect bone marrow/blood toxicity. (Tice et al. 1997).

#### 4.5 Carcinogenic effects

The carcinogenic potential of TPGDA was investigated in mice by dermal administration. The test group consisted of 50 male C3H/HeJ mice that were treated dermally with approximately 100 mg/kg TPGDA (2.5 mg/mouse) twice a week for 80 weeks or until tumours were diagnosed or animals died. The dose used in the study was selected in a preliminary pilot study, where male C3H/HeJ mice were treated with different dilutions of TPGDA. The concentration that only produced minimal skin irritation was selected for the study. Two negative control groups (one untreated and one treated with mineral oil) and one positive control group (treated with benzo(a)pyrene) were included. No obvious skin irritation was seen although fibrosis and changes in pigmentation occurred. At necropsy, skin and body cavities were examined and tissues were taken for

histopathological analysis, which did not reveal any increased incidence of skin or visceral tumours. Ten of 50 mice died in the study. In the positive control group, 42 of 50 mice developed carcinomas and in the negative control groups, 1 of 50 mice developed skin papilloma among non-treated and mineral oil treated mice. The test method is not further specified and the data are unpublished. (Celanese Corporation - quoted from Andrews & Clary 1986).

According to Mortensen (1991), the study is not in accordance with OECD guidelines and is inadequate for an evaluation of the carcinogenic potential of TPGDA.

Insertion of the zeta-globin promoted v-Ha-ras transgene into the FVB mouse genome (Tg.AC) produce a defined lesion, which is critical but insufficient by itself to induce benign or malignant tumours in the skin unless activated. Groups of 10 female Tg.AC (v-Ha-ras) mice (12 weeks old) were administered dermal doses of 1, 5 or 10  $\mu$ moles/mouse of TPGDA either alone or mixed with acetone (totally 200  $\mu$ l per application) or as an equimolar amount of a lacquer (lacquer A), three times per week for 20 weeks to the shaved dorsal skin (8 cm<sup>2</sup>). Negative controls were vehicle treated animals and positive controls were 12-*O*-tetradecanoylphorbol-13-acetate (TPA) treated mice. The treatment with 5 and 10  $\mu$ moles of TPGDA either as the substance itself or as lacquer A induced a dose related increase in papillomas between 6 and 12 weeks of treatment that reached a maximum number of papillomas per mouse between 19 and 20 weeks of treatment. These result indicate that TPGDA may be predicted to be carcinogenic at the site of contact in a long-term cancer bioassay. More studies are advised to clarify the significance of the role of the TPGDA-induced cellular proliferation in the induction of papillomas. (Nylander-French & French 1998).

## 5 Regulations, limit values

<i>Ambient air</i>	Denmark (C-value): -
<i>Drinking water</i>	Denmark: -
<i>Soil</i>	-
<i>OELs</i>	Denmark: -
<i>Classification</i>	TPGDA is classified for irritative effects (Xi;R36/37/38 - irritating to eyes, respiratory system and skin), for sensitising effects (R43 - may cause sensitisation by skin contact), and for environmental effects (N;R51-53 - toxic to aquatic organism, may cause long-term adverse effects in the aquatic environment) (EU 2000).
<i>EU</i>	-
<i>IARC/WHO</i>	-
<i>US-EPA</i>	-
<i>RD<sub>50</sub></i>	-

## 6 Summary

<i>Description</i>	Tripropyleneglycol diacrylate (TPGDA) is a pale, yellow tinted liquid with a mild odour. It is insoluble in water but soluble in many organic solvents. It has a very low vapour pressure (0.0106 mmHg at 25°C).
<i>Environment</i>	No data were found.
<i>Human exposure</i>	No data on human exposure have been found. However, the general population may be exposed to tripropyleneglycol diacrylate by inhalation of contaminated air and through contact with TPGDA containing products.
<i>Toxicokinetics</i>	No data have been found with respect to absorption and distribution after inhalation or oral intake. Absorption after dermal contact has not been examined but systemic effects have been observed in rabbits after repeated topical application indicating that absorption through the skin takes place. Detoxification of TPGDA would most likely be by conjugation with glutathione. Acrylates most likely react on the site of contact.
<i>Human toxicity</i>	A number of individuals using TPGDA occupationally have developed allergic contact dermatitis.
<i>Animal toxicity</i>	An LD <sub>50</sub> -value of 6200 mg/kg b.w. has been reported for oral administration to rats and of > 2000 mg/kg b.w. for dermal application to rabbits.
<i>single dose toxicity</i>	
<i>irritation</i>	TPGDA was at first only moderately irritating to rabbit skin but had a delayed effect corresponding to a corrosiveness. It was only slightly irritating to the rabbit eye.
<i>sensitisation</i>	TPGDA has shown equivocal results in the Guinea Pig Maximisation Tests (GPMT) with both positive and negative results being observed. However, the vehicle strongly influences the sensitising response. Cross reactions with other multifunctional acrylates have been observed.
<i>repeated dose toxicity</i>	Systemic toxicity, including convulsions, tremors and ataxia was observed in rabbits following application to the skin of 500 mg TPGDA for 5 times a week for 2 weeks. Systemic toxicity was observed in rats receiving topically doses of 200 mg/kg b.w. for 5 days a week for 90 days; the NOAEL in this study was 67 mg/kg b.w.
<i>Reproductive and developmental effects</i>	TPGDA was not foetotoxic or teratogenic in female rats when 250 mg/kg b.w./day of TPGDA was applied to the skin during day 6 to 15 of gestation.
<i>Mutagenic and genotoxic effects</i>	Tripropyleneglycol diacrylate was not mutagenic in Ames' test with or without metabolic activation, but gave a positive response in the mouse lymphoma cell mutagenicity assay both with and without metabolic activation. Following dermal application (3 times a week for 20 weeks) to transgenic mice (Tg.AC (v-Ha-ras)), no DNA damage (single-strand breaks, alkali labile sites, DNA crosslinking) was observed in peripheral blood leukocytes using the alkaline single cell gel assay and the frequency of

micronucleated erythrocytes (polychromatic and normochromatic) was not altered.

### *Carcinogenicity*

No signs of carcinogenicity were found in male CH3/HeJ mice treated topically twice every week for 80 weeks with 2.5 mg TPGDA (100 mg/kg b.w.).

An increased number of skin tumours were observed in TPGDA-treated female Tg.AC (v-Ha-ras) mice in a twenty week short-term tumorigenesis study. TPGDA was applied topically 3 times a week for 20 weeks in doses of 1, 5 or 10  $\mu$ moles/mouse either in form of technical quality TPGDA or as a lacquer intended for UV cured coatings. Negative controls were vehicle treated animals and positive controls were 12-*O*-tetradecanoylphorbol-13-acetate treated mice (10 animals per dose group). Number of papillomas was increased in mice treated with 5 and 10  $\mu$ moles and all doses of the lacquer and likewise the latency periods (time to occurrence) were shorter than for the negative controls.

## 7 Evaluation

The available data on human health effects are limited to some cases of allergic contact dermatitis. No data on respiratory sensitisation have been found.

The critical effects in humans following exposure to tripropyleneglycol diacrylate (TPGDA) is considered to be the irritative effects on the respiratory system as also observed following exposure to other acrylates, the skin damaging effects observed in animal studies upon repeated dermal exposure, and the sensitising potential (delayed contact hypersensitivity) observed among workers as well as in animal studies.

Systemic effects (not further specified in the publication) have been observed in one study of rats following dermal application. Based on the available data, it cannot be excluded that systemic effects may occur in humans following inhalation of TPGDA.

The available data on TPGDA are considered to be inadequate for the purpose of estimating a health based limit value in air. As TPGDA, in analogy to other acrylates as e.g., 2-ethylhexyl acrylate, is irritative to the respiratory system and a skin sensitiser, the C-value of 0.01 mg/m<sup>3</sup> proposed for 2-ethylhexyl acrylate is proposed for TPGDA as well.



## 8 C-value

The available data on TPGDA are considered to be inadequate for the purpose of estimating a health based limit value in air. As TPGDA, in analogy to other acrylates, is irritative to the respiratory system and a skin sensitiser, the C-value of 0.01 mg/m<sup>3</sup> proposed for 2-ethylhexyl acrylate and placing in Main Group 2 is proposed for TPGDA as well.

*C-value*

0.01 mg/m<sup>3</sup>, Main Group 2.

## 9 References

Andrews LS and Clary JJ (1986). Review of the toxicity of multifunctional acrylates. *J Toxicol Environ Health* **19**, 149-164.

Anonymous (1999). Vurdering af UV-hærdende trykfarver og lakker i et samlet miljøperspektiv. Miljø og Energiministeriet, Miljøstyrelsen.

Björkner B (1984). The sensitising capacity of multifunctional acrylates in the Guinea pig. *Cont Derm* **11**, 236-346.

Björkner B and Niklasson B (1984). Influence of the vehicle on contact allergic reactions to acrylic compounds in the Guinea pig. *Cont Derm* **11**, 268-278.

Clouzeau J (1989). TPGDA sensitisation test in the guinea-pig (study No. 4680 TSG). Centre International de Toxicologie (C.I.T.), France. Unpublished report.

Clouzeau J (1989). TPGDA sensitisation test in the guinea-pig (study No. 4683 TSG). Centre International de Toxicologie (C.I.T.), France. Unpublished report.

Denton SM (1993). Photomer 4061 Bx.92315 skin sensitisation in the guinea-pig. HCR Report. Huntingdon Research Centre. Unpublished report.

EU (2000). Commission directive 2000/32/EC of 19 May 2000 adapting to technical progress for the 26<sup>th</sup> time Council Directive 67/548/EEC on the approximation of the laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances. *Official Journal of the European Communities* L 136.

Golden R (1997). Safety and handling of UV/EB curing materials. *J Coat Technol* **69**, 83-89.

Goossens A, Connix D, Rommens K and Verhamme B (1998). Occupational dermatitis in a silk-screen maker. *Cont Derm* **39**, 40-42.

Kanerva L, Jolanki R and Estlander T (1997). 10 years of patch testing with the (meth)acrylate series. *Cont Derm* **37**, 255-258.

Kanerva L, Mikola H, Henriks-Eckerman ML, Jolanki R and Estlander T (1998). Fingertip paresthesia and occupational allergic contact dermatitis caused by acrylics in a dental nurse. *Cont Derm* **38**, 114-116.

Mortensen B (1991). Tripropylene glycol diacrylate. In: Health effects of selected chemicals. Nordic Chemicals Group Vol. **1**, 123-132.

Nylander-French LA, Fischer T, Hultengren M, Lewné M and Rosén G (1994). Exponering vid ytbehandling med ultravioletthärdande akryllacker i träindustrin. *Arbete och Hälsa* **13**, 1-33.

Nylander-French LA and French JE (1998): Tripropyleneglycol diacrylate but not ethyl acrylate induces skin tumours in a twenty-week short-term tumorigenesis study in Tg.AC (v-Ha-ras) mice. *Toxicol Pathol* **26**, 476-483.

Nylander-French LA, Priha E, Berglund GB and Rosén G (1994). A method for monitoring worker exposure to airborne multifunctional acrylates. *Appl Occup Environ Hyg* **9**, 977-983.

Parker D and Turk JL (1983). Contact sensitivity to acrylate compounds in guinea pigs. *Cont Derm* **9**, 55-60.

RTECS (through April 1999).

Roberts DW (1987). Structure-activity relationships for skin sensitisation potential of diacrylates and dimethacrylates. *Cont Derm* **17**, 281-289.

Tice RR, Nylander-French LA and French JE (1997). Absence of systemic *in vivo* genotoxicity after dermal exposure to ethyl acrylate and tripropylene glycol diacrylate in Tg.AC (v-Ha-ras) mice. *Environ Mol Mutagen* **29**, 240-249.

Voog L and Jansson B (1992). Identification and control of contact dermatitis from polyfunctional acrylic monomers in five Swedish furniture companies. *J Environ Sci Health* **27**, 1925-1938.

In this report, the toxicological documentation for the setting of limit values for 2-ethylhexyl acrylate, propylene carbonate, quaternary ammonium compounds, triglycidyl isocyanurate, and tripropyleneglycol diacrylate are presented. The principles upon which the Danish Environmental Protection Agency bases the health based limit values for chemical substances are briefly outlined.